Abstract:
The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Title: 2-oxo-piperidinyl derivatives

(1) International Application
(8) Publication Number
WO 2013/053725 A1

(51) International Patent Classification:
C07D 401/10 (2006.01)
C07D 417/14 (2006.01)
A61K 31/444 (2006.01)
A61P 25/06 (2006.01)

(21) International Application Number:
PCT/EP20 12/070000

(22) International Filing Date:
10 October 2012 (10.10.2012)

(26) Publication Language:
English

(54) Title: 2-oxo-piperidinyl derivatives

(57) Abstract: The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
2-OXO-PIPERIDINYL DERIVATIVES

Introduction
The present invention relates to 2-oxo-piperidinyl derivatives, their preparation as well as their use in the treatment of migraine.

Migraine, with a prevalence of ±10% in the general population, is ranked as one of the most debilitating diseases by the WHO and represents a significant burden on society in terms of indirect costs due to losses in revenues. In the European community, 600,000 workdays/day are missed by migraine sufferers. Migraine is grossly under-diagnosed and under-treated. There are two types of treatment: acute treatment seeks to abort an ongoing migraine headache and preventive or prophylactic treatment aims to diminish the frequency and severity of headache episodes. Acute and prophylactic treatments are usually prescribed by general practitioners and specialists, respectively. The benchmarks for acute and preventive treatments are the triptans and topiramate, respectively. Both approaches have clear unmet medical needs in terms of efficacy (overall only 50 to 65% of patients are relieved by these treatments) and side-effects (experienced by 40-50% of patients).

Migraine headache results from cranial blood vessel vasodilatation, associated with exacerbated neuronal activity of the trigeminal complex, leading to peripheral sensitization (neurogenic inflammation accompanied by release of CGRP, a potent vasodilator) and subsequently central sensitization (hyper-responsiveness of neurons in the trigeminal nucleus caudalis leading to increased transmission of pain signals). The mechanism of action of current acute treatments is largely focused on counteracting vasodilatation (e.g., all triptans are 5-HT1B/D/E/F agonists inducing vasoconstriction; CGRP antagonists are also approved for acute therapy, having shown efficacy comparable to the triptans, while NO inhibitors are being evaluated in clinical trials). Common analgesics are poorly efficacious in migraine. Mechanisms of action for preventive treatments include raising the threshold to migraine activation, enhancing anti-nociception, inhibiting cortical spreading depression (a phenomenon preceding headache and consisting of a wave of neural hyperactivity followed by neural depression; this wave moves across the brain at a speed about 2-3 mm/min and is speculated to underlie the aura experienced by 30% of migraineurs), inhibiting peripheral and central sensitization, blocking neurogenic inflammation and modulating sympathetic, parasympathetic or serotoninergic tones. Topiramate, valproate and beta-adrenergic antagonists are the oral drugs approved by the FDA for the prophylactic treatment of migraine. These have been joined over the last year by cranial
intramuscular injections of onabotulinumtoxin A (Botox®). Other drugs are used off-label and include 5-HT antagonists (5-HT2, poorly selective), calcium antagonists and antidepressants (none are active in acute migraine treatment).

Migraine, depression and sleep disorders are characterized by a dysfunction in serotonin levels and transmission. They share patterns of rhythmicity in their occurrence and are often associated as co-morbidities, suggesting partially common underlying mechanisms. Literature evidence demonstrates that 5-HT7 antagonists have promising efficacy in pre-clinical models of depression (Wesolowska et al., Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression, Neuropharmacology, 2006, 51 578-586) and sleep disorders (Shelton et al. "5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT7 receptor” Neuropharmacology 2009, 56, 448-454).

5-HT7 receptors belong to the large family of serotonin receptors composed of 14 members. 5-HT7 receptors are distributed in the central nervous system where they are highly expressed in the brainstem, the hypothalamus, thalamus and hippocampus. In the periphery, high levels are detected in the intestine and arteries, while much lower levels are measured in the heart. Pre-clinical experiments with SB-269970, a purportedly selective 5-HT7 antagonist, and knock-out data show convincing evidence for the involvement of 5-HT7 receptors in mood, sleep and circadian rhythm regulation (Shelton et al. "5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT7 receptor" Neuropharmacology 2009, 56 448-454). 5-HT7 receptors have also clearly been demonstrated to induce vasodilatation of blood vessels including cerebral arteries (Terron, J.A., Br J Pharmacol, 1997, 121 :563-571 "Role of 5-HT7 receptors in the long lasting hypotensive response induced by 5-hydroxytryptamine in the rat"). Vasodilatation of cerebral blood vessels is an early event in the cascade leading to migraine headaches. Therefore, inhibition of serotonin-induced vasodilatation by 5-HT7 antagonists is expected to bring pain relief in migraine. These observations led Terron to formulate an original hypothesis about the potential roles of 5-HT7 receptors in migraine (Terron, J.A., 2002, Eur. J. Pharmacol., 439:1 -1 1 "Is the 5-HT7 receptor involved in the pathogenesis and prophylactic treatment of migraine? ").

5-HT7 antagonists are expected to have efficacy in the prophylactic (and potentially acute) treatment of migraine by:

2) By inhibiting peripheral and central sensitization. Inhibition of neurogenic inflammation by SB-269970, a reference 5-HT7 receptor antagonist and by our most advanced compounds has been observed in the plasma protein extravasation (PPE) model of migraine. In this rat model of migraine, dural protein extravasation is induced by electrical stimulation of the trigeminal ganglion. 5-HT7 antagonists were as efficacious as sumatriptan and topiramate in reducing protein extravasation. Additionally, a recent study showed that SB-269970 inhibits the release of CGRP after electrical stimulation of the trigeminal ganglion (Wang et al., "Selective Inhibition of 5-HT7 Receptor Reduces CGRP Release in an Experimental Model for Migraine", Headache, 2010, 50, 579-587), lending further support to the potential efficacy of 5-HT7 antagonists in treating migraine.

Although the triptans have been shown to reduce peripheral and central sensitization as well as counteracting vasodilatation, their chronic use for prophylactic treatment is precluded by their cardiovascular side-effects, due mainly to their active vasoconstriction. 5-HT7 antagonists do not actively provoke vasoconstriction but prevent vasodilatation and should not suffer from the same limitation as the triptans during chronic administration (an internal study has shown that SB-269970 does not induce human coronary artery contraction; sumatriptan used as a comparator did). Topiramate, the current standard of care, as well as the other drugs used for prophylaxis treatment suffer from side-effects and limited efficacy. Side effects with topiramate are severe enough to provoke high drop-out rates (25-30%) in clinical trials. In addition, topiramate is not effective against acute migraine. From current pre-clinical data, selective 5-HT7 antagonists are not expected to have the side-effects seen with most of the current prophylactic drugs. We don't know at this stage if they could be more efficacious, but we anticipate that they could also be active in the acute treatment of migraine. In addition,
the pre-clinical data showing activity of 5-HT7 antagonists in depression models and in modulating sleep patterns indicate that there is a potential to treat two common migraine comorbidities.

Antagonists of 5-HT7 receptors, in particular for the treatment of migraine, have been disclosed in WO 2009/029439 and in WO 2009/048765.

It has been an objective of the present invention to provide 5-HT7 receptor antagonists, preferably selective 5-HT7 receptor antagonists. A further objective was to provide a new form for the treatment of migraine.

Summary of the invention

The invention provides new 2-oxo-piperidinyl derivatives, their preparation as well as their use in the treatment of migraine. Further aspects of the invention will become apparent from the detailed description.

Detailed description of the invention

The present invention relates to 2-oxo-piperidinyl derivatives according to formula I,

![Chemical Structure](attachment:image.png)

wherein

X is either CH or N;

Y is either -NR^4_ or -CH=CH_, however with the proviso that X shall be N when Y is -NR^4_; whereby R^4_t is either hydrogen or a C-1-4 alkyl.

n is an integer selected from 1, 2 or 3; m is 1 or 2;

R^1_t is selected from the group comprising or consisting of a substituted or unsubstituted C-1-6 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocycle, a substituted or unsubstituted C3-8 cycloalkyl; or R^1_t is a -O-R^8 moiety, whereby R^2 is selected from the group comprising or consisting of a substituted or unsubstituted C-1-8 alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl.
R\textsuperscript{3} is hydrogen, substituted or unsubstituted C-1.4 alkyl or halogen.

The present invention relates in particular to 2-oxo-piperidinyl derivatives according to formula I-A,

\[
\text{(I-A)}
\]

wherein

X is either CH or N;

n is an integer selected from 1, 2 or 3; m is 1 or 2;

R\textsuperscript{1} is selected from the group comprising or consisting of a substituted or unsubstituted C\textsubscript{1-6} alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocycle, a substituted or unsubstituted C\textsubscript{3-8} cycloalkyl; or R\textsuperscript{1} is a -O-R\textsuperscript{2} moiety, wherein R\textsuperscript{2} is selected from the group comprising or consisting of a substituted or unsubstituted C\textsubscript{1-6} alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and

R\textsuperscript{3} is hydrogen, substituted or unsubstituted C-1.4 alkyl or halogen.

In one embodiment of the formula I-A, X is CH. In a further embodiment X is N.

The present invention relates also to 2-oxo-piperidinyl derivatives according to formula I-B,

\[
\text{(I-B)}
\]

wherein

n is an integer selected from 1, 2 or 3; m is 1 or 2;
R\(^1\) is selected from the group comprising or consisting of a substituted or unsubstituted C\(_{1-6}\) alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocycle, a substituted or unsubstituted C\(_{3-8}\) cycloalkyl; or R\(^1\) is a -O-R\(^n\) moiety, wherein R2 is selected from the group comprising or consisting of a substituted or unsubstituted C\(_{1-6}\) alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and

R\(^4\) is hydrogen or C\(_{1-4}\) alkyl, preferably methyl.

In one embodiment m is 1. In a further embodiment, n is 1, in another n is 2, and in another it is 3.

In one embodiment of any of formulae I, I-A or I-B, R\(^1\) or R2 may be substituted by one, two or more halogens, or a C\(_{1-4}\) alkyl, C\(_{1-4}\) alkoxy, cyano, amido, acyl, hydroxy, or an aryl, an heteroaryl, a heterocycloalkyl, which in their turn may optionally be substituted with from 1 to 5 substituents selected from the group consisting of C\(_{1-4}\) alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, heterocycloalkyl, amino, aryl, heteroaryl, alkoxy, halogen, cyano, hydroxy, amido.

In a further specific embodiment, R\(^1\) of formulae I, I-A or I-B, is a substituted or unsubstituted C\(_{1-4}\) alkyl.

In a further specific embodiment, R\(^1\) is selected from the group comprising or consisting of a substituted or unsubstituted C\(_{1-4}\) alkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted pyridinyl, a substituted or unsubstituted pyrimidinyl, a substituted or unsubstituted thiazolyl, a substituted or unsubstituted piperidinyl, a substituted or unsubstituted tetrahydropyranyl, a substituted or unsubstituted tetrahydrofuranyl, a substituted or unsubstituted cyclohexyl; or R\(^1\) is a -O-R\(^n\) moiety.

In another specific embodiment, R\(^1\) is benzyl, 2-bromobenzyl, tert-butyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, 2-chloro-2,2-difluoroethyl, 2-oxo-2-(pyrrolidin-1-yl)ethyl, 2,2,2-trifluoroethyl, propyl, phenyl, 2-carbamoylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3,4-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-(methylcarbamoyl)phenyl, 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 2-(pyrrolidin-1-ylcarbonyl)phenyl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, cyclohexyl, 4,4-difluorocyclohexyl, pyridin-2-yl, 6-cyanopyridin-2-yl, 3-fluoropyridin-2-yl, 5-fluoropyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methylpyridin-2-yl, 6-(4-fluorophenyl)pyridin-2-yl, 6-(propan-2-yloxy)pyridin-2-yl, 6-(1H-pyrazol-1-yl)pyridin-2-yl, 6-trifluoromethylpyridin-2-yl, 6-(cyclo-
butyloxy)pyridin-2-yl, 6-(difluoromethoxy)pyridin-2-yl, 6-(2,2,2-trifluoroethoxy)pyridin-2-yl, pyridin-3-yl, 2-fluoropyridin-3-yl, pyridin-4-yl, 4-methoxypyrimidin-2-yl, 4-methyl-1,3-thiazol-2-yl, 4-methyl-1,3-thiazol-5-yl, 1-acetyl Piperidin-2-yl, tetrahydro-2H-pyran-3-yl, tetrahydro-2H-pyran-4-yl, tetrahydrofuran-2-yl; or R^1 is a -O-R^ moiety.

In one embodiment, R^2 of formulae I, I-A or I-B is selected from the group comprising or consisting of a substituted or unsubstituted C_1-4 alkyl, or a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

In another specific embodiment of formulae I, I-A or I-B, R^2 is selected from the group comprising or consisting of a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted pyridinyl; preferably a benzyl or a substituted or unsubstituted phenyl.

In a further specific embodiment of formulae I, I-A or I-B, R^2 is benzyl, phenyl, 5-bromo-2-methoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-fluorophenyl, 4-fluorophenyl, 2-methoxy-phenyl, 3-methoxyphenyl or 5-fluoropyridin-2-yl.

In one specific embodiment, R^3 is hydrogen, fluorine or trifluoromethyl.

In one specific embodiment, R^4 is methyl.

In a further specific embodiment, the present invention relates to 2-oxo-piperidinyl derivatives according to formula I-C,

\[
\begin{array}{c}
\text{N} \\
\text{R}^1 \\
\text{N-CHO} \\
\text{R}^2
\end{array}
\]

\text{(I-C)}

wherein

X is either CH or N;

R^1 is selected from the group comprising or consisting of a substituted or unsubstituted C_1-4 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyi, a substituted or unsubstituted C_3-6 cycloalkyl; or R^1 is a -O-R^ moiety, wherein R^2 is selected from the group comprising or
consisting of a substituted or unsubstituted C$_4$-alkyl aryl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; and

$R^3$ is hydrogen, substituted or unsubstituted C-1$_4$ alkyl or halogen.

In another particular embodiment, $R^1$ in compounds of formula I-C is benzyl, 2-methylpropyl, 2,2,2-trifluoroethyl, propyl, phenyl, 2-carbamoylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3,4-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-(methylcarbamoyl)phenyl, 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 2-(pyrrolidin-1-ylcarbonyl)phenyl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, cyclohexyl, 4,4-difluorocyclohexyl, pyridin-2-yl, 6-cyanopyridin-2-yl, 3-fluoropyridin-2-yl, 6-methoxypyridin-2-yl, 6-(propan-2-yloxy)pyridin-2-yl, 6-(1H-pyrazol-1-yl)pyridin-2-yl, 6-trifluoromethylpyridin-2-yl, 6-(cyclobutyloxy)pyridin-2-yl, 6-(difluoromethoxy)pyridin-2-yl, pyridin-4-yl, 4-methoxypyrimidin-2-yl, 4-methyl-1,3-thiazol-2-yl, 4-methyl-1,3-thiazol-5-yl; or $R^1$ is a group of formula -OR^2 wherein $R^2$ is 4-cyanophenyl.

In a preferred embodiment, $R^1$ in compounds of formula I-C is phenyl, 2-carbamoylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyanophenyl, 3,4-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 2-(trifluoromethyl)phenyl, cyclohexyl, 6-cyanopyridin-2-yl, 3-fluoropyridin-2-yl, 6-methoxypyridin-2-yl, 6-(propan-2-yloxy)pyridin-2-yl, 6-(cyclobutyloxy)pyridin-2-yl, 6-(difluoromethoxy)pyridin-2-yl, 6-(2,2,2-trifluoroethoxy)pyridin-2-yl, 6-(cyclobutyloxy)pyridin-2-yl, 6-(difluoromethoxy)pyridin-2-yl, pyridin-4-yl, 4-methoxypyrimidin-2-yl, 4-methyl-1,3-thiazol-2-yl, 4-methyl-1,3-thiazol-5-yl.

In another preferred embodiment, $R^1$ in compounds of formula I-C is phenyl, 2-carbamoylphenyl, 2-fluorophenyl, 4-fluorophenyl, 2-hydroxyphenyl, cyclohexyl, 6-methoxypyridin-2-yl, 6-(propan-2-yloxy)pyridin-2-yl or 6-(cyclobutyloxy)pyridin-2-yl.

In a preferred embodiment, $R^3$ in compounds of formula I-C is hydrogen, fluorine or trifluoromethyl. More preferably $R^3$ in compounds of formula I-C is hydrogen or trifluoromethyl, most preferably hydrogen.

In still a further specific embodiment, the present invention relates to 2-oxo-piperidinyl derivatives according to formula I-D,
wherein

X is either CH or N;

R¹ is selected from the group comprising or consisting of a substituted or unsubstituted C₁-₄ alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted C₃-₆ cycloalkyl; or R¹ is a -O-R² moiety, wherein R² is selected from the group comprising or consisting of a substituted or unsubstituted C₁-₄ alkyl aryl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

In another particular embodiment, R¹ in compounds of formula I-D is benzyl, 2-bromobenzyl, 3-cyanophenyl, 2-fluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl; or R¹ is a group of formula -OR² wherein R² is phenyl, 5-bromo-2-methoxyphenyl, 2-cyanophenyl, 2-fluorophenyl or 4-fluorophenyl.

In a preferred embodiment, R¹ in compounds of formula I-D is 2-bromobenzyl, 2-methoxyphenyl; or R¹ is a group of formula -OR² wherein R² is 5-bromo-2-methoxyphenyl or 4-fluorophenyl.

In another preferred embodiment, R¹ in compounds of formula I-D is 2-bromobenzyl or a group of formula -OR² wherein R² is 5-bromo-2-methoxyphenyl.

In still another particular embodiment, the present invention relates to 2-oxo-piperidinyl derivatives according to formula I-E,

wherein

X is either CH or N;
R¹ is selected from the group comprising or consisting of a substituted or unsubstituted C₄ alkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted pyridinyl, a substituted or unsubstituted pyrimidinyl, a substituted or unsubstituted thiazolyl, a substituted or unsubstituted piperidinyl, a substituted or unsubstituted tetrahydropyranyl, a substituted or unsubstituted tetrahydrofuranyl, a substituted or unsubstituted cyclohexyl; or R¹ is a -O-R² moiety, wherein R² is a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted pyridinyl; preferably a benzyl or a substituted or unsubstituted phenyl.

In another particular embodiment, R¹ in compounds of formula I-E is phenyl, 2-carbamoylphenyl, 4-cyanophenyl or 2-methoxyphenyl, preferably 2-methoxyphenyl.

Also comprised are tautomers, geometrical isomers, enantiomers, diastereomers and mixtures, or a pharmaceutically acceptable salt of compounds of formula I, I-A, I-B, I-C, I-D and I-E, as well as any deuterated variant, at any position. Any moiety "H" in formula I, I-A, I-B, I-C, I-D and I-E may be the isotope hyrdogen, deuterium or tritium.

Specific compounds of the present invention are those selected from the group consisting of:

(+)-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate;
N-methyl-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzamide oxalate;
1-[2-(2-{3-[2-(trifluoromethyl)phenyl]pyrrolidin-1-yl}ethyl]phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(2-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(3-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(4-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(2-fluorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(2-chlorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-[2-(2-{3-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]pyrrolidin-1-yl}ethyl]phenyl)piperidin-2-one;
(+)-2-(1-[(2-(2-oxopiperidin-1-yl)phenyl)ethyl]pyrrolidin-3-yl)benzonitrile oxalate;  
(-)-2-(1-[(2-(2-oxopiperidin-1-yl)phenyl)ethyl]pyrrolidin-3-yl)benzonitrile oxalate;  
1-[(2-(3-phenylpyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one;  
3-[(2-(2-oxopiperidin-1-yl)phenyl)ethyl]pyrrolidin-3-yl)benzonitrile oxalate;  
4-[(2-(2-oxopiperidin-1-yl)phenyl)ethyl]pyrrolidin-3-yl)benzonitrile oxalate;  
(-)-1-[(2-(3-[2-(pyrrolidin-1-ylcarbonyl)phenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one;  
1-[(2-(3-[2-methoxyphenyl]piperidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
(+)-1-[(2-(3-[2-methoxyphenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
(-)-1-[(2-(3-[2-methoxyphenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-[3-(fluorophenyl)pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-[3-methoxyphenyl]piperidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-phenylpiperidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-[4-chlorophenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-[4-chlorophenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-(benzyloxy)pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-[4-fluorophenyl]azetidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
3-[(2-(2-oxopiperidin-1-yl)phenyl)ethyl]azetidin-3-yl)benzonitrile oxalate;  
1-[(2-(3-[2-fluorophenyl]azetidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;  
1-[(2-(3-cyclohexylpyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;
1-(2-{3-(2-hydroxyphenyl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(pyridin-2-yl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one dioxalate;  
1-(2-{3-(4-fluorophenyl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(3-methoxyphenyl)azetidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(2-methoxyphenoxy)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(benzyldiazetidin-1-yl)ethyl}phenyl)piperidin-2-one;  
1-(2-{3-(3-methoxyphenyl)azetidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(benzylpyrrolidin-1-yl)ethyl}phenyl)piperidin-2-one oxalate;  
1-(2-{3-(2-methoxyphenoxy)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
4-[(1-{2-(2-oxopiperidin-1-yl)ethyl}pyrrolidin-3-yl)oxy]benzonitrile;  
1-(2-{3-(2-hydroxyphenyl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one;  
1-(2-{3-(3-fluorophenyl)azetidin-1-yl}ethyl)phenyl)piperidin-2-one oxalate;  
1-(2-{3-(4,4-difluorocyclohexyl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one trifluoroacetate;  
1-{2-[2-(3-benzylpyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one;  
1-{2-[2-(3-benzylpyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one;  
1-(2-{3-(4,4-difluorocyclohexyl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one trifluoroacetate;  
4-[(1-{2-[2-(2-oxopiperidin-1-yl)ethyl]azetidin-3-yl}oxy]benzonitrile oxalate;
1-(2-{3-(2-methylpropyl)pyrrolidin-1-yl}ethyl)phenyl)piperidin-2-one trifluoroacetate;
1-2-[2-(3-propylpyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one trifluoroacetate;
3-[(1-2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)azetidin-3-yl]oxy]benzonitrile;
2-[(1-2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)azetidin-3-yl]oxy]benzonitrile;
1-(2-[3-(4-fluorophenoxy)azetidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(3-methoxyphenoxy)azetidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(2-bromobenzyl)azetidin-1-yl]ethyl)phenyl)piperidin-2-one;
4-(1-[2-[2-(2-oxopiperidin-1-yl)pyridin-3-yl]ethyl]pyrrolidin-3-yl]benzonitrile;
1-(2-[3-(4-methyl-1,3-thiazol-5-yl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(5-bromo-2-methoxyphenoxy)azetidin-1-yl]ethyl)benzonitrile oxalate;
1-[2-(3-phenoxyazetidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;
1-[2-(3-tert-butylpyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one;
1-(2-[3-(2-methoxyphenoxy)azetidin-1-yl]ethyl)phenyl)piperidin-2-one oxalate;
1-(2-[3-(2-chloro-2,2-difluoroethyl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(3-[2-(pyridin-2-yl]pyrrolidin-1-yl]ethyl)pyrrolidin-2-one;
1-(3-[2-(pyridin-2-yl]pyrrolidin-1-yl]ethyl)pyrrolidin-2-one oxalate;
1-(2-[3-(1-acetyl)piperidin-2-yl]pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(pyridin-4-yl]pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(2-fluoropyridin-3-yl]pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(tetrahydrofuran-2-yl]pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one;
1-(2-[3-(tetrahydrofuran-2-yl]pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one oxalate;
(+)-1-(2-[3-(tetrahydro-2H-pyran-4-yl]pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one trifluoroacetate;
(+)-1-(2-{2-[3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;

1-(3-{2-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;

1-(3-{2-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one trifluoroacetate;

1-(2-{2-[3-(tetrahydro-2H-pyran-3-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;

1-(2-{2-[3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;

1-(2-{2-[3-(5-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;

1-(2-{2-[3-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;

1-(2-{2-[3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;

1-(2-[(2-{3-[6-(propan-2-yloxy)pyridin-2-yl]pyrrolidin-1-yl}ethyl)pyridin-2-yl]piperidin-2-one oxalate;

(+)1-(3-2-[(3,4-difluorocyclohexyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;

(-)-1-(3-2-[(3,4-difluorocyclohexyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;

1-(3-2-[(3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;

1-(3-2-[(3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;

1-(3-2-[(3-6-(propan-2-yloxy)pyridin-2-yl]pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;
1-(3-{2-[3-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one oxalate;  
6-(1-{2-[2-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]ethyl}pyrrolidin-3-yl)pyridine-2-carbonitrile oxalate;  
1-(3-{2-[3-(fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one oxalate;  
1-[3-(2-{3-[6-(trifluoromethyl)pyridin-2-yl]pyrrolidin-1-yl}ethyl)pyrrolidin-2-yl]piperidin-2-one;  
1-[3-(2-{3-[4-fluorophenoxy]azetidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one oxalate;  
1-(3-{2-[3-(2-fluorophenoxy)azetidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one oxalate;  
(-)-1-(3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one oxalate;  
1-(3-{2-[3-(6-methylpyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one;  
1-[3-(2-{3-[6-(1H-pyrazol-1-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl]piperidin-2-one oxalate;  
1-(3-{2-[3-(4-methoxypyrimidin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one;  
1-[3-{2-[3-(4-fluorophenyl)pyrrolidin-2-yl]pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl]piperidin-2-one oxalate;  
1-[3-{2-[3-(2,2,2-trifluoroethoxy)pyrrolidin-2-yl]pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl]piperidin-2-one;  
1-[3-{2-[3-(difluoromethoxy)pyrrolidin-2-yl]pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl]piperidin-2-one;  
1-[3-{3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}-5-(trifluoromethyl)pyridin-2-one;  
1-{3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one;  
1-(5-fluoro-3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one, as a mixture of (+)-1-(5-fluoro-3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one;  
1-(3-{2-[3-(3R)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one.
2-one and (-)-1-(5-fluoro-3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one.

The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.

"C₁₅ alkyl" or "C₄ alkyl" refers to a group which represents saturated, monovalent hydrocarbon radicals having straight (unbranched) or branched moieties or combinations thereof, and containing 1 to 6 carbon atoms, or 1 to 4 carbon atoms. Examples of C₁₅ alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, ie/f-butyl. "C₁₅ alkyl" or "C₄ alkyl" groups may be substituted by one or more substituents selected from halogen, amido, aryl or alkoxy. Particular alkyl groups according to the present invention are methyl, difluoromethyl, trifluoromethyl, 2-chloro-2,2-difluoroethyl, 2,2,2-trifluoroethyl, propyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, tert-butyl, 2-oxo-2-(pyrrolidin-1-yl)ethyl, benzyl and 2-bromobenzyl.

"Alkoxy" refers to the group -O-R where R includes "C₄ alkyl". Examples of alkoxy groups according to the present invention are methoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, propan-2-yloxy, and cyclobutoxy.

"C₃₋₈ cycloalkyl" refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl). Cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of aryl groups according to the present invention are cyclobutyl, cyclohexyl, and 4,4-difluorocyclohexyl.

"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl). The "aryl" groups may be unsubstituted or substituted by 1 to 3 substituents independently selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, cyano, amido, hydroxy or heterocycle. Aryl include phenyl and the like. Examples of aryl groups according to the present invention are phenyl, 2-bromophenyl, 5-bromo-2-methoxyphenyl, 2-carbamoylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3,4-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-(methylcarbamoyl)phenyl, 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 2-(pyrrolidin-1-ylcarbonyl)phenyl, 2-(trifluoromethyl)phenyl, and 3-(trifluoromethyl)phenyl.
C\textsubscript{1-4}-alkyl aryl refers to a C\textsubscript{1-4} alkyl having an aryl substituent as defined hereabove. Examples of C\textsubscript{1-4}-alkyl aryl groups according to the present invention are benzyl and 2-bromobenzyl.

"Heterocycle" refers to a saturated or unsaturated ring system containing, in addition to carbon atoms, at least one hetero atom, such as nitrogen, oxygen and/or sulfur. "Heterocycle" includes both "heteroaryl" and "heterocycloalkyl".

"Heteroaryl" refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrimidinyl, pyrrolyl, furyl, thienc, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothiophenyl, isobenzothiophenyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyi, quinazolinyi, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, pyrido[3,4-b]pyridyl, pyrido[2,3-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazyly, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzocinolyl, imidazopyrimidine, imidazopyridazine, imidazothiazole, imidazothiadiazole, preferably pyridyl, pyrimidylyi, oxazolyl, thiazolyl, pyrazolyl and 1,2,4-oxadiazolyl. Examples of heteroaryl groups according to the present invention are pyridin-2-yl, 1-acetylpiperidin-2-yl, 3-fluoropyridin-2-yl, 5-fluoropyridin-2-yl, 6-cyanopyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl, 6-methylpyridin-2-yl, 6-methoxypyridin-2-yl, 6-(propan-2-yl)pyridin-2-yl, 6-(4-fluorophenyl)pyridin-2-yl, 6-(cyclobutoxy)pyridin-2-yl, 6-(difluoromethoxy)pyridin-2-yl, 6-(2,2,2-trifluoroethoxy)pyridin-2-yl, 6-(1H-pyrazol-1-yl)pyridin-2-yl, pyridin-3-yl, 2-fluoropyridin-3-yl, pyridin-4-yl, 3-methyl-1,2,4-oxadiazol-5-yl, 4-methyl-1,3-thiazol-2-yl, 4-methyl-1,3-thiazol-5-yl, 1H-pyrazol-1-yl, and 4-methoxypyrimidin-2-yl.

"Heterocycloalkyl" refers to a C\textsubscript{3-9} cycloalkyl group according to the definition above, in which 1 to 3 carbon atoms are replaced by hetero atoms chosen from the group consisting of O, S, NR, R being defined as hydrogen, acyl or C\textsubscript{1-9} alkyl. Preferred heterocycloalkyl include pyrrolidinyl, piperidinyl, piperazinyli, 1-acetylpiperazinyl, 1-methylpiperazinyl, morpholinyl, tetrahydropranylyi, tetrahydrofuranylyi, and the like. Examples of heterocycloalkyl groups according to the present invention are pyrrolidin-1-yl, tetrahydro-2H-pyran-4-yl, tetrahydro-2H-pyran-3-yl and tetrahydrofuran-2-yl.
"C2-6 alkenyl" refers to alkenyl groups preferably having from 2 to 6 carbon atoms and having at least 1 or 2 sites of alkenyl unsaturation. Preferable alkenyl groups include ethenyl (vinyl, -CH=CH2), n-2-propenyl (allyl, -CH2CH=CH2) and the like.

"C2-6 alkynyl" refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having at least 1-2 sites of alkynyl unsaturation, preferred alkynyl groups include ethynyl (-C≡CH), propargyl (-CH2C≡CH), and the like.

"Amido" refers to the group -C(=0)NRR' where each R, R' is independently hydrogen, "C-i-6 alkyl", "C2-6 alkenyl", "C2-6 alkynyl", "C3.8 cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring. Examples of amido groups according to the present invention are carbamoyl, methylcarbamoyl and pyrrolidin-1-ylcarbonyl.

"Amino" refers to the group -NRR' where each R, R' is independently hydrogen, "C-1.4 alkyl", "C2-6 alkenyl", "C2-6 alkynyl", "C3.8 cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring.

"Halogen" refers to fluoro, chloro, bromo and iodo atoms.

"Cyano" refers to -CN.

"Acyl" refers to the group -C(=0)R where R is "C-1.4 alkyl", "C2-6 alkenyl", "C2-6 alkynyl", "C3.8 cycloalkyl", "heterocycloalkyl", "aryl" or "heteroaryl". Example of acyl group according to the present invention is acetyl.

"Substituted or unsubstituted" : Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like "alkyl", "alkenyl", "alkynyl", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from 1 to 5 substituents selected from the group consisting of "C-1.4 alkyl" or "C-1.4 alkyl", "C2-6 alkenyl", "C2-6 alkynyl", "cycloalkyl", "heterocycloalkyl", "amino", "aryl", "heteroaryl", "alkoxy", "halogen", cyano, hydroxy, mercapto, nitro, "amido", "acyl", and the like.

The "pharmacologically acceptable salts" according to the invention include therapeutically active, non-toxic acid or base salt forms which the compounds of formula I are able to form.

The acid addition salt form of a compound of formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an
inorganic acid, for example, a hydrohalic such as hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like; or an organic acid, such as, for example, acetic, trifluoroacetic, oxalic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like.

The compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine salts, by treatment with appropriate organic and inorganic bases. Appropriate base salt forms include, for example, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.

Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid.

Compounds of the formula I and their salts can be in the form of a solvate, which is included within the scope of the present invention. Such solvates include for example hydrates, alcoholates and the like.

Compounds of formula I and some of their intermediates may have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem., 45 (1976) 11-30.

The invention also relates to all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers).

With respect to the present invention reference to a compound or compounds is intended to encompass that compound in each of its possible isomeric forms and mixtures thereof, unless the particular isomeric form is referred to specifically.

The expression "enantiomerically pure" as used herein refers to compounds which have enantiomeric excess (ee) greater than 95%.

Compounds according to the present invention may exist in different polymorphic forms. Although not explicitly indicated in the above formula, such forms are intended to be included within the scope of the present invention.
In one embodiment, the compounds of formula (I) show a good affinity for the 5-HT7 receptor. Such property may be determined with methods known to a person skilled in the art, including the one set out in example 20.

In one embodiment of the present invention, the compounds of formula (I) are antagonists of 5-HT7, i.e. they inhibit the activity of 5-HT7 agonists. Such property may be determined with methods known to a person skilled in the art, including the one set out in example 21.

In further embodiment of the present invention, some compounds of formula (I) have a high selectivity ratio ranging from 10 to 1000 or more for 5-HT7 receptors compared to other serotonin receptor subtypes.

The compounds of formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.

According to one embodiment, some compounds of general formula (I) may be prepared by reaction of an amine of formula II (or a corresponding salt) with an aldehyde of formula III according to the equation:

\[
\text{(II)} + \text{(III)} \rightarrow \text{(I)}
\]

wherein X, Y, m, n, R1 and R3 have the same definitions as defined above for compounds of formula I.

This reductive amination may be carried out in an alcohol such as methanol, in the presence of an acid such as acetic acid and of a mild reducing agent such as sodium cyanoborohydride, at a temperature comprise between 0°C and room temperature, or according to any other method known to the person skilled in the art.

According to another embodiment, some compounds of formula I-A wherein X is C, R3 is hydrogen, m=1 and n=2 or 3 may be prepared by reaction of an amine of formula II (or a corresponding salt) with an alkylating agent such as a tosylate of formula IV according to the equation:
wherein $X$ is C, $m=1$, $n=2$ or 3, $R^3$ is hydrogen and $R^1$ has the same definition as defined above for compounds of formula I.

This reaction may be performed in an inert solvent, for example acetonitrile, in the presence of a base such as K2CO3 and at reflux temperature, or according to any method known to the person skilled in the art.

Alternatively, some compounds of formula I-A wherein $X$ is C, $m=1$, $n=2$, $R^3$ is hydrogen and $R^1$ is heteroaryl, may be prepared by reaction of a vinyl aromatic of formula V with a compound of formula VI according to the equation:

\[
\begin{align*}
\text{(V)} & \quad + \quad \text{(VI)} \\
\text{R}^1 & \quad \text{N} \quad \text{O} \quad \text{Si} \\
\text{(I-A)} & \quad \text{R}^1 \quad \text{N} \quad \text{O} \\
\end{align*}
\]

wherein $X$ is C, $m=1$, $n=2$, $R^3$ is hydrogen and $R^1$ is heteroaryl.

This reaction may be performed in a polar solvent such as dichloromethane, in the presence of a Bronstedt acid such as trifluoroacetic acid, at room temperature, or according to any method known to the person skilled in the art.

Alternatively, some compounds of formula I-A wherein $X$ is N, $m=1$, $n=2$, $R^3$ is substituted or unsubstituted C-1-4 alkyl or halogen and $R^1$ has the same definition as defined above for compounds of formula I-A, may be prepared by hydroamination of a vinyl heteroaromatic of formula VII with an amine of formula II according to the equation:

\[
\begin{align*}
\text{(VII)} & \quad + \quad \text{amine (II)} \\
\text{R}^1 & \quad \text{N} \quad \text{O} \quad \text{Si} \\
\text{R}^1 & \quad \text{N} \quad \text{O} \\
\text{(I-A)} & \quad \text{R}^1 \quad \text{N} \quad \text{O} \\
\end{align*}
\]
wherein X is N, m=1, n=2, R^3 is substituted or unsubstituted C-1,4 alkyl or halogen and R^1 has the same definition as defined above for compounds of formula I-A.

This reaction may be performed in a polar solvent such as ethanol, in the presence of a Bronstedt base such as triethylamine, at reflux, or according to any method known to the person skilled in the art.

Alternatively, some compounds having the general formula I may be prepared by functional group conversion on already assembled analogs of compounds having the general formula I, using procedures described in the literature or known to the person skilled in the art.

Amines of formula II wherein m=1, n=2 and R^1 is heteroaryl may be prepared by reaction of a heteroaromatic vinyl of formula V with a compound of formula VIII, followed by deprotection of the obtained compound of formula IX according to the equation:

wherein m=1, n=2, R^1 is heteroaryl and PG represents a protecting group such as benzyl or allyl. This reaction may be performed in a polar solvent such as dichloromethane, in the presence of a Bronstedt acid such as trifluoroacetic acid, at room temperature, or according to any method known to the person skilled in the art.

The subsequent deprotection of compound of formula IX may be performed using procedures described in the literature such as palladium based deprotection (when PG is an allyl), hydrogenolysis using ammonium acetate as hydrogen source (when PG is a benzyl), or according to any other method known to the person skilled in the art.
Alternatively amines of formula II wherein \( m=1 \), \( n=2 \) and \( R^1 \) is substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl may be prepared by reduction of the corresponding pyrrolidones of formula X according to the equation:

![Chemical Structure](image)

\[
\text{(X)} \xrightarrow{\text{Reduction}} \text{(II)}
\]

This reaction may be performed in THF, in the presence of UA\(\text{H}_4\), at reflux temperature, or according to any method known to the person skilled in the art.

Alternatively, some amines of formula II wherein \( m \) is 1 and \( n \) is 1, 2 or 3 may be prepared by functional group transformation(s) on commercially available pyrrolidines or pyrrolin-3-ones (when \( n=2 \)) or commercially available azetidines (when \( n=1 \)) or commercially available piperidines (when \( n=3 \)) using procedures described in the literature or known to the person skilled in the art.

Alternatively, some amines of formula II wherein \( m=1 \) and \( n=3 \) may be prepared by hydrogenation of the corresponding substituted pyridines using procedures described in the literature or known to the person skilled in the art.

The synthesis of aldehydes of formula III can be performed using procedures described in the literature such as Dess Martin periodinane oxidation of the corresponding alcohol of formula XI (Dess, D. B., Martin, J. C., J. Org. Chem. 1983, 48, 4155-4156), or hydrolysis of an enol ether of formula XII, or according to any other method known to the person skilled in the art.

![Chemical Structure](image)

Tosylate of formula IV may be prepared from the corresponding alcohol of formula XI wherein \( X \) is C according to any method known to the person skilled in the art.

The synthesis of compounds of formula V can be performed using procedures described in the literature such as heteroaromatic aldehyde olefination or
heteroaromatic halide cross coupling, or according to any other method known to the
person skilled in the art.

Compound of formula VI may be prepared by reaction of a tosylate of formula IV with 1-
(trimethylsilyl)methanamine in an inert solvent such as acetonitrile, in the presence of a
base such as K2CO3 and at reflux temperature followed by treatment with a mixture of
aqueous formaldehyde and methanol in the presence of K2CO3 at 0°C, or according to
any method known to the person skilled in the art.

Vinyl heteroaromatic compound of formula VII may be prepared by cross coupling
reaction between vinylboronic acid pinacol ester and the corresponding heteroaromatic
halide of formula XIII wherein Hal is bromide, chloride or iodide, or according to any
method known to the person skilled in the art.

Compound of formula VIII wherein PG is allyl may be prepared according to the method
described in PCT patent application WO2009/087058 or according to any other
method known to the person skilled in the art.

The synthesis of compounds of formula X can be performed using procedures
described in the literature or known to the person skilled in the art.

Alcohol of formula XI may be prepared according to any conventional method known to
the person skilled in the art.

Some enol ether of formula XII may be preformed via a Wittig type reaction on
aldehyde of formula XIV or according to any other method known to the person skilled
in the art.
Some enol ether of formula XII may be preformed via a lactamisation of the corresponding aromatic amine of formula XV, or according to any other method known to the person skilled in the art.

![Structure of formula XV](image)

In another embodiment, the present invention includes the synthesis of the following intermediates:
- tert-butyl 3-[2-(methoxycarbonyl)phenyl]pyrrolidine-1-carboxylate;
- tert-butyl 3-(2-carbamoylphenyl)pyrrolidine-1-carboxylate;
- tert-butyl 3-(2-carbamoylphenyl)pyrrolidine-1-carboxylate, enantiomer 1;
- tert-butyl 3-(2-carbamoylphenyl)pyrrolidine-1-carboxylate, enantiomer 2;
- 2-(pyrrolidin-3-yl)benzamide, enantiomer 1;
- 2-(pyrrolidin-3-yl)benzamide, enantiomer 2;
- (3R)-3-(2,2,2-trifluoroethyl)pyrrolidine;
- (3S)-3-(2,2,2-trifluoroethyl)pyrrolidine;
- 3-(2-chloro-2,2-difluoroethyl)pyrrolidine;
- methyl 3-(4,4-difluorocyclohexyl)prop-2-enoate;
- methyl 3-(tetrahydro-2H-pyran-4-yl)prop-2-enoate;
- methyl 3-(tetrahydrofuran-2-yl)prop-2-enoate;
- methyl 3-(tetrahydro-2H-pyran-3-yl)prop-2-enoate;
- methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate;
- methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate enantiomer 1;
methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate enantiomer 2;
methyl 4-nitro-3-(tetrahydro-2H-pyran-4-yl)butanoate;
methyl 4-nitro-3-(tetrahydrofuran-2-yl)butanoate;
methyl 4-nitro-3-(tetrahydro-2H-pyran-3-yl)butanoate;
4-(4,4-difluorocyclohexyl)pyrrolidin-2-one;
4-(4,4-difluorocyclohexyl)pyrrolidin-2-one enantiomer 1;
4-(4,4-difluorocyclohexyl)pyrrolidin-2-one enantiomer 2;
4-(tetrahydro-2H-pyran-4-yl)pyrrolidin-2-one;
4-(tetrahydro-2H-pyran-4-yl)pyrrolidin-2-one enantiomer 1;
4-(tetrahydro-2H-pyran-4-yl)pyrrolidin-2-one enantiomer 2;
4-(tetrahydrofuran-2-yl)pyrrolidin-2-one;
4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-2-one;
3-(4,4-difluorocyclohexyl)pyrrolidine;
3-(4,4-difluorocyclohexyl)pyrrolidine enantiomer 1;
3-(4,4-difluorocyclohexyl)pyrrolidine enantiomer 2;
3-(tetrahydro-2H-pyran-4-yl)pyrrolidine enantiomer 1;
3-(tetrahydro-2H-pyran-4-yl)pyrrolidine enantiomer 2;
3-(tetrahydrofuran-2-yl)pyrrolidine;
3-(tetrahydro-2H-pyran-3-yl)pyrrolidine;
tert-butyl 3-(3-cyanophenoxy)azetidine-1-carboxylate;
tert-butyl 3-(5-bromo-2-methoxyphenoxy)azetidine-1-carboxylate;
3-(5-bromo-2-methoxyphenoxy)azetidine;
tert-butyl 3-[(5-fluoropyridin-2-yl)oxy]azetidine-1-carboxylate;
2-(azetidin-3-yloxy)-5-fluoropyridine;
2-ethenyl-6-(propan-2-yloxy)pyridine;
2-ethenyl-6-(1 H-pyrazol-1-yl)pyridine;
2-methoxy-6-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyridine;
4-methoxy-2-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyrimidine;
2-(propan-2-yloxy)-6-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyridine;
2-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]-6-(1 H-pyrazol-1-yl)pyridine;
4-methoxy-2-(pyrrolidin-3-yl)pyrimidine;
2-(propan-2-yloxy)-6-(pyrrolidin-3-yl)pyridine;
2-(1 H-pyrazol-1-yl)-6-(pyrrolidin-3-yl)pyridine;
2-(1-benzylpyrrolidin-3-yl)pyridine enantiomer 1;
2-(1-benzylpyrrolidin-3-yl)pyridine enantiomer 2;
2-(pyrrolidin-3-yl)pyridine enantiomer 1 dihydrochloride;
2-(pyrrolidin-3-yl)pyridine enantiomer 2 dihydrochloride;
4-(pyrrolidin-3-yl)benzonitrile enantiomer 2;
4-(pyrrolidin-3-yl)benzonitrile enantiomer 1;
2-(cyclobutyloxy)-6-(pyrrolidin-3-yl)pyridine;5-bromo-N-[2-(2-hydroxyethyl)phenyl]pentanamide;
1-[2-(2-hydroxyethyl)phenyl]piperidin-2-one;
2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl 4-methylbenzenesulfonate;
[2-(2-oxopiperidin-1-yl)phenyl]acetaldehyde;
2-(2-oxopiperidin-1-yl)pyridine-3-carbaldehyde;
1-[3-(2-methoxyethenyl)pyridin-2-yl]piperidin-2-one;
[2-(2-oxopiperidin-1-yl)pyridin-3-yl]acetaldehyde;
1-[2-(2-[(trimethylsilyl)methyl]amino)ethyl]piperidin-2-one;
1-[2-(2-{(methoxymethyl)[(trimethylsilyl)methyl]amino}ethyl)phenyl]piperidin-2-one;
3-ethenyl-2-fluoropyridine;
2-ethenyl-3-fluoropyridine;
methyl 2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzoate;
methyl 2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzoate;
methyl 2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzoate enantiomer 1;
methyl 2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzoate enantiomer 2;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzoic acid;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzoic acid;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzoic acid enantiomer 1;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzoic acid enantiomer 2;
1-{2-[2-(3-hydroxypropyl)pyrrolidin-3-yl]ethyl}phenyl)piperidin-2-one;
1-{2-[2-(3-hydroxypropyl)pyrrolidin-3-yl]ethyl}phenyl)piperidin-2-one methyl methanesulfonate;
1-{2-[2-(3-hydroxypropyl)pyrrolidin-3-yl]ethyl}phenyl)piperidin-2-one; 
1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl methanesulfonate;
1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl methanesulfonate;
1-(2-{2-[3-(2-oxopiperidin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;
methyl (1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)acetate;
1-(2-{2-[3-(2-hydroxy-2-methylpropyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;
(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)acetic acid;
1-(3-{2-[3-(6-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one;
The compounds of the present invention are for use as a medicament, in the acute or prophylactic treatment of migraine.

The methods of the invention comprise administration to a mammal (preferably a human) suffering from migraine of a compound according to the invention in an amount sufficient to alleviate or prevent the disorder or condition.

The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 0.1 to 2000 mg, preferably 0.1 to 1000 mg, more preferably 0.1 to 500 mg of active ingredient per unit dosage form.

The term “treatment” as used herein includes curative treatment and prophylactic treatment.

By “prophylactic” is meant prevention of the occurrence or recurrence of a disorder or condition.

A further aspect of the present invention relates to a pharmaceutical composition comprising an effective amount of a compound of formula I in combination with a pharmaceutically acceptable diluent or carrier.

For treating diseases, compounds of formula I or their pharmaceutically acceptable salts may be employed at an effective daily dosage and administered in the form of a pharmaceutical composition.
Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.

To prepare a pharmaceutical composition according to the invention, one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to the skilled practitioner.

Suitable diluents and carriers may take a wide variety of forms depending on the desired route of administration, e.g., oral, rectal, parenteral or intranasal.

Pharmaceutical compositions comprising compounds according to the invention can, for example, be administered orally, parenterally, i.e., intravenously, intramuscularly or subcutaneously, intrathecally, transdermal^ (patch), by inhalation or intranasally.

Pharmaceutical compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatin capsules, solutions, syrups, chewing-gums and the like.

To this end the active ingredient may be mixed with an inert diluent or a non-toxic pharmaceutically acceptable carrier such as starch or lactose. Optionally, these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as peppermint or methyl salicylate.

The invention also contemplates compositions which can release the active substance in a controlled manner.

Pharmaceutical compositions which can be used for parenteral administration are in conventional form such as aqueous or oily solutions or suspensions generally contained in ampoules, disposable syringes, glass or plastics vials or infusion containers.

In addition to the active ingredient, these solutions or suspensions can optionally also contain a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents,
antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetic acid, buffers such as acetates, citrates or phosphates and agents for adjusting the osmolarity, such as sodium chloride or dextrose.

These pharmaceutical forms are prepared using methods which are routinely used by pharmacists.

The amount of active ingredient in the pharmaceutical compositions can fall within a wide range of concentrations and depends on a variety of factors such as the patient's sex, age, weight and medical condition, as well as on the method of administration. Thus the quantity of compound of formula I in compositions for oral administration is at least 0.5 % by weight and can be up to 80 % by weight with respect to the total weight of the composition.

For oral compositions, the daily dosage is in the range 0.1 mg to 2000 mg of compounds of formula I. For oral compositions the dosage unit is in the range 0.1 mg to 1000 mg of compounds of formula I, preferably 0.1 mg to 500 mg.

In compositions for parenteral administration, the quantity of compound of formula I present is at least 0.5 % by weight and can be up to 33 % by weight with respect to the total weight of the composition. For the preferred parenteral compositions, the dosage unit is in the range 0.1 mg to 2000 mg of compounds of formula I.

The daily dose can fall within a wide range of dosage units of compound of formula I and is generally in the range 0.1 to 2000 mg, preferably 0.1 to 1000 mg. However, it should be understood that the specific doses can be adapted to particular cases depending on the individual requirements, at the physician's discretion.

EXAMPLES

The following examples illustrate how the compounds covered by formula (I) may be synthesized. They are provided for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that routine variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention.

NMR spectra are recorded on a BRUKER AVANCE 400 NMR Spectrometer fitted with a Linux workstation running XWIN NMR 3.5 software and a 5 mm inverse $^1$H/$^2$H probehead, or BRUKER DRX 400 NMR fitted with a SG Fuel running XWIN NMR 2.6.
software and a 5 mm inverse geometry $^1H^{13}C^{19}F$ triple probehead. The compound is studied in dg-dimethylsulfoxide (or d3-chloroform) solution at a probe temperature of 300 K and at a concentration of 10 mg/ml. The instrument is locked on the deuterium signal of dg-dimethylsulfoxide (or d3-chloroform). Chemical shifts are given in ppm downfield from TMS (tetramethylsilane) taken as internal standard.

HPLC analyses are performed using an Agilent 1100 series HPLC system mounted with a Waters XBridge MS C18, 5 µm, 150 X 4.6 mm column. The gradient runs from 100% solvent A (water/acetonitrile/ammonium formate solution 85/5/10 (v/v/v)) to 100% solvent B (water/acetonitrile/ammonium formate solution 5/85/10 (v/v/v)) in 6 minutes with a hold at 100% B of 5 minutes. The flow rate is set at 1.8 ml/min during 6 minutes then increased at 2.3 ml/min during 2 minutes with a hold at 2.3 ml/min during 3 minutes. A split of 1/25 is used just before API source. The chromatography is carried out at 45°C. The ammonium formate solution (pH~8.5) is prepared by dissolution of ammonium formate (630 mg) in water (1 l) and addition of ammonium hydroxide 30% (500 µl).

Mass spectrometric measurements in LC/MS mode are performed as follows:

**HPLC conditions**

- For basic elution, analyses are performed using:

  • a WATERS Alliance HPLC system with diode array detector mounted with a WATERS XBridge MS C18, 5 µm, 150 x 4.6 mm column. The gradient runs from 100% solvent A (water/acetonitrile/ammonium formate solution 85/5/10 (v/v/v)) to 100% solvent B (water/acetonitrile/ammonium formate solution 5/85/10 (v/v/v)) in 6 minutes with a hold at 100% B of 5 minutes. The flow rate is set at 1.8 ml/min during 6 minutes then increased at 2.3 ml/min during 2 minutes with a hold at 2.3 ml/min during 3 minutes. A split of 1/25 is used just before API source. The chromatography is carried out at 45°C. The ammonium formate solution (pH~8.5) is prepared by dissolution of ammonium formate (630 mg) in water (1 l) and addition of ammonium hydroxide 30% (500 µl).

  • A WATERS Acquity UPLC system with diode array detector mounted with an Acquity UPLC BEH C18, 1.7 µm, 100 x 2.1 mm column. The gradient runs from a mixture of solvent A/solvent B 99/1 (v/v) to solvent A/solvent B 5/95 (v/v) in 4.5 minutes with a 2 minutes hold. The flow rate is set at 0.4 ml/min during 4.5 minutes then increased at 0.5 ml/min with a hold at 0.5 ml/min during 2 minutes without split before API source. The chromatography is carried out at 55°C.
Solvent A (pH~8.5) is prepared by dissolution of ammonium formate (63 mg) in water (1 l) and addition of ammonium hydroxide 30% (50 μl), solvent B is acetonitrile.

- For acidic elution analyses are performed using a WATERS Alliance HPLC system with diode array detector mounted with a Waters Sunfire MS C18, 5µm, 150 X 4.6 mm column. The gradient runs from 100% solvent A (water/acetonitrile/trifluoroacetic acid solution 85/5/10 (v/v/v)) to 100% solvent B (water/acetonitrile/trifluoroacetic acid solution 5/85/10 (v/v/v) in 6 minutes with a hold at 100% B of 5 minutes. The flow rate is set at 1.8 ml/min during 6 minutes then increased at 2.3 ml/min during 2 minutes with a hold at 2.3 ml/min during 3 minutes. A split of 1/25 is used just before API source. The chromatography is carried out at 45°C. The trifluoroacetic acid solution is prepared with water, acetonitrile and trifluoroacetic acid (49.75/49.75/0.5, v/v/v) and has a pH around 2.

**MS conditions**

Samples are dissolved in acetonitrile/water 70/30 (v/v) at the concentration of about 250 μg/ml. API spectra (+ or -) are performed using:

- a FINNIGAN LCQ ion trap mass spectrometer. APCI source operated at 450°C and the capillary heater at 160°C. ESI source operated at 3.5 kV and the capillary heater at 210°C.

- a SQD Waters single quadrupole mass spectrometer with an ESI source. The source parameters are as follows: ESI capillary voltage 3.0 kV, Cone and Extractor voltage 25 and 2 V respectively, Source block temperature 130°C, Desolvatation temperature 370°C, Cone gaz flow 120 L/Hr (Nitrogen), Desolvatation gaz flow 800 L/Hr.

- a Quattro Micro Waters triple quadrupole mass spectrometer with an ESI source. The source parameters are as follows: ESI capillary voltage 2.8 kV, Cone and Extractor voltage 30 and 2 V respectively, Source block temperature 120°C, Desolvatation temperature 320°C, Cone gaz flow 120 L/Hr (Nitrogen), Desolvatation gaz flow 550 L/H.

- Mass spectrometric measurements in DIP/EI mode are performed as follows: samples are vaporized by heating the probe from 50°C to 250°C in 5 min. EI (Electron Impact) spectra are recorded using a FINNIGAN TSQ 700 tandem quadrupole mass spectrometer. The source temperature is set at 150°C.
Mass spectrometric measurements on a TSQ 700 tandem quadrupole mass spectrometer (Finnigan MAT) in GC/MS mode are performed with a gas chromatograph model 3400 (Varian) fitted with a split/splitless injector and a DB-5MS fused-silica column (15 m x 0.25 mm I.D., 1 μm) from J&W Scientific. Helium (purity 99.999 %) is used as carrier gas. The injector (CTC A200S autosampler) and the transfer line operate at 290 and 250°C, respectively. Sample (1 μl) is injected in splitless mode and the oven temperature is programmed as follows: 50°C for 5 min., increasing to 280°C (23°C/min) and holding for 10 min. The TSQ 700 spectrometer operates in electron impact (EI) or chemical ionization (CI/CH4) mode (mass range 33 - 800, scan time 1.00 sec). The source temperature is set at 150°C.

- High resolution mass spectrometry measurements are run on a Waters LCT Time of flight mass spectrometer equipped with an ESI source. The source parameters are as follows: ESI capillary voltage 2.5 kV, cone voltage 135 V, source block temperature 135°C, desolvation temperature 350°C, cone gas flow 20 L/Hr (Nitrogen), desolvation gas flow 800 L/Hr. The detector is set with a flight tube at 7.2 KV and an MCP detector at 2,500 V.

Specific rotation is recorded on a Perkin-Elmer 341 polarimeter. The angle of rotation is recorded at 25°C on solutions in methanol, at 589 nm or 365 nm.

Melting points are determined on a Buchi 535 or 545 Tottoli-type fusionometre, and are not corrected, or by the onset temperature on a Perkin Elmer DSC 7.

Preparative chromatographic separations are performed on Kromasil spherical silica, particle size 10-13 μm, 100 Å, using Novasep dynamic axial compression columns (80 mmI.D.), flow rates 140 ml/min. Solvent mixtures are described in individual procedures. Reverse phase separations are carried out using 500 g of either Kromasil C18 10 μm (acidic or neutral conditions) or Phenomenex Gemini C18 10 μM (basic conditions) in 80 mm ID columns with a flow rate of 150 ml/min. Products are detected at 215 nm unless otherwise specified.

Preparative Chiral Chromatographic separations are performed on using liquid phase chromatography instrument with various mixtures of lower alcohols and C5 to C8 linear, branched or cyclic alkanes at ± 350 ml/min. Solvent mixtures as well as columns are described in individual procedures.

Experiments requiring microwave irradiation are performed on a Biotage Initiator Sixty microwave oven upgraded with version 2.0 of the operating software. Experiments are
run to reach the required temperature as quickly as possible (maximum irradiation power: 400 W, no external cooling).

Example 1. Synthesis of amines of formula II.

1.1 Synthesis of 2-(pyrrolidin-3-yl)benzamide, enantiomer 1 a8.

1.1.1 Synthesis of tert-butyl 3-[2-(methoxycarbonyl)phenyl]pyrrolidine-1-carboxylate a1-2.

To a stirred solution of methyl 2-(pyrrolidin-3-yl)benzoate hydrochloride a1-1 (4.83 g, 20 mmol, 1 eq) in dichloromethane (100 ml) at room temperature are added 4-dimethylaminopyridine (244 mg, 2 mmol, 0.1 eq) and triethylamine (8.43 ml, 60 mmol, 3 eq). The solution is stirred at room temperature for 5 minutes and a solution of (Boc)20 (4.58 g, 21 mmol, 1.05 eq) in dichloromethane is added. The reaction mixture is stirred at room temperature overnight and quenched with 1M HCl (100 ml). The organic layer is dried over MgSO4, filtered off and evaporated under vacuum to give 6.1 g of pure tert-butyl 3-[2-(methoxycarbonyl)phenyl]pyrrolidine-1-carboxylate a1-2.

Yield: 100 %.
1.1.2 Synthesis of 2-[1-(tert-butoxycarbonyl)pyrrolidin-3-yl]benzoic acid a1-3.

NaOH 5 M (7.7 ml, 38.6 mmol, 2 eq) is added to a stirred solution of 3-[2-(methoxycarbonyl)phenyl]pyrrolidine-1-carboxylate a1-2 (5.9 g, 19.3 mmol, 1 eq) in MeOH (50 ml) at 65°C. The reaction mixture is stirred overnight at 65°C, then evaporated under vacuum and water (40 ml) is added. The resulting mixture is extracted with ethyl acetate/ethanol (100 ml/10 ml) and again with ethyl acetate (100 ml). The combined organic layers are dried over MgSO4, filtered off and evaporated under vacuum to afford 5.5 g of pure 2-[1-(tert-butoxycarbonyl)pyrrolidin-3-yl]benzoic acid a1-3.

Yield: assumed quantitative.

1.1.3 Synthesis of tert-butyl 3-(2-carbamoylphenyl)pyrrolidine-1-carboxylate a1-4 and enantiomers a1-5 and a1-6.

A stirred solution of 2-[1-(tert-butoxycarbonyl)pyrrolidin-3-yl]benzoic acid a1-3 (5.5 g, 19 mmol, 1 eq) in dichloromethane (150 ml) is saturated, at 0°C, with gaseous ammonia NH3 for 1 hour. BOP reagent (8.82 g, 19.9 mmol, 1.05 eq) is added portionwise to this solution. The reaction mixture is warmed to room temperature and stirred overnight. The reaction mixture is filtered off and the solid washed with dichloromethane (100 ml). The organic layer is evaporated under vacuum and the residue obtained is purified by chromatography over silicagel (eluent: CH2Cl2/MeOH 98.5/1.5) to give 5.4 g of tert-butyl 3-(2-carbamoylphenyl)pyrrolidine-1-carboxylate a1-4.

Yield: 100 %.

LC-MS (MH+): 291 .

The two enantiomers are separated by chiral chromatography (Phase: LUX-CELL-2; 76x370 mm column; 200 ml/min; eluent: iPrOH/Heptane 30/70) to afford 2.5 g of enantiomer 1 a1-5 (first eluted) and 2.35 g of enantiomer 2 a1-6 (second eluted).

Yield for a1-5: 45 %.
Yield for a1-6: 42 %.
LC-MS (MH+): 291 .

1.1.4 Synthesis of 2-(pyrrolidin-3-yl)benzamide, enantiomer 1 a1-8.

Tert-butyl 3-(2-carbamoylphenyl)pyrrolidine-1-carboxylate, enantiomer 1 a1-5 (2.5 g, 8.61 mmol, 1 eq) is dissolved in ethanol (100 ml). A saturated solution of HCl in EtOH is added (10 ml). The reaction mixture is stirred for 20 h and evaporated to dryness to afford 1.64 g of 2-(pyrrolidin-3-yl)benzamide, enantiomer 1 a1-8 which is used in the next step without any further purification.

Yield: assumed quantitative.
LC-MS (MH\(^+\)): 191.2-(pyrrolidin-3-yl)benzamide a1-7 and 2-(pyrrolidin-3-yl)benzamide, enantiomer 2 a1-9 may be prepared according to the same method.

1.2 Synthesis of 3-(2,2,2-trifluoroethyl)pyrrolidine a1-11.

To a solution of 4-(2,2,2-trifluoroethyl)pyrrolidin-2-one a1-10 (4.0 g, 23.9 mmol, 1 eq) in freshly distilled THF, UAIH4 (2.27 g, 60 mmol, 2.5 eq) is added carefully at 0\(^\circ\)C. After completion of the addition, the mixture is heated at reflux for 1.5 h in a flask equipped with a condenser cooled at -10\(^\circ\)C. The reaction mixture is then carefully quenched with water at 0\(^\circ\)C and filtered on a pad of celite/MgSO\(_4\). The filtrate is concentrated under reduced pressure at room temperature to afford 2.82 g of 3-(2,2,2-trifluoroethyl)pyrrolidine a1-11.

Yield: 77\%.

LC-MS (MH\(^+\)): 154.

The following intermediates may be synthesized according to the same method.

<table>
<thead>
<tr>
<th>a1-12</th>
<th>(3R)-3-(2,2,2-trifluoroethyl)pyrrolidine</th>
<th>LC-MS (MH(^+)): 154</th>
</tr>
</thead>
<tbody>
<tr>
<td>a1-13</td>
<td>(3S)-3-(2,2,2-trifluoroethyl)pyrrolidine</td>
<td>LC-MS (MH(^+)): 154</td>
</tr>
<tr>
<td>a1-14</td>
<td>3-(2-chloro-2,2-difluoroethyl)pyrrolidine</td>
<td>LC-MS (MH(^+)): 170/172</td>
</tr>
</tbody>
</table>

1.3 Synthesis of 3-(4,4-difluorocyclohexyl)pyrrolidine a1-34.

1.3.1 Synthesis of methyl 3-(4,4-difluorocyclohexyl)prop-2-enoate a1-16.

Methyl(triphenylphosphoranylidene)acetate (8.827 g, 26 mmol, 1.1 eq) is added at room temperature to a solution of 4,4-difluorocyclohexanecarbaldehyde (3.55 g, 24 mmol, 1 eq) in dry THF (60 ml). The mixture is stirred for 6 h and the solvent is evaporated. Hexane (50 ml) is added to the crude, the mixture is put a few minutes in
an ultrasonic bath, stirred for 1 h and filtered. The filtrate is concentrated under reduced pressure to afford 4.05 g of methyl 3-(4,4-difluorocyclohexyl)prop-2-enoate \textbf{a1-16}.

Yield: 83 %.

$^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 6.91 (m, 1 H), 5.85 (m, 1 H), 3.75 (m, 3 H), 2.29 (m, 1 H), 2.12 (m, 3 H), 1.80 (m, 5 H), 1.56 (t, 2 H, $J = 12.5$ Hz).

The following intermediates may be synthesized according to the same method.

<table>
<thead>
<tr>
<th>a1-17</th>
<th>methyl 3-(tetrahydro-2H-pyran-4-yl)prop-2-enoate</th>
<th>GC-MS (MH$^+$): 170</th>
</tr>
</thead>
<tbody>
<tr>
<td>a1-18</td>
<td>methyl 3-(tetrahydrofuran-2-yl)prop-2-enoate</td>
<td>$^1$H NMR $\delta$ 6.91 (dd, $J = 15.7$, 4.9 Hz, 1 H), 6.01 (dd, $J = 15.7$, 1.6 Hz, 1 H), 4.50 (m, 1 H), 3.86 (m, 6 H), 3.72 (s, 3 H), 2.12 (m, 2 H), 1.90 (m, 8 H), 1.68 (m, 1 H)</td>
</tr>
<tr>
<td>a1-19</td>
<td>methyl 3-(tetrahydro-2H-pyran-3-yl)prop-2-enoate</td>
<td>$^1$H NMR $\delta$ 6.81 (dd, $J = 15.8$, 7.2 Hz, 1 H), 5.84 (d, $J = 15.8$ Hz, 1 H), 3.88 (d, $J = 11.3$ Hz, 2 H), 3.72 (m, 3 H), 3.39 (m, 1 H), 3.24 (t, $J = 10.4$ Hz, 1 H), 2.47 (m, 1 H), 1.91 (m, 1 H), 1.66 (m, 2 H), 1.44 (m, 1 H)</td>
</tr>
</tbody>
</table>

1.3.2 Synthesis of methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate \textbf{a1-20}.

Methyl 3-(4,4-difluorocyclohexyl)prop-2-enoate (4.054 g, 0.198 mol, 1 eq) is dissolved in nitromethane (23 L, 0.423 mol, 21.3 eq) and 1,8-diazabicyclo[5,4,0]undec-7-ene (3.025 g, 0.198 mol, 1 eq) is added at room temperature. The solution is stirred overnight at room temperature then evaporated. The residue is dissolved in ethyl acetate and the solution is washed with 1 M HCl and water. The organic phase is dried with MgSO$_4$ and evaporated under vacuum. The residue is purified by chromatography over silicagel (eluent: CH$_2$Cl$_2$ 100 %) to afford methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate \textbf{a1-20}.

Yield: 68 %.

LC-MS (MH$^+$): 266.

The following intermediates may be synthesized according to the same method.

<table>
<thead>
<tr>
<th>a1-23</th>
<th>methyl 4-nitro-3-(tetrahydro-2H-pyran-4-yl)butanoate</th>
<th>LC-MS (MH$^+$): 232</th>
</tr>
</thead>
<tbody>
<tr>
<td>a1-24</td>
<td>methyl 4-nitro-3-(tetrahydrofuran-2-yl)butanoate</td>
<td>LC-MS (MH$^+$): 218</td>
</tr>
<tr>
<td>a1-25</td>
<td>methyl 4-nitro-3-(tetrahydro-2H-pyran-3-yl)butanoate</td>
<td>LC-MS (MH$^+$): 232</td>
</tr>
</tbody>
</table>

Methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate enantiomer 1 \textbf{a1-21} (first eluted) and enantiomer 2 \textbf{a1-22} (second eluted) may be obtained by chiral chromatography of \textbf{a1-20} (Phase: Chiralpak ASV; 50x490 mm column; 80 ml/min; eluent: i-PrOH/Heptane 50/50). Yield for \textbf{a1-21}: 70 %.
Yield for a1-22: 70%.
LC-MS (MH⁺): 266.

1.3.3 Synthesis of 4-(4,4-difluorocyclohexy1)pyrrolidin-2-one a1-26.
Methyl 3-(4,4-difluorocyclohexyl)-4-nitrobutanoate a1-20 (1.390 g, 5.24 mmol, 1 eq) is dissolved in methanol (35 ml) and Raney Nickel (50% in water, 200 mg, 1.7 mmol, 0.3 eq) is rinsed 3 times with methanol and added to the solution. The mixture is heated overnight at 50°C under a H₂ atmosphere (20 bars). The mixture is then filtered and the filtrate is evaporated under reduced pressure to afford 4-(4,4-difluorocyclohexyl)pyrrolidin-2-one a1-26.
Yield: assumed quantitative.
LC-MS (MH⁺): 204.

The following intermediates may be synthesized according to the same method.

| a1-27 | 4-(4,4-difluorocyclohexyl)pyrrolidin-2-one enantiomer 1 | LC-MS (MH⁺): 204 |
| a1-28 | 4-(4,4-difluorocyclohexyl)pyrrolidin-2-one enantiomer 2 | LC-MS (MH⁺): 204 |
| a1-29 | 4-(tetrahydro-2H-pyran-4-yl)pyrrolidin-2-one | LC-MS (MH⁺): 169 |
| a1-32 | 4-(tetrahydrofuran-2-yl)pyrrolidin-2-one | LC-MS (MH⁺): 156 |
| a1-33 | 4-(tetrahydro-2H-pyran-3-yl)pyrrolidin-2-one | LC-MS (MH⁺): 170 |

4-(Tetrahydro-2H-pyran-4-yl)pyrrolidin-2-one enantiomer 1 a1-30 (first eluted) and enantiomer 2 a1-31 (second eluted) may be obtained by chiral chromatography of a1-29 (Chiracel OJ Phase; solvent: iPrOH/Heptane 30/70).
Yield for a1-30 and a1-31: overall yield before chiral separation (over 4 steps, starting from corresponding aldehyde): 55%.
LC-MS (MH⁺): 169.

1.3.4 Synthesis of 3-(4,4-difluorocyclohexyl)pyrrolidine a1-34.
Lithium aluminium hydride (397.6 mg, 10.49 mmol, 2 eq) is added portionwise at 0°C to a solution of 4-(4,4-difluorocyclohexyl)pyrrolidin-2-one a1-26 (assumed quantitative from previous step, 5.24 mmol, 1 eq) in dry THF (10 ml). The reaction mixture is allowed to warm to room temperature and stirred overnight, then quenched by water at 0°C and filtered on celite. The solvent is evaporated under reduced pressure to afford 3-(4,4-difluorocyclohexyl)pyrrolidine a1-34.
Yield: assumed quantitative.
LC-MS (MH⁺): 190.

The following intermediates may be synthesized according to the same method.

| a1-35 | 3-(4,4-difluorocyclohexyl)pyrrolidine enantiomer 1 | LC-MS (MH⁺): 190 |
| a1-36  | 3-(4,4-difluorocyclohexyl)pyrrolidine enantiomer 2 | LC-MS (MH\(^+\)) : 190 |
| a1-37  | 3-(tetrahydro-2H-pyran-4-yl)pyrrolidine          | LC-MS (MH\(^+\)) : 156 |
| a1-38  | 3-(tetrahydro-2H-pyran-4-yl)pyrrolidine enantiomer 1 | LC-MS (MH\(^+\)) : 156 |
| a1-39  | 3-(tetrahydro-2H-pyran-4-yl)pyrrolidine enantiomer 2 | LC-MS (MH\(^+\)) : 156 |
| a1-40  | 3-(tetrahydrofuran-2-yl)pyrrolidine             | LC-MS (MH\(^+\)) : 142 |
| a1-41  | 3-(tetrahydro-2H-pyran-3-yl)pyrrolidine         | LC-MS (MH\(^+\)) : 142 |

### 1.4 Synthesis of 3-(azetidin-3-yloxy)benzonitrile \textit{a1-45.}

#### 1.4.1 Synthesis of tert-butyl 3-(3-cyanophenoxy)azetidine-1-carboxylate \textit{a1-43.}

3-cyanophenol (284 mg, 2.38 mmol, 1.2 eq) is added to a mixture of tert-butyl 3-[(methylsulfonyl)oxy]azetidine-1-carboxylate (500 mg, 1.99 mmol, 1 eq) and CS\(_2\)CO\(_3\) (2.27 g, 6.96 mmol, 3.5 eq) in DMF (20 ml). The reaction is heated overnight at 80\(^{\circ}\)C, then cooled to room temperature. Brine (100 ml) is added and the mixture is extracted twice with diethyl ether. The combined organic phases are washed with brine, dried over MgSO\(_4\) and evaporated under reduced pressure. The residue is purified by basic reverse phase chromatography (gradient: acetonitrile/H\(_2\)O/NH\(_4\)OH from 50/50/0.1 to 80/20/0.1) to afford 262.4 mg of tert-butyl 3-(3-cyanophenoxy)azetidine-1-carboxylate \textit{a1-43.}

Yield: 48%.

LC-MS (MH\(^+\)) : 275.

Tert-butyl 3-(5-bromo-2-methoxyphenoxy)azetidine-1-carboxylate \textit{a1-44} may be synthesized according to the same method.

#### 1.4.2 Synthesis of 3-(azetidin-3-yloxy)benzonitrile \textit{a1-45.}

Trifluoroacetic acid (10 ml) is added to a solution of tert-butyl 3-(3-cyanophenoxy)azetidine-1-carboxylate \textit{a1-43} (260 mg, 0.95 mmol, 1 eq) in dichloromethane (10 ml). The reaction mixture is stirred for 2 hours at room temperature, then concentrated to dryness to afford 262.3 mg of crude 3-(azetidin-3-yloxy)benzonitrile \textit{a1-45} as an oil. This oil is used in the next step without any further purification.

Yield: 100%.
1.5 Synthesis of 2-(azetidin-3-yloxy)-5-fluoropyridine \textit{a1-49}.

1.5.1 Synthesis of tert-butyl 3-[(5-fluoropyridin-2-yl)oxy]azetidine-1-carboxylate \textit{a1-48}.

Potassium tert-butoxide (1 M in THF, 14.4 ml, 14.4 mmol, 5 eq) and 2,5-difluoropyridine (498.3 mg, 4.33 mmol, 1.5 eq) are added to a mixture of tert-butyl 3-hydroxyazetidine-1-carboxylate \textit{a1-47} (500 mg, 2.89 mmol, 1 eq) in DMSO (50 ml). The reaction is stirred for 4 h at room temperature. Brine (70 ml) and water (10 ml) are added. The resulting mixture is extracted with ethyl acetate (3 x 50 ml). The combined organic phases are dried over MgSC\textsubscript{4}, filtered and concentrated in vacuo. The residue of evaporation is purified by flash chromatography over silicagel (eluent: EtOAc/Heptane 10/90) to afford 240 mg of tert-butyl 3-[(5-fluoropyridin-2-yl)oxy]azetidine-1-carboxylate \textit{a1-48}. Yield: 31%.

LC-MS (MH\textsuperscript{+}) : 269.

1.5.2 Synthesis of 2-(azetidin-3-yloxy)-5-fluoropyridine \textit{a1-49}.

2-(Azetidin-3-yloxy)-5-fluoropyridine \textit{a1-49} may be prepared by deprotection of tert-butyl 3-[(5-fluoropyridin-2-yl)oxy]azetidine-1-carboxylate \textit{a1-48} as described in example 1.4.2.

LC-MS (MH\textsuperscript{+}) : 169.

1.6 Synthesis of 2-methoxy-6-(pyrrolidin-3-yl)pyridine \textit{a1-59}.
1.6.1 Synthesis of 2-ethenyl-6-methoxypyridine \textbf{a1-51}.

To a suspension of methyl(triphenyl)phosphonium bromide (7.07 g, 19.8 mmol, 1.1 eq) in dry THF (50 ml) at 0°C is added n-butyl lithium (1.6M in cyclohexane, 12.5 ml, 19.8 mmol, 1.1 eq). After stirring at 0°C for 20 minutes, a solution of 6-methoxypyridine-2-carbaldehyde \textbf{a1-50} (2.5 g, 18 mmol, 1 eq) in dry THF (10 ml) is added dropwise to the mixture. The reaction mixture is warmed to room temperature for 30 minutes. The reaction mixture is quenched with 3 drops of water, and Rochelle salt is added (10 g). The mixture is filtered over Celite and MgSCl\textsubscript{4}. The crude residue is distilled to afford 400 mg of pure 2-ethenyl-6-methoxypyridine \textbf{a1-51}.

Yield: 16 %.

\textsuperscript{1}H NMR \(\delta\) 7.51 (t, \(J = 7.6\) Hz, 1 H), 6.82 (d, \(J = 7.2\) Hz, 1 H), 6.72 (dd, \(J = 17.0, 10.6\) Hz, 1 H), 6.62 (d, \(J = 8.2\) Hz, 1 H), 6.29 (dd, \(J = 17.2, 1.4\) Hz, 1 H), 5.41 (dd, \(J = 10.6, 1.4\) Hz, 1 H), 3.96 (s, 3 H).

Alternatively 2-ethenyl-4-methoxypyrimidine \textbf{a1-52} and 2-ethenyl-6-(1 H-pyrazol-1-yl)pyridine \textbf{a1-54} may be prepared by reaction of 2-bromo-4-methoxypyrimidine with potassium ethenyl(trifluoroborate).

\textbf{a1-52}, LC-MS (MH\textsuperscript{+}): 137.

\textbf{a1-54}, LC-MS (MH\textsuperscript{+}): 172.

Alternatively, 2-ethenyl-6-(propan-2-yl)pyridine \textbf{a1-53} may be prepared by reaction 2-bromo-6-(propan-2-yl)pyridine of with tributyl(ethenyl)stannane.

LC-MS (MH\textsuperscript{+}): 400.

1.6.2 Synthesis of 2-methoxy-6-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyridine \textbf{a1-55}.

To a solution of 2-ethenyl-6-methoxypyridine \textbf{a1-51} (400 mg, 3 mmol, 1eq) in trifluoroacetic acid/dichloromethane (200 \(\mu\)l/2 ml) is added N-(methoxymethyl)-N-[(trimethylsilyl)methyl]prop-2-en-1-amine until all styrene \textbf{a1-51} is consumed. The solvent is removed under vacuum and the crude residue is purified by basic reverse phase chromatography over silicagel (gradient: CH3CN/H2O/NH4OH from 50/50/0.1 to 80/20/0.1) to afford 210 mg of pure 2-methoxy-6-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyridine \textbf{a1-55}.

Yield: 30 %.

LC-MS (MH\textsuperscript{+}): 219.

The following intermediates may be synthesized according to the same method.

| \textbf{a1-56} | 4-methoxy-2-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyrimidine | LC-MS (MH\textsuperscript{+}): 220 |
| \textbf{a1-57} | 2-(propan-2-yl)oxy-6-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyridine | LC-MS (MH\textsuperscript{+}): 247 |
1.6.3 Synthesis of 2-methoxy-6-(pyrrolidin-3-yl)pyridine a1-59.

To a solution of 2-methoxy-6-[1-(prop-2-en-1-yl)pyrrolidin-3-yl]pyridine a1-55 (218 mg, 1 mmol, 1 eq) in dichloromethane (3 ml) are added 1,3-dimethylbarbituric acid (470 mg, 3 mmol, 3 eq) and Pd(PPh3)4 (20 mg) and the mixture is warmed overnight at 40°C. The reaction mixture is loaded on an ion exchange acidic resin cartridge, washed with methanol (2x50 ml) and then released with a 1M solution of ammonia in methanol (20 ml) to afford 150 mg of crude 2-methoxy-6-(pyrrolidin-3-yl)pyridine a1-59 that is used in the next step without any further purification.

Yield: 84%.

The following intermediates may be synthesized according to the same method.

| a1-60 | 4-methoxy-2-(pyrrolidin-3-yl)pyrimidine | - |
| a1-61 | 2-(propan-2-ylxy)-6-(pyrrolidin-3-yl)pyridine | LC-MS (MH⁺): 207 |
| a1-62 | 2-(1H-pyrazol-1-yl)-6-(pyrrolidin-3-yl)pyridine | LC-MS (MH⁺): 215 |

1.7 Synthesis of 2-(pyrrolidin-3-yl)pyridine enantiomers a1-66 and a1-67.

1.7.1 Synthesis of 2-(1-benzylpyrrolidin-3-yl)pyridine enantiomers a1-64 and a1-65.

2-(1-Benzylpyrrolidin-3-yl)pyridine enantiomers a1-64 and a1-65 are obtained by chiral chromatography of the racemic mixture a1-63 (Phase: Chiralpak AD; 80°475 mm column; 200 ml/min; eluent: CH3CN).

2-(1-Benzylpyrrolidin-3-yl)pyridine enantiomer 1 a1-64:

$^1$H NMR (400 MHz, CDCl3) δ 8.53 (d, 1 H, J = 4.3 Hz), 7.58 (td, 1 H, J = 7.7, 1.4 Hz), 7.33 (m, 4 H), 7.23 (m, 2 H), 7.09 (m, 1 H), 3.69 (m, 2 H), 3.55 (m, 1 H), 3.08 (t, 1 H, J = 8.6 Hz), 2.87 (m, 1 H), 2.69 (m, 2 H), 2.34 (m, 1 H), 2.10 (m, 1 H).
2-(1-Benzylpyrrolidin-3-yl)pyridine enantiomer 2 a1-65:

$^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 8.53 (d, 1 H, $J = 4.1$ Hz), 7.58 (td, 1 H, $J = 7.7, 1.7$ Hz), 7.33 (m, 4 H), 7.23 (m, 2 H), 7.09 (m, 1 H), 3.69 (m, 2 H), 3.55 (m, 1 H), 3.08 (t, 1 H, $J = 8.6$ Hz), 2.87 (m, 1 H), 2.69 (m, 2 H), 2.34 (m, 1 H), 2.11 (m, 1 H).

1.7.2 Synthesis of 2-(pyrrolidin-3-yl)pyridine enantiomer 1 dihydrochloride a1-66.

To 2-(1-benzylpyrrolidin-3-yl)pyridine enantiomer 1 a1-64 (10.01 g, 41.96 mmol, 1 eq) in methanol (340 ml) is added Pd/C (5 %, 1.98 g). A solution of ammonium formate (10.69 g, 167.83 mmol, 4 eq) in water (55 ml) is then added dropwise over a period of 10 minutes. The reaction mixture is heated for 45 mins at 68 °C, then cooled to room temperature. The catalyst is filtered off using Celite, washed with methanol (60 ml) and the pooled filtrates evaporated to dryness. The residue is retaken in methanol (50 ml) and evaporated again. Dichloromethane (100 ml) is added to the residue, the solid obtained is filtered, washed with dichloromethane (30 ml) and the pooled filtrates are evaporated to dryness to give a yellow oil. This oil is dissolved in isopropanol (60 ml) and a mixture of isopropanol (21 ml)/aqueous HCl 6N (21 ml, 3 eq) is added slowly over a period of 15 minutes to the solution. The mixture is stirred at room temperature overnight, the precipitate obtained is filtered, washed with isopropanol (10 ml) and dried under vacuum for 4 hours at 40°C to afford 7.90 g of 2-(pyrrolidin-3-yl)pyridine enantiomer 1 dihydrochloride a1-66. Yield: 85 %.

LC-MS (MH$^+$): 149.

2-(pyrrolidin-3-yl)pyridine enantiomer 2 dihydrochloride a1-67 may be prepared according to the same method. Yield: 85 %.

LC-MS (MH$^+$): 149.

1.8 Chiral separation of 4-(pyrrolidin-3-yl)benzonitrile a1-68.

4-(pyrrolidin-3-yl)benzonitrile enantiomer 1 a1-70 and 4-(pyrrolidin-3-yl)benzonitrile enantiomer 2 a1-69 may be prepared by chiral chromatography of 4-(pyrrolidin-3-yl)benzonitrile a1-68.

1.9 Synthesis of 2-(cyclobutyloxy)-6-(pyrrolidin-3-yl)pyridine a1-72.

Potassium tert-butoxide (337 mg, 3 mmol, 3 eq) is added portionwise at room temperature to a solution of cyclobutanol (144 mg, 2 mmol, 2 eq) in DMSO (2 ml) and
the mixture is stirred for 2 days. 2-Fluoro-6-(pyrrolidin-3-yl)pyridine hydrochloride (202 mg, 1 mmol, 1 eq) in DMSO (2 ml) is added and the mixture is stirred for 48 hours. Dichloromethane and water are then added to the reaction mixture, and the two phases are separated after vigorous shaking. The aqueous layer is reextracted with dichloromethane. The combined organic layers are dried on MgSO₄, filtered and the filtrate condensed under reduced pressure to afford crude 2-(cyclobutyloxy)-6-(pyrrolidin-3-yl)pyridine a1-72, which is used in the next step without any further purification.

Yield: assumed quantitative.

LC-MS (MH⁺): 219.

Example 2. Synthesis of 1-(2-{2-[3-(3-fluorophenyl)piperidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate 24.

2.1 Synthesis of 5-bromo-N-[2-(2-hydroxyethyl)phenyl]pentanamide a2-1.

A solution of 2-(2-aminophenyl)ethanol a2-0 (450 g, 3.28 mol, 1 eq) and triethylamine (332 g, 3.28 mol, 1 eq) in dichloromethane (2 l) is cooled at -5°C and bromovaleryl chloride (654 g, 3.28 mol, 1 eq) in dichloromethane (2 l) is added dropwise without exceeding 0°C. The organic phase is washed with HCl 1N (4 x 2 l) and brine (1 x 2 l). The aqueous layer is extracted with dichloromethane (1 x 2 l). The combined organic layers are dried over MgSO₄, filtered and evaporated under vacuum to afford 1008 g of 5-bromo-N-[2-(2-hydroxyethyl)phenyl]pentanamide a2-1.

Yield: 100 %.

LC-MS (MH⁺): 301.
2.2 Synthesis of 1-[2-(2-hydroxyethyl)phenyl]piperidin-2-one a2-2.

A solution of 5-bromo-N-[2-(2-hydroxyethyl)phenyl]pentanamide a2-1 (938 g, 3.28 mol, 1 eq) in THF (6 l) is cooled at -5°C. Potassium tert-butoxide (552 g, 4.92 mol, 1.5 eq) is added portionwise, without exceeding 0°C, then the mixture is warmed up to room temperature. The reaction mixture is washed with a saturated aqueous solution of NaCl (3 x 2 l). The aqueous layers are extracted with dichloromethane (2 x 2 l), the combined organic layers are dried over MgSC>4, filtered and condensed under reduced pressure. The residue is recrystallized from tert-butyl methyl ether to afford 510 g of 1-[2-(2-hydroxyethyl)phenyl]piperidin-2-one a2-2.

Yield: 71 %.

LC-MS (MH+): 220.

2.3 Synthesis of 2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl 4-methylbenzenesulfonate a2-3.

Dimethylaminopyridine (1.83 g, 15 mmol, 0.05 eq) and triethylamine (63.5 ml, 450 mmol, 1.5 eq) are added to a solution of 1-[2-(2-hydroxyethyl)phenyl]piperidin-2-one a2-2 (65.7 g, 300 mmol, 1 eq) in dichloromethane (250 ml) at 0°C. The mixture is stirred at 0°C for 15 minutes, then a solution of 4-toluenesulfonyl chloride (63 g, 330 mmol, 1.1 eq) in dichloromethane (250 ml) is added dropwise. The reaction mixture is then warmed up to room temperature and stirred overnight. The reaction mixture is washed with water, 1N HCl, then dried over MgSC>4, filtered and evaporated under vacuum. The residue is purified by chromatography over silicagel (gradient: CH2Cl2/MeOH from 100/0 to 98/2) to afford 99 g of 2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl 4-methylbenzenesulfonate a2-3.

Yield: 88 %.

LC-MS (MH+): 374.

2.4 Synthesis of 1-(2-[3-(3-fluorophenyl)piperidin-1-yl]ethyl)phenyl)piperidin-2-one oxalate 24.

3-(3-Fluorophenyl)piperidine hydrochloride a2-4 (432 mg, 2 mmol, 1 eq) and K2CO3 (829 mg, 6 mmol, 3 eq) are added to a solution 2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl 4-methylbenzenesulfonate a2-3 (747 mg, 2 mmol, 1 eq) in acetonitrile (10 ml). The reaction mixture is stirred at 85°C overnight, then filtered and the filtrate is condensed under reduced pressure. The residue is purified by basic reverse phase chromatography over silicagel (gradient CH3CN/H2O/NH4OH from 50/50/0.1 to 80/20/0.1 ) to afford 472 mg (1.24 mmol) of 1-(2-[2-[3-(3-fluorophenyl)piperidin-1-yl]ethyl]phenyl)piperidin-2-one as a free base. Oxalic acid (111 mg, 1.24 mmol, 1 eq) is added to the residue dissolved in diethylether. The precipitate obtained is filtered and
dried under vacuum to afford 517 mg of 1-(2-{2-[3-(3-fluorophenyl)piperidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate 24.

Yield: 55 %.

LC-MS (MH⁺): 381.

Compounds 1, 3, 5, 6, 7, 8, 9, 10, 14, 15, 16, 18, 21, 22, 24, 25, 26, 27, 28, 29, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 46, 48, 49, 51, 53, 54, 56, 57, 67, 69, 73, 75, 76, 77, 78 and 81 may be synthesized according to the same method.

Compounds 12 and 13 may be obtained by chiral chromatography of 3.

Compounds 19 and 20 may be obtained by chiral chromatography of 6.


3.1 Synthesis of [2-(2-oxopiperidin-1-yl)phenyl]acetaldehyde a3-1.

Dess Martin periodinane (3.36 g, 7.91 mmol, 1.3 eq) is added portionwise under stirring to 1-[2-(2-hydroxyethyl)phenyl]piperidin-2-one a2-2 (1.33 g, 6.09 mmol, 1 eq) in dichloromethane (40 ml). After a few hours additional Dess Martin periodinane (1.29 g, 3.04 mmol, 0.5 eq) is added and the reaction mixture is stirred overnight at room temperature, then filtrated and evaporated to dryness to afford crude [2-(2-oxopiperidin-1-yl)phenyl]acetaldehyde a3-1, which is used in the next step without any further purification.

Yield: assumed quantitative.
3.2 Synthesis of 3-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl)benzonitrile oxalate 31.

To [2-(2-oxopiperidin-1-yl)phenyl]acetaldehyde a3-1 (108.6 mg, 0.5 mmol, 1 eq) and 3-(azetidin-3-yl)benzonitrile a3-2 (97.33 mg, 0.5 mmole, 1 eq) in methanol (4 ml) are added acetic acid (42.9 µl, 0.75 mmol, 1.5 eq) then NaBH\(^{CN}\) (94.3 mg, 1.5 mmol, 3 eq). The reaction mixture is stirred overnight at room temperature. The crude reaction mixture is then loaded on an ion exchange acidic resin cartridge (2 g) prewashed with methanol. The cartridge is washed twice with approximately 3 column volumes of methanol, then eluted with 3 column volumes of 1M NH3 in methanol. This eluate is evaporated to dryness to give 141 mg of a crude material which is purified by reverse phase chromatography (basic mode; gradient: h\(^{2}O/acetonitrile/NI-^\text{OH} \) from 60/40/0.1 to 30/70/0.1 in 10 minutes). The residue obtained is redissolved in acetone (approximately 3 ml), and after addition of oxalic acid (22.7 mg, 0.25 mmol, 1 eq), a precipitate slowly appeared. This precipitate is filtered, washed with diethyl ether and dried overnight under vacuum at 40°C to afford 69.6 mg of 3-(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]azetidin-3-yl)benzonitrile oxalate 31.

Yield: 31 %.

LC-MS (MH\(^{+}\)):360.

Compounds 23, 30, 32, 44, 45, 47, 52, 58, 60, 61, 62, 65, 66 and 68 may be synthesized according to the same method.

4.1 Synthesis of 2-(2-oxopiperidin-1-yl)pyridine-3-carbaldehyde \textbf{a4-1}.

2-Bromopyridine-3-carbaldehyde \textbf{a4-0} (0.5 g, 2.7 mmol, 1 eq) is dissolved in dry and degassed 1,4-dioxane (15 ml). Piperidin-2-one (0.4 g, 4.03 mmol, 1.5 eq), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (0.31 g, 0.538 mmol, 0.2 eq), tris(dibenzylideneacetone)dipalladium(0) \textit{(0.123 g, 0.134 mmol, 0.05 eq) and cesium carbonate} \textit{(1.752 g, 5.376 mmol, 2 eq) are added. The mixture is heated in a sealed tube in a microwave oven at 120°C for 45 min. The resulting suspension is filtered over celite and the celite washed with 1,4-dioxane. The filtrate is evaporated under reduced pressure. The residue is then dispersed in ethyl acetate, sonicated, filtered and the filtrate is evaporated under reduced pressure to afford 1.1 g of crude 2-(2-oxopiperidin-1-yl)pyridine-3-carbaldehyde \textbf{a4-1} which is used in the next step without any further purification.

Yield: 50 %.

LC-MS (MH\(^+\)): 204.

4.2 Synthesis of 1-[3-(2-methoxyethenyl)pyridin-2-yl]piperidin-2-one \textbf{a4-2}.

Methoxymethyl-triphenylphosphonium chloride (3.59 g, 10.48 mmol, 1.3 eq) is dissolved in dry tetrahydrofuran (150 ml) under nitrogen. This solution is cooled at 0°C and potassium tert-butoxide \textit{(1.085 g, 9.67 mmol, 1.2 eq) is added. The reaction mixture is stirred at 0°C for 30 min. A solution of crude 2-(2-oxopiperidin-1-yl)pyridine-3-carbaldehyde \textbf{a4-1} (4.2 g, 8.06 mmol, 1 eq) in dry THF (50 ml) is added, then the reaction mixture is warmed up to room temperature and stirred for 1 hour. The solvent is removed under reduced pressure, the residue is taken with ethyl acetate, stirred, filtered and the solid cake washed with ethyl acetate (2 times). The filtrate is evaporated under reduced pressure. The residue is purified by chromatography over silicagel (gradient: \textit{CH}_2\textit{Cl}_2/MeOH/N\(_4\)OH 100/0/0 to 97/3/0.3). The product obtained is redissolved in methanol, caught over an acidic column, washed with methanol and then released with ammonia 1M in methanol. The solvent is evaporated under reduced pressure to afford 540 mg of 1-[3-(2-methoxyethenyl)pyridin-2-yl]piperidin-2-one \textbf{a4-2}.

Yield: 11 %.

LC-MS (MH\(^+\)): 233.

4.3 Synthesis of [2-(2-oxopiperidin-1-yl)pyridin-3-yl]acetaldehyde \textbf{a4-3}.

1-[3-(2-Methoxyethenyl)pyridin-2-yl]piperidin-2-one \textbf{a4-2} (0.340 g, 1.464 mmol, 1 eq) is dissolved in a mixture of formic acid and water (10 ml/0.5 ml). The reaction mixture is heated at 50°C overnight. The solvent is removed under reduced pressure to afford crude [2-(2-oxopiperidin-1-yl)pyridin-3-yl]acetaldehyde \textbf{a4-3} which is used in the next step without any further purification.
4.4 Synthesis of 1-[3-(2-{3-[6-(propan-2-yloxy)pyridin-2-yl]pyrrolidin-1-yl}ethyl)pyridin-2-yl]piperidin-2-one oxalate 94.

2-(Propan-2-yloxy)-6-(pyrrolidin-3-yl)pyridine a1-61 (0.302 g, 1.464 mmol, 1 eq) is dissolved in methanol (15 ml) and the solution is cooled at 0°C. Acetic acid (0.527 g, 8.784 mmol, 6 eq), N,N-diisopropylethylamine (0.378 g, 2.928 mmol, 2 eq) and sodium cyanoborohydride (0.552 g, 8.784 mmol, 6 eq) are added. The reaction mixture is stirred for 5 min, and then poured on crude [2-(2-oxopiperidin-1-yl)pyridin-3-yl]acetaldehyde a4-3 (1.46 mmol, 1 eq) cooled at 0°C. After 10 min at 0°C, the reaction mixture is warmed up to room temperature. Hydrochloric acid 1N is added until acidic pH. The solution is caught over an acidic column, washed with methanol and then released with ammonia 1M in methanol. The solvent is evaporated under reduced pressure. The residue is purified by LC-MS basic reverse phase (gradient CH$_3$CN/H$_2$O/NaHCO$_3$ from 5/95/0.5 to 95/5/0.5). The residue of evaporation is dissolved in a minimum of acetone and oxalic acid (1 eq) is added to form the salt. The solvent is removed under reduced pressure. The residue is taken in diethyl ether, the mixture is stirred, sonicated and filtered. The precipitate is washed with diethyl ether (2 times) to afford 75 mg of 1-[3-(2-{3-[6-(propan-2-yloxy)pyridin-2-yl]pyrrolidin-1-yl}ethyl)pyridin-2-yl]piperidin-2-one oxalate 94.

Yield: 12.5%.

LC-MS (MH$^+$): 409.

Compounds 63, 70, 71, 79, 80, 88, 89, 90, 91, 92, 93, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 and 106 may be synthesized according to the same method.
Example 5. Synthesis of 1-(2-[2-[3-(4-methyl-1,3-thiazol-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate 87.

5.1 Synthesis of 1-[2-(2-[[trimethylsilyl]methyl]amino)ethyl]phenyl)piperidin-2-one \(a5-1\).

To 2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl 4-methylbenzenesulfonate \(a2-3\) (22.4 g, 0.060 mol, 1 eq) in acetonitrile (100 ml) are added 1-(trimethylsilyl)methanamine (6.8 g, 0.066 mol, 1.1 eq) and K2CO3 (16.6 g, 0.120 mol, 2 eq). The reaction mixture is heated at 85°C for 2 hours under nitrogen. After filtration the solvent is removed under reduced pressure and the residue obtained is purified by basic reverse phase chromatography (gradient CH3CN/H2O/NaHC03 from 50/50/0.1 to 80/20/0.1) to afford 7.66 g of 1-[2-(2-[[trimethylsilyl]methyl]amino)ethyl]phenyl)piperidin-2-one \(a5-1\).

Yield: 42 %.

LC-MS (MH+): 305.

5.2 Synthesis of 1-[2-(2-[(methoxymethyl)][(trimethylsilyl)methyl]amino)ethyl]phenyl)piperidin-2-one \(a5-2\).

1-[2-(2-[[[(trimethylsilyl)methyl]amino]ethyl]phenyl)piperidin-2-one \(a5-1\) (912 mg, 3 mmol, 1 eq) is slowly added at -10°C to a solution of methanol (220 µl, 5.4 mmol, 1.8 eq) and aqueous formaldehyde (37 %, 600 µl). The reaction mixture is stirred at 0°C for 1 h. Potassium carbonate (2 g) is added and the mixture is stirred 1 h at 0°C. Dichloromethane (15 ml) is added, the mixture obtained is dried over MgSO4, filtered, and the filtrate is concentrated under vacuum to afford 2.34 g of 1-[2-(2-[(methoxymethyl)][(trimethylsilyl)methyl]amino)ethyl]phenyl)piperidin-2-one \(a5-2\).

Yield: 99 %.
5.3 Synthesis of 2-ethenyl-4-methyl-1,3-thiazole a5-3.

In a three-necked round bottom flask under argon, BuLi (1.6 M solution in hexane, 3.43 ml, 5.5 mmol, 1.1 eq) is slowly added to methyl(phenyl)phosphonium bromide (1.79 g, 5 mmol, 1 eq) in THF (15 ml) without exceeding 5 °C. After 1 h under stirring at 0°C, 4-methyl-1,3-thiazole-2-carbaldehyde (635 mg, 5 mmol, 1 eq) is added. The reaction mixture is allowed to return to ambient temperature and stirred overnight. The reaction is quenched with Rochelle salt (potassium sodium tartrate) (2 g) and 3 drops of water. The mixture is diluted with diethyl ether and dried over magnesium sulfate. Solvents are removed under vacuum and the crude product is distilled (+/- 60°C; 10^-2 Bar) to afford 335 mg of 2-ethenyl-4-methyl-1,3-thiazole a5-3 as a clear oil.

Yield: 54 %.

1H NMR (CDCl3 , 400MHz) δ: 6.87 (dd, J 1 = 17.5 Hz, J 2 = 10.9 Hz, 1 H), 6.78 (s, 1 H), 6.01 (d, J = 17.5 Hz, 1 H), 5.50 (d, J = 10.9 Hz, 1 H), 2.44 (s, 3 H).

The following intermediates may be synthesized according to the same method.

<table>
<thead>
<tr>
<th>a5-4</th>
<th>3-ethenyl-2-fluoropyridine</th>
<th>LC-MS (M+): 123</th>
</tr>
</thead>
<tbody>
<tr>
<td>a5-5</td>
<td>2-ethenyl-3-fluoropyridine</td>
<td>1H NMR (CDCl3 , 400MHz) δ: 8.27 (d, J = 4.4 Hz, 1 H), 7.26 (t, J = 9.3 Hz, 1 H), 7.08 (m, 1 H), 6.90 (dd, J1 = 17.4 Hz, J2 = 11.0 Hz, 1 H), 6.32 (dd, J1 = 17.4 Hz, J2 = 1.1 Hz, 1 H), 5.49 (d, J = 11.1 Hz, 1 H)</td>
</tr>
</tbody>
</table>

5.4 Synthesis of 1-(2-[2-[3-(4-methyl-1,3-thiazol-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate 87.

At 0°C, 1-[2-(2-[(methoxymethyl)[[(trimethylsilyl)methyl]amino]ethyl]phenyl]piperidin-2-one a5-2 (696 mg, 2 mmol, 2 eq) is slowly added to 2-ethenyl-4-methyl-1,3-thiazole a5-3 (125 mg, 1 mmol, 1 eq) diluted in dichloromethane/TFA (90 µl/10 µl). The mixture is stirred at room temperature overnight. Solvent is removed under reduced pressure and the residue is purified by basic reverse phase chromatography on silica gel (gradient: acetonitrile/H2O/0.1%NH4OH from 30/70/0.1 to 60/40/0.1 in 10 minutes). The product is dissolved in a minimum of acetone and oxalic acid (1 eq) is added to form the salt that is filtered, washed with diethyl ether and dried under vacuum to afford 215 mg of 1-(2-[2-[3-(4-methyl-1,3-thiazol-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate 87.
Yield: 47 %.

LC-MS (MH\(^+\)): 370.

Compounds 64, 74, 82, 83 and 84 may be synthesized according to the same method.


Methyl 2-(1-[(2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl]benzoate a6-1 may be prepared according to the procedure described in example 2.4.

LC-MS (MH\(^+\)): 421.

This is also the case of the following compounds:

<table>
<thead>
<tr>
<th>a6-2</th>
<th>methyl 2-(1-[(2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl]benzoate</th>
<th>LC-MS (MH(^+)): 407</th>
</tr>
</thead>
<tbody>
<tr>
<td>a6-3</td>
<td>methyl 2-(1-[(2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl]benzoate enantiomer 1</td>
<td>LC-MS (MH(^+)): 407</td>
</tr>
<tr>
<td>a6-4</td>
<td>methyl 2-(1-[(2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl]benzoate enantiomer 1</td>
<td>LC-MS (MH(^+)): 407</td>
</tr>
</tbody>
</table>

6.2 Synthesis of 2-(1-[(2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl]benzoic acid a6-5.

Methyl 2-(1-[(2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl]benzoate a6-1 (0.35 g, 0.84 mmol, 1 eq) is dissolved in methanol (5 ml). NaOH 5N (0.84 ml, 4.20 mmol, 5 eq) is added and the mixture is heated at 80°C for 16h. The reaction mixture is concentrated under reduced pressure and the residue obtained is taken up in
MeOH, filtered, and evaporated to afford 0.34 g of crude 2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl)benzoic acid **a6-5** which is used in the next step without further purification.

Yield: assumed quantitative.

LC-MS (MH⁺): 407.

The following intermediates may be synthesized according to the same method.

<table>
<thead>
<tr>
<th><strong>a6-6</strong></th>
<th>2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl)benzoic acid</th>
<th>LC-MS (MH⁺): 393</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a6-7</strong></td>
<td>2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl)benzoic acid enantiomer 1</td>
<td>LC-MS (MH⁺): 393</td>
</tr>
<tr>
<td><strong>a6-8</strong></td>
<td>2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl)benzoic acid enantiomer 2</td>
<td>LC-MS (MH⁺): 393</td>
</tr>
</tbody>
</table>

6.3 Synthesis of 2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl)benzamide oxalate **4**.

2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl)benzoic acid **a6-5** (0.34 g, 0.84 mmol, 1 eq) is dissolved in dry dichloromethane. Gaseous ammonia is bubbled through the solution for 15 min at 0°C. BOP (0.56 g, 1.27 mmol, 1.5 eq) is added and the mixture allowed to warm to room temperature overnight while a stream of ammonia is maintained. The mixture is evaporated to dryness and redissolved in dichloromethane. The organic layer is washed with 10% aqueous NaHCO₃, dried over MgSO₄ and concentrated under vacuum. The residue is purified by reverse phase HPLC (gradient: acetonitrile/H₂O/TFA from 20/80/0.1 to 50/50/0.1). The solution is caught over an acidic column, washed with methanol and then released with ammonia 1M in methanol. The solvent is evaporated under reduced pressure. The residue is recrystallized from ethyl acetate as an oxalic acid salt to afford 62 mg of 2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)piperidin-3-yl)benzamide oxalate **4**.

Yield: 15%.

LC-MS (MH⁺): 406.

**Example 7. Synthesis of N-methyl-2-(1-[2-(2-oxopiperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl)benzamide oxalate 2.**
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzoic acid a6-6 (0.67 g, 1.71 mmol, 1 eq) is dissolved in dichloromethane (13 ml). Gaseous MeNH₂ is bubbled through the solution for 5 min at 0°C. BOP (1.13 g, 2.56 mmol, 1.5 eq) is added and a stream of MeNH₂ was maintained for 5 min. The mixture is allowed to warm up to room temperature, stirred overnight, and then concentrated under vacuum. The residue obtained is purified by chromatography over silicagel (eluent: CH₂Cl₂/MeOH/NH₄OH 94/6/0.6) followed by reverse phase HPLC (gradient: acetonitrile/H₂O/NH₄OH (aqueous, 0.1%) from 30/60/10 to 60/30/10 in 15 minutes). The residue is recrystallized from ethyl acetate as an oxalic acid salt to afford 250 mg of N-methyl-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate 2.

Yield: 36%.

LC-MS (MH⁺): 406.

Example 8. Synthesis of 1-[2-(2-[3-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]pyrrolidin-1-yl]ethyl)phenyl]piperidin-2-one 11.

2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzoic acid a6-6 (0.31 g, 0.79 mmol, 1 eq) is dissolved in DMF and N,N'-carbonyldiimidazole (140 mg, 0.87 mmol, 1.1 eq) is added. The mixture is stirred at room temperature for 30 min, N-hydroxyacetamidine hydrochloride (95 mg, 0.87 mmol, 1.1 eq) is added and stirring is pursued for 4 hours. Another 1.1 eq of N,N'-carbonyldiimidazole and 1.1 eq of N-hydroxyacetamidine hydrochloride are added and the reaction mixture is stirred at reflux overnight. Dichloromethane and water are added and the organic layer is subsequently washed with water, HCl 1N, aqueous saturated NaHCC>3 and brine. The organic layer is dried over MgSC>4, evaporated and purified by preparative basic LC/MS (gradient: H₂O/acetonitrile/NH₄I-IC0₃ 0.5% w/v from 85/5/10 to 5/95/0 in 6.5 minutes) to afford 19 mg of 1-[2-(2-[3-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]pyrrolidin-1-yl]ethyl)phenyl]piperidin-2-one 11.

Yield: 6%.

LC-MS (MH⁺): 431

2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzoic acid enantiomer 2a6-8 (2.72 g, 6.97 mmol, 1 eq) is dissolved in dichloromethane (100 ml). Pyrrolidine (0.69 ml, 8.36 mmol, 1.2 eq) is added followed by BOP reagent (Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate; 4.62 g, 10.45 mmol, 1.5 eq) and the reaction mixture is stirred at room temperature for 4h. The mixture is evaporated to dryness, redissolved in dichloromethane and the organic layer is washed with HCl 1N and water, dried over MgSO4 and evaporated. The residue is purified by reverse phase HPLC (gradient: acetonitrile/H2O/ammonium formate from 5% to 95% of acetonitrile in 8 minutes) to afford 385 mg of (-)-1-[2-[2-{3-[2-(pyrrolidin-1-ylcarbonyl)phenyl]pyrrolidin-1-yl}ethyl]phenyl]piperidin-2-one 17. Yield: 12%.

LC-MS (MH+): 446.

Example 10. Synthesis of 4-[(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)oxy]benzonitrile 50.

10.1 Synthesis of 1-[2-[2-(3-hydroxy pyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one a10-1. To a solution of 2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl 4-methylbenzenesulfonate a2-3 (11.95 g, 32 mmol, 1eq) in acetonitrile (70 ml) is added K2CO3 (9.95 g, 48 mmol,
1.5 eq) then pyrrolidin-3-ol \textit{a10-0} (2.78 g, 32 mmol, 1 eq). The reaction mixture is stirred
overnight at 85°C. After filtration on celite and solvent removal, the residue is purified by
chromatography over silicagel (eluent: CH$_2$C|$_2$/MeOH 93/7) to afford 6.68 g of 1-[2-[2-
(3-hydroxypyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one \textit{a10-1}.

Yield: 72%.

LC-MS (MH$^+$): 289.

10.2 Synthesis of 1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl
methanesulfonate \textit{a10-2}.

To a stirred solution of 1-[2-[2-(3-hydroxypyrrolidin-1-yl)ethyl]phenyl]piperidin-2-
one \textit{a10-1} (5.6 g, 19.5 mmol, 1eq) in acetonitrile (50 ml) at room temperature is added
dimethylaminopyridine (0.238 g, 1 mmol, 0.1 eq) and triethylamine (10.9 ml, 78 mmol,
4 eq). The solution is stirred at room temperature for 30 minutes. Mesyl chloride (4.5 ml,
59.5 mmol, 3 eq) is added to this solution. The reaction mixture is stirred at room
temperature overnight. After solvent removal, the residue is redissolved in
dichloromethane (250 ml) and the organic layer washed with water (100 ml), 1M HCl
(120 ml) and water (250 ml). The combined aqueous phases are neutralised by addition
of aqueous NaOH and extracted with dichloromethane (3x200 ml). The combined
organic layers are dried over MgSO$_4$ and evaporated under vacuum. Purification of the
residue obtained by chromatography over silicagel (eluent: CH$_2$Cl$_2$/MeOH/NH$_3$
97/2.7/0.3) affords 5.07 g of pure 1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl
methanesulfonate \textit{a10-2}.

Yield: 71%.

LC-MS (MH$^+$): 367.

10.3 Synthesis of 4-[(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-
yl)oxy]benzonitrile \textit{50}.

To a solution of 1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl
methanesulfonate \textit{a10-2} (0.183 g, 0.5 mmol, 1 eq) in acetonitrile (4 ml) is added K$_2$CO$_3$
(0.138 g, 1 mmol, 2 eq) and 4-hydroxybenzonitrile (0.060 g, 0.5 mmol, 1 eq). The
solution is stirred overnight at 85°C. After filtration and solvent removal, the residue is
purified by basic reverse phase chromatography on silicagel (gradient: CH$_3$CN/H$_2$O/NH$_4$OH from 40/60/0.1 to 70/30/0.1) to give 85 mg of pure 4-[(1-[2-[2-(2-
oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl)oxy]benzonitrile \textit{50}.

Yield: 43%.

LC-MS (MH$^+$): 390.

11.1 Synthesis of 1-{2-[2-(3-hydroxyazetidin-1-yl)ethyl]phenyl}piperidin-2-one a11-1.

To [2-(2-oxopiperidin-1-yl)phenyl]acetaldehyde a3-1 (1.32 g, 6.09 mmol, 1 eq) in methanol (50 ml) is added azetidin-3-ol hydrochloride a11-0 (0.76 g, 6.96 mmol, 1.14 eq). After stirring at room temperature for approximately 30 minutes, acetic acid (522 µl, 9.13 mmol, 1.5 eq), then NaBH₃CN (1.15 g, 18.26 mmol, 3 eq) are added. The reaction mixture is stirred overnight at room temperature, then filtered and loaded on an ion exchange acidic resin cartridge prewashed with methanol. The cartridge is then washed with approximately 3 column volumes of methanol, then eluted with 3 column volumes of 1M ammonia in methanol. This eluate is evaporated to dryness. To the residue obtained is added water (50 ml) and dichloromethane (50 ml). After vigorous shaking and addition of brine, the 2 phases are separated. The organic phase is washed with water (50 ml). The aqueous phases are pooled and washed 3 times with iPrOH/CH₂Cl₂ (25ml/50ml). The organic phases are combined, evaporated to dryness to give 212.6mg of 1-{2-[2-(3-hydroxyazetidin-1-yl)ethyl]phenyl}piperidin-2-one a11-1 (212.6mg, 0.775mmole if assumed pure, 12.7% yield), which is used in next step without any further purification.

Yield: 13 %.

LC-MS (M⁺H): 275.

11.2 Synthesis of 1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl methanesulfonate a11-2.

To 1-{2-[2-(3-hydroxyazetidin-1-yl)ethyl]phenyl}piperidin-2-one a11-1 (212 mg, 0.77 mmol, 1 eq) in dichloromethane (15 ml) under nitrogen is added triethylamine (216.04 µl, 1.55 mmol, 2 eq). Methanesulfonyl chloride (106.53 mg, 0.93 mmol, 1.2 eq) is added at 0°C and the reaction mixture is allowed to reach room temperature while
stirring for 2 hours under a nitrogen atmosphere. Additional triethylamine (216 µl, 1.55 mmol, 2 eq) and methanesulfonyl chloride (106.53 mg, 0.93 mmol, 1.2 eq) are added, and the reaction mixture stirred at room temperature for an additional hour. Water (50 ml) is then added, the two phases vigorously shaken and separated. The organic phase is dried over MgSO₄, filtered and evaporated to dryness to give 1-{2-[(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl methanesulfonate a11-2 which is used in next step without any further purification.

Yield: assumed quantitative.

LC-MS (MH⁺): 353.

11.3 Synthesis of 4-{1-[2-[(2-oxopiperidin-1-yl)phenyl]ethyl]azetidin-3-yl]oxy}benzonitrile oxalate 55.

To 1-{2-[(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl methanesulfonate a11-2 (273 mg, 0.775 mmol, 1 eq) and 4-hydroxybenzonitrile (110.8 mg, 0.93 mmol, 1.2 eq) in acetonitrile (5 ml) is added, under stirring, K₂CO₃ (374.9 mg, 2.71 mmol, 3.5 eq). The reaction mixture is heated at 100°C for 10 minutes under microwave conditions. The reaction mixture is cooled, diluted with a mixture of acetonitrile/CH₂Cl₂/MeOH/DMF (1/1/1/1) (approximately 10 ml) to ensure the solubilisation of the expected product. The suspension obtained is loaded on an ion exchange acidic resin cartridge (2 g) prewashed with methanol. The cartridge is washed with approximately 3 column volumes of methanol, then eluted with 3 column volumes of 1M ammonia in methanol.

The eluate is evaporated to dryness and the crude material is purified by reverse phase chromatography (gradient: acetonitrile/H₂O/NH₄OH from 40/60/0.1 to 70/30/0.1 in 10 minutes). The residue obtained is dissolved in acetone (approximately 2 ml) and oxalic acid (4.4 mg, 0.05 mmole, 1 eq) in acetone (2 ml) is added. This solution is evaporated slowly and some crystals appear. Acetone (approximately 2 ml) then diethyl ether (approximately 10 ml) are added to give a white precipitate which is filtrated, extensively washed with diethyl ether and dried overnight at 40°C under vacuum to afford 15.5 mg of 4-{1-[2-[(2-oxopiperidin-1-yl)phenyl]ethyl]azetidin-3-yl]oxy}benzonitrile oxalate 55.

Yield: 4.3 % over 2 steps.

LC-MS (MH⁺): 376.

12.1 Synthesis of 1-(2-{2-[3-(piperidin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one a12-1.

1-(2-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one 36 (30 mg, 0.085 mmol, 1 eq) in glacial acetic acid is hydrogenated on PtC>2 at 40°C and 40 Psi for 0.5 hour in a H-cube reactor. The solvent is removed under vacuum to afford 28 mg of crude 1-(2-{2-[3-(piperidin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one a12-1 as a yellow oil which is used in the next step without any further purification. Yield: 93 %.

LC-MS (MH⁺): 356.

12.2 Synthesis of 1-(2-{2-[3-(1-acetylpiperidin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one 72.

To a solution of 1-(2-{2-[3-(piperidin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one a12-1 (25 mg, 0.070 mmol, 1 eq) in diethylether (2 ml) at 0°C are added triethylamine and acetic anhydride (7 µl, 0.077 mmol, 1.1 eq). The mixture is stirred for 1 hour at room temperature. The solvent is removed under vacuum. The residue obtained is purified by basic reverse phase chromatography (gradient: acetonitrile/H2O/ammonium formate from 5% to 95% of acetonitrile in 8 minutes) to afford 14.5 mg of 1-(2-{2-[3-(1-acetylpiperidin-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one 72 as a yellow oil. Yield: 50 %.

LC-MS (MH⁺): 398.

13.1 Synthesis of methyl (1-[2-[2-oxopiperidin-1-yl]phenyl]ethyl)pyrrolidin-3-yl)acetate a13-1.

To a solution of 2-[2-[2-oxopiperidin-1-yl]phenyl]ethyl 4-methylbenzenesulfonate a2-3 (2.85 g, 7.65 mmol, 1 eq) in DMF (10 ml) at room temperature are added diisopropylethylamine (2.65 ml, 15.30 mmol, 2 eq) and methyl pyrrolidin-3-ylacetate a13-0 (1.08 g, 7.65 mmol, 1 eq). The mixture is stirred at 80 °C overnight. The solvent is removed under vacuum. The residue obtained is purified by chromatography over silicagel (eluent: CH2Cl2/EtOH 95/5) to afford 1.05 g of methyl (1-[2-[2-oxopiperidin-1-yl]phenyl]ethyl)pyrrolidin-3-yl)acetate a13-1 as a yellow oil.

Yield: 42 %.

LC-MS (MH+): 345.


Methyl (1-[2-[2-oxopiperidin-1-yl]phenyl]ethyl)pyrrolidin-3-yl)acetate a13-1 (0.15 g, 0.435 mmol, 1 eq) is dissolved in THF (5ml). MeMgBr (3M in diethyl ether, 435 ml, 1.3 mmol, 3 eq) is added dropwise at 0°C. The reaction mixture is stirred at room temperature for 1 hour, and then quenched with saturated aqueous NH4Cl. The two phases are separated, the aqueous layer is further extracted with AcOEt (3x20 ml), the pooled organic phases are then washed with brine (20 ml), dried with Na2SC>4 and concentrated under reduced pressure to afford 54 mg of 1-(2-[2-[3-(2-hydroxy-2-methylpropyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one a13-2 as a yellow oil which is used in the next step without any further purification.
Yield: 36%.
LC-MS (MH⁺): 345.


Diethylaminosulfur trifluoride (31 µl, 0.235 mmol, 1.5 eq) is added to 1-(2-[2-[3-(2-hydroxy-2-methylpropyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one a13-2 (54 mg, 0.157 mmol, 1 eq) in dichloromethane (5 ml) dropwise and the reaction mixture stirred at room temperature overnight. The reaction mixture is poured into water and stirring is pursued for 1 hour. After phase separation, the aqueous phase is further extracted with dichloromethane (3 times). The combined organic phases are washed with brine (1 time), dried over Na2SC>4, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by basic reverse phase chromatography (gradient: acetonitrile/H2O/ammonium formiate from 5% to 40% of acetonitrile in 8 minutes) to afford 6 mg of 1-(2-[2-[3-(2-fluoro-2-methylpropyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one 85 as a yellow oil.

Yield: 65%.
LC-MS (MH⁺): 347.


14.1 Synthesis of (1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl)acetic acid a14-1.

Methyl (1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl)acetate a13-1 (500 mg, 0.87 mmol, 1 eq) is dissolved in MeOH/H2O (4 ml/1 ml) and LiOH (47 mg, 1.7 mmol, 2 eq) is added. The reaction mixture is stirred at 30°C for 1 hour, then quenched with HCl 1M (100 µl). The resulting mixture is diluted with n-butanol (15 ml), and stirred overnight at room temperature. After phase separation the organic layer is dried on Na2SC>4, filtered and the filtrate is concentrated under reduced pressure to
afford 229 mg of (1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)acetic acid a14-1 as a colorless oil which is used in the next step without any further purification.

Yield: 80%.

LC-MS (MH+=) : 331.

14.2 Synthesis of 1-[2-{2-[3-[2-oxo-2-(pyrrolidin-1-yl)ethyl]pyrrolidin-1-yl]ethyl}phenyl]piperidin-2-one 86.

To (1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)acetic acid a14-1 (115 mg, 0.348 mmol, 1 eq) and pyrrolidine (32 µl, 0.382 mmol 1.1 eq) in dichloromethane (5 ml) are added dicyclohexylcarbodiimide (79 mg, 0.82 mmol, 1.1 eq), hydroxybenzotriazole (52 mg, 0.382 mmol, 1.1 eq) and diisopropylethylamine (131 µl, 0.731 mmol, 2.1 eq). The reaction mixture is stirred overnight at room temperature, then filtered and concentrated under reduced pressure. The residue is purified by reverse phase chromatography (gradient: CH$_3$CN/H$_2$O/NH$_4$OH from 30/70/0.1 to 60/40/0.1) to afford 9 mg of 1-[2-{2-[3-[2-oxo-2-(pyrrolidin-1-yl)ethyl]pyrrolidin-1-yl]ethyl}phenyl]piperidin-2-one 86 as a yellow oil.

Yield: 7%.

LC-MS (MH+=) : 384.


15.1 Synthesis of 1-(3-{2-[3-(6-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one a15-1.

1-(3-{2-[3-(6-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-yl)piperidin-2-one a15-1 may be prepared according to the procedure described in example 4.4.

LC-MS (MH+=) : 369.
15.2 Synthesis of 1-[3-(2-{3-[6-(2,2,2-trifluoroethoxy)pyridin-2-yl]pyrrolidin-1-yl}ethyl)pyridin-2-yl]piperidin-2-one 108.

1-(3-{2-[3-(6-fluoropyridin-2-yl)pyrrolidin-1-yl}ethyl]pyridin-2-yl)piperidin-2-one [a15-1] (32 mg, 0.087 mmol, 1 eq), 2,2,2-trifluoroethanol (13 mg, 0.13 mmol, 1.5 eq) and t-BuOK (48.8 mg, 0.43 mmol, 5 eq) are dissolved in DMSO. The reaction mixture is stirred at room temperature. After 2 hours, 2,2,2-trifluoroethanol (8.7 mg, 0.087 mmol, 1 eq) is added and the reaction mixture is stirred overnight. Ethyl acetate and aqueous saturated NaCl solution are then added, the two phases separated and the aqueous layer is reextracted with ethyl acetate (3 times). The organic layers are pooled, dried with MgSC>4, filtered and condensed under reduced pressure. The residue is purified by basic reverse phase chromatography (gradient: water/acetonitrile/solvent C from 90/0/10 to 5/85/10 in 10 minutes; solvent C: acetonitrile/water 1/1 + NH4CO3 0.4 % w/v and NH4OH 0.05 % v/v) to afford 11.7 mg of 1-[3-(2-[3-(6-(2,2,2-trifluoroethoxy)pyridin-2-yl]pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one 108.

Yield: 30 %.

LC-MS (MH+): 449.


1-(3-{2-[3-(6-hydroxy)pyridin-2-yl]pyrrolidin-1-yl}ethyl]pyridin-2-yl)piperidin-2-one a16-1 may be prepared from 6-(pyrrolidin-3-yl)pyridin-2-ol a16-0 according to the method described in example 4.4.

Yield: 46 %.

LC-MS (MH+): 367.

2,2-Difluoro-2-(fluorosulfonyl)acetic acid (9.72 mg, 0.054 mmol, 1 eq) is added slowly, under stirring, to a mixture of 1-(3-{2-[3-(6-hydroxypyridin-2-yl)pyrrolidin-1-yl]ethyl)pyridin-2-yl]piperidin-2-one a16-1 (20 mg, 0.054 mmol, 1 eq) and dry sodium sulfate (0.78 mg, 0.005 mmol, 0.1 eq) in dry acetonitrile (400 µl). The reaction is stirred for 2 h at room temperature, then water (100 µl) is added. The resulting solution is concentrated in vacuo. The residue is purified by basic reverse phase chromatography (gradient: H₂O/acetonitrile/NH₄OH from 50/50/0.1 to 20/80/0.1) to afford 9.4 mg of 1-[3-(2-[3-[6-(difluoromethoxy)pyridin-2-yl]pyrrolidin-1-yl]ethyl)pyridin-2-yl]piperidin-2-one 109.

Yield: 41%.

LC-MS (MH⁺): 417.

Example 17. Synthesis of 1-[1-methyl-4-(2-[3-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]ethyl)-1H-pyrazol-3-yl]piperidin-2-one oxalate 111.

17.1 Synthesis of 4-(2-methoxyvinyl)-1-methyl-1H-pyrazol-3-amine a17-1.

4-(2-methoxyvinyl)-1-methyl-1H-pyrazol-3-amine a17-1 may be prepared from 3-amino-1-methyl-1H-pyrazole-4-carbaldehyde a17-0 according to the procedure described in example 4.2.

Yield: assumed quantitative.

LC-MS (MH⁺): 154.
17.2 Synthesis of 1-[4-(2-methoxyvinyl)-1-methyl-1H-pyrazol-3-yl]piperidin-2-one a17-2.
A mixture of 4-(2-methoxyvinyl)-1-methyl-1H-pyrazol-3-amine a17-1 (500 mg, 3.27 mmol, 1 eq), 5-bromovaleryl chloride (651.9 mg, 3.27 mmol, 1 eq), potassium hydroxide (550.1 mg, 9.80 mmol, 3 eq), 4-dimethylaminopyridine (39.9 mg, 0.33 mmole, 0.1 eq) and N,N,N-tributylbutan-1-aminium bromide (105.3 mg, 0.33 mmole, 0.1 eq) in toluene (15 ml) is heated to reflux overnight. After filtration and evaporation the residue is purified by reverse phase chromatography (basic mode, gradient: H₂O/acetonitrile/NH₄OH from 80/20/0.1 to 50/50/0.1 in 10 minutes) to afford 1-[4-(2-methoxyvinyl)-1-methyl-1H-pyrazol-3-yl]piperidin-2-one a17-2.
LC-MS (MH⁺): 236.

17.3 Synthesis of 1-[1-methyl-3-(2-oxopiperidin-1-yl)-1H-pyrazol-4-yl]acetaldehyde a17-3.
[1-methyl-3-(2-oxopiperidin-1-yl)-1H-pyrazol-4-yl]acetaldehyde a17-3 may be prepared from 1-[4-(2-methoxyvinyl)-1-methyl-1H-pyrazol-3-yl]piperidin-2-one a17-2 according to the procedure described in example 4.3.

17.4 Synthesis of 1-[1-methyl-4-(2-[3-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]ethyl)-1H-pyrazol-3-yl]piperidin-2-one oxalate 111.
1-[1-methyl-4-(2-[3-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]ethyl)-1H-pyrazol-3-yl]piperidin-2-one oxalate 111 may be prepared from [1-methyl-3-(2-oxopiperidin-1-yl)-1H-pyrazol-4-yl]acetaldehyde a17-3 according to the procedure described in example 4.4.
Yield: 39 % from a17-2 (over 2 steps).
LC-MS (MH⁺): 421.

18.1 Synthesis of 1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one a18-1.

To a solution of 3-chloro-5-(trifluoromethyl)pyridin-2-amine a18-0 (700 mg, 3.54 mmol, 1 eq) in dry THF (15 ml) cooled at 0°C is added NaH 60% in mineral oil (283 mg, 7.08 mmol, 2 eq). The reaction mixture is stirred at 0°C for 10 minutes then at room temperature for 20 minutes. The reaction mixture is then cooled down to 0°C and 5-bromovaleryl chloride (707 mg, 3.543 mmol, 1 eq) is added. The reaction mixture is stirred at 70°C for 3 hours then evaporated to dryness. The residue obtained is retaken in dichloromethane, washed with aqueous NH₄Cl (1 time), washed with saturated aqueous NaHCO₃ (1 time). The organic phase is dried over MgSO₄, filtered and evaporated to dryness. The residue obtained is purified by flash chromatography over silicagel (24 g, gradient: dichloromethane/MeOH from 100/0 to 94/6) to afford 480 mg of 1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one a18-1.

Yield: 49%.

LC-MS (MH⁺): 279/281.

18.2 Synthesis of 1-[5-(trifluoromethyl)-3-vinylpyridin-2-yl]piperidin-2-one a18-2.

To a solution of 1-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one a18-1 (260 mg, 0.933 mmol, 1 eq) and vinylboronic acid pinacol ester (287 mg, 1.866 mmol, 2 eq) in a mixture of acetonitrile/water (3/2) is added tripotassium phosphate (793 mg, 3.732 mmol, 2 eq), (2,6-dimethoxy-1,1'-biphenyl-2-yl)dicyclohexylphosphine (77 mg, 0.187 mmol, 0.2 eq), Palladium(II) acetate (21 mg, 0.093 mmol, 0.1 eq) and the reaction mixture is heated at 120°C for 40 minutes. After evaporation the residue is retaken in
dichloromethane, this organic phase is washed with saturated aqueous NaHCC\(_3\) (2 times), dried over MgSC\(_4\), filtered and evaporated to dryness. The residue obtained is purified by flash chromatography over silicagel (12 g; gradient: dichloromethane/MeOH from 100/0 to 94/6) to afford 380 mg of 1-[5-(trifluoromethyl)-3-vinylpyridin-2-yl]piperidin-2-one **a18-2**.

Yield: assumed quantitative.

**LC-MS** (MH\(^+\)): 271.

### 18.3 Synthesis of 1-[3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one **110**.

To a solution of 1-[5-(trifluoromethyl)-3-vinyl]pyridin-2-yl]piperidin-2-one **a18-2** (310 mg, 1.147 mmol, 1 eq) and 2-pyrrolidin-3-yl pyridine (221 mg, 1.491 mmol, 1.3 eq) in ethanol (10 ml) is added triethylamine (348 mg, 479 \(\mu\)l, 3.441 mmol, 3 eq). The reaction mixture is stirred at 90°C for 7 hours, then heated overnight at 85°C. The reaction mixture is evaporated to dryness and retaken in dichloromethane. This organic phase is washed with aqueous NH\(_4\)Cl (1 time), saturated aqueous NaHCC\(_3\) (2 times), then dried over MgSC\(_4\), filtered and evaporated to dryness. The residue obtained is purified by flash chromatography over silicagel (12 g; gradient: from dichloromethane/MeOH 100/0 to 94/6), dried under vacuum to afford 91.4 mg of 1-[3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one **110**.

Yield: 19%.

**LC-MS** (MH\(^+\)): 419.

### **Example 19. Synthesis of 1-(5-fluoro-3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one (80/20 mixture of enantiomers) **112**.**
19.1 Synthesis of 5-fluoro-2-(2-oxopiperidin-1-yl)nicotinaldehyde a19-1.

5-Fluoro-2-(2-oxopiperidin-1-yl)nicotinaldehyde a19-1 may be prepared from 2-bromo-5-fluoronicotinaldehyde a19-0 according to the procedure described in example 4.1.

Yield: assumed quantitative.

LC-MS (MH+): 223.

19.2 Synthesis of 1-[5-fluoro-3-(2-methoxyvinyl)pyridin-2-yl]piperidin-2-one a19-2.

1-[5-Fluoro-3-(2-methoxyvinyl)pyridin-2-yl]piperidin-2-one a19-2 may be prepared from 5-fluoro-2-(2-oxopiperidin-1-yl)nicotinaldehyde a19-1 according to the procedure described in example 4.2.

Yield: 80 %.

LC-MS (MH+): 251.

19.3 Synthesis of 1-(5-fluoro-3-[2-(pyridin-2-yl)pyrrolidin-1-yl]ethyl)piperidin-2-yl)piperidin-2-one (80/20 mixture of enantiomers) 112.

To a solution of 1-[5-fluoro-3-(2-methoxyvinyl)pyridin-2-yl]piperidin-2-one a19-2 (620 mg, 2.477 mmol, 1 eq) in acetonitrile (25 ml) is added at 0°C sodium iodide (557 mg, 3.716 mmol, 1.5 eq) and trimethylsilyl chloride (404 mg, 3.716 mmol, 1.5 eq), and the reaction mixture is stirred at room temperature for 16 hours to form in situ [5-fluoro-2-(2-oxopiperidin-1-yl)pyridin-3-yl]acetaldehyde a19-3. In parallel, 2-(pyrrolidin-3-yl)pyridine enantiomer 2 dihydrochloride a1-67 (654 mg, 2.973 mmol, 1.2 eq) is dissolved in acetonitrile, loaded on a carbonate resin, the resin washed with dichloromethane and the pooled filtrates are evaporated to dryness to afford 2-(pyrrolidin-3-yl)pyridine enantiomer 2 as a free base. The residue obtained is added to intermediate a19-3. NaBH(OAc)3 (1050 mg, 4.954 mmol, 2 eq) is added, the reaction mixture is stirred overnight and is still incomplete. Racemic 2-(pyrrolidin-3-yl)pyridine (0.4 eq) is added, the reaction mixture heated overnight at 90°C and evaporated to dryness. The residue of evaporation is retaken in dichloromethane. This organics phase is washed with saturated aqueous NaHCC>3 (2 times), dried over MgSC>4, filtered and evaporated to dryness. The residue obtained is dissolved in acetonitrile (12 ml), HCl 5M (approximately 4ml) is added and the mixture is stirred at 40°C for 3 hours. Dichloromethane is then added, and the organic phase washed with saturated aqueous NaHCC>3 (2 times), dried over MgSC>4, filtered and evaporated to dryness. This residue is purified by flash chromatography over silicagel (12 g; gradient: from CH2Cl2/Methanol 100/0 to 94/6), then by reverse phase chromatography (basic conditions: gradient: acetonitrile/H2O/NH4OH from 20/80/0.1 to 50/50/0.1 ) to afford 38 mg of 1-(5-fluoro-3-[2-
[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one 112 as a 80/20 mixture of enantiomers.

Yield: 4.2%.

LC-MS (MH⁺): 369.

Table (I) indicates the IUPAC name of the compound, the ion peak observed in mass spectroscopy, the 1H NMR description, the melting point or onset on DSC, and the alphaD.
Table I: Physical Characterization of Example Compounds.

<table>
<thead>
<tr>
<th>n°</th>
<th>ADDUCT</th>
<th>IUPAC_NAME</th>
<th>LC-MS (MH&lt;sup&gt;+&lt;/sup&gt;)</th>
<th>NMR description (CDCl&lt;sub&gt;3&lt;/sub&gt; otherwise specified)</th>
<th>αD (589 nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.oxalic acid</td>
<td>(+)-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate</td>
<td>392</td>
<td>7.57 (dd, J = 7.8, 3.8 Hz, 1 H), 7.45 (m, 1 H), 7.39 (m, 2 H), 7.31 (m, 3 H), 7.23 (m, 1 H), 3.91 (m, 1 H), 3.69 (m, 1 H), 3.59 (m, 1 H), 3.47 (m, 2 H), 3.39 (m, 1 H), 3.33 (d, J = 6.3 Hz, 2 H), 3.26 (m, 1 H), 2.83 (m, 2 H), 2.45 (m, 1 H), 2.38 (s, 1 H), 2.33 (d, J = 5.8 Hz, 1 H), 2.10 (m, 1 H), 1.91 (s, 2 H), 1.85 (d, J = 0.8 Hz, 2 H)</td>
<td>+0.005 (0.51%)</td>
</tr>
<tr>
<td>2</td>
<td>1.oxalic acid</td>
<td>N-methyl-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate</td>
<td>406</td>
<td>8.34 (q, J = 3.8 Hz, 1 H), 7.58 (dd, J = 7.8, 4.5 Hz, 1 H), 7.45 (m, 1 H), 7.32 (m, 6 H), 3.81 (m, 5 H), 3.58 (m, 1 H), 3.35 (m, 1 H), 2.84 (m, 2 H), 2.76 (d, J = 4.5 Hz, 3 H), 2.42 (m, 2 H), 2.30 (d, J = 1.8 Hz, 2 H), 2.11 (m, 1 H), 1.88 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1.oxalic acid</td>
<td>2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate</td>
<td>374</td>
<td>7.84 (d, J = 7.8 Hz, 1 H), 7.76 (m, 2 H), 7.47 (s, 1 H), 7.40 (m, 1 H), 7.32 (m, 2 H), 7.22 (m, 1 H), 3.88 (m, 2 H), 3.69 (d, J = 9.3 Hz, 1 H), 3.58 (m, 1 H), 3.43 (d, J = 1.5 Hz, 2 H), 3.36 (m, 1 H), 3.33 (s, 1 H), 3.25 (m, 2 H), 2.81 (m, 2 H), 2.47 (s, 1 H), 2.35 (d, J = 16.6 Hz, 2 H), 2.06 (m, 1 H), 1.87 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1.oxalic acid</td>
<td>2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzamide oxalate</td>
<td>406</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>1.oxalic acid</td>
<td>1-[2-{2-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl}ethyl]phenyl)piperidin-2-one oxalate</td>
<td>417</td>
<td>7.87 (t, J = 7.0 Hz, 1 H), 7.73 (m, 2 H), 7.49 (m, 1 H), 7.40 (m, 1 H), 7.32 (m, 2 H), 7.22 (m, 1 H), 3.83 (m, 1 H), 3.40 (m, 8 H), 2.82 (m, 2 H), 2.46 (s, 1 H), 2.39 (m, 1 H), 2.30 (m, 1 H), 2.08 (m, 1 H), 1.89 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1.oxalic acid</td>
<td>1-(2-{2-[3-(2-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate</td>
<td>379</td>
<td>7.32 (m, 6 H), 7.03 (d, J = 8.0 Hz, 1 H), 6.96 (t, J = 7.5 Hz, 1 H), 3.81 (s, 3 H), 3.52 (m, 9 H), 2.82 (m, 2 H), 2.44 (m, 1 H), 2.32 (m, 2 H), 2.08 (m, 1 H), 1.89 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT IUPAC_NAME</td>
<td>LC-MS (MH+)</td>
<td>NMR description (CDCl3 otherwise specified)</td>
<td>&lt;x0 (589 nm)</td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>------------------</td>
<td>-------------</td>
<td>-------------------------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>1-oxalic acid 1-2-[2-[3-(3-methoxyphenyl)pyrroli...</td>
<td>379</td>
<td>7.40 (m, 1 H), 7.27 (m, 4 H), 6.93 (m, 2 H), 6.84 (dd, J = 7.8, 1.5 Hz, 1 H), 3.76 (s, 3 H), 3.40 (m, 9 H), 2.83 (m, 2 H), 2.37 (m, 3 H), 2.04 (m, 1 H), 1.86 (m, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>1-oxalic acid 1-2-[2-[3-(4-methoxyphenyl)pyrroli...</td>
<td>379</td>
<td>7.40 (m, 1 H), 7.28 (m, 5 H), 6.92 (d, J = 8.5 Hz, 2 H), 3.72 (m, 4 H), 3.58 (m, 1 H), 3.47 (m, 3 H), 3.30 (m, 3 H), 3.15 (m, 1 H), 2.84 (m, 2 H), 2.46 (m, 1 H), 2.34 (m, 2 H), 2.00 (m, 1 H), 1.88 (m, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>1-oxalic acid 1-2-[2-[3-(2-fluorophenyl)pyrroli...</td>
<td>367</td>
<td>7.50 (m, 1 H), 7.41 (m, 1 H), 7.32 (m, 3 H), 7.21 (m, 3 H), 3.77 (m, 1 H), 3.69 (m, 1 H), 3.58 (m, 1 H), 3.40 (m, 3 H), 3.25 (m, 3 H), 2.82 (m, 2 H), 2.46 (s, 1 H), 2.35 (m, 2 H), 2.07 (m, 1 H), 1.90 (m, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>1-oxalic acid 1-2-[2-[3-(2-chlorophenyl)pyrroli...</td>
<td>383/385</td>
<td>7.58 (m, 1 H), 7.47 (s, 1 H), 7.39 (m, 2 H), 7.31 (m, 3 H), 7.22 (m, 1 H), 3.92 (m, 1 H), 3.62 (m, 2 H), 3.39 (m, 3 H), 3.23 (m, 3 H), 2.82 (m, 2 H), 2.45 (m, 1 H), 2.34 (m, 2 H), 2.05 (m, 1 H), 1.88 (d, J = 4.5 Hz, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>1-2-[2-[3-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]pyrroli...</td>
<td>431</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>1-oxalic acid (+)-2-{1-[2-[2-(2-oxopiperidin-1-...</td>
<td>374</td>
<td>7.84 (d, J = 7.5 Hz, 1 H), 7.75 (m, 2 H), 7.47 (s, 1 H), 7.40 (m, 1 H), 7.31 (m, 2 H), 7.22 (m, 1 H), 3.90 (m, 1 H), 3.70 (m, 1 H), 3.59 (m, 1 H), 3.45 (m, 2 H), 3.34 (d, J = 11.8 Hz, 1 H), 3.25 (m, 2 H), 2.82 (m, 2 H), 2.47 (s, 1 H), 2.34 (d, J = 16.8 Hz, 2 H), 2.06 (m, 1 H), 1.84 (m, 4 H)</td>
<td>+0.042 (0.52%)</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>1-oxalic acid (-)-2-{1-[2-[2-(2-oxopiperidin-1-...</td>
<td>374</td>
<td>7.84 (d, J = 7.5 Hz, 1 H), 7.75 (m, 2 H), 7.47 (s, 1 H), 7.40 (m, 1 H), 7.31 (m, 2 H), 7.22 (m, 1 H), 3.90 (m, 1 H), 3.70 (m, 1 H), 3.59 (m, 1 H), 3.45 (m, 2 H), 3.34 (d, J = 11.8 Hz, 1 H), 3.25 (m, 2 H), 2.82 (m, 2 H), 2.47 (s, 1 H), 2.34 (d, J = 16.8 Hz, 2 H), 2.06 (m, 1 H), 1.84 (m, 4 H)</td>
<td>-0.073 (0.92%)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>αD (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>14</td>
<td>1-oxalic acid</td>
<td>1-(2-[2-(3-phenylpyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one</td>
<td>349</td>
<td>7.26 (m, 9 H), 3.58 (m, 1 H), 3.45 (m, 1 H), 3.31 (m, 1 H), 2.96 (td, J = 8.5, 2.8 Hz, 1 H), 2.70 (m, 2 H), 2.63 (m, 2 H), 2.56 (m, 2 H), 2.45 (s, 1 H), 2.36 (m, 2 H), 2.23 (m, 1 H), 1.86 (m, 4 H), 1.74 (m, 1 H)</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>1-oxalic acid</td>
<td>3-(1-[2-(2-oxoperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl)benzonitrile oxalate</td>
<td>374</td>
<td>7.95 (m, 1 H), 7.75 (m, 2 H), 7.60 (t, J = 7.8 Hz, 1 H), 7.44 (m, 1 H), 7.35 (d, J = 3.5 Hz, 2 H), 7.26 (m, 1 H), 3.63 (m, 9 H), 2.86 (m, 2 H), 2.41 (m, 3 H), 2.19 (m, 1 H), 1.92 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>1-oxalic acid</td>
<td>4-(1-[2-(2-oxoperidin-1-yl)phenyl]ethyl)pyrrolidin-3-yl)benzonitrile oxalate</td>
<td>374</td>
<td>7.86 (d, J = 8.0 Hz, 2 H), 7.62 (m, 2 H), 7.44 (d, J = 3.8 Hz, 1 H), 7.35 (d, J = 3.3 Hz, 2 H), 7.27 (m, 1 H), 3.63 (m, 9 H), 2.88 (m, 2 H), 2.44 (m, 3 H), 2.18 (m, 1 H), 1.93 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>1-oxalic acid</td>
<td>(-)-1-[2-(2-[3-[2-(pyrrolidin-1-yl)carbonyl]phenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one</td>
<td>446</td>
<td>7.48 (dd, J = 7.8, 4.3 Hz, 1 H), 7.37 (m, 2 H), 7.24 (m, 3 H), 7.14 (m, 2 H), 3.58 (m, 1 H), 3.47 (t, J = 6.8 Hz, 2 H), 3.32 (s, 14 H), 3.25 (d, J = 8.0 Hz, 1 H), 3.02 (t, J = 6.5 Hz, 2 H), 2.84 (t, J = 7.5 Hz, 1 H), 2.66 (m, 6 H), 2.55 (m, 1 H), 2.36 (t, J = 5.3 Hz, 2 H), 2.17 (m, 1 H), 1.88 (m, 6 H), 1.75 (m, 3 H)</td>
<td>-0.037 (0.45%)</td>
</tr>
<tr>
<td>18</td>
<td>1-oxalic acid</td>
<td>1-(2-[2-[3-(2-methoxyphenyl)piperidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate</td>
<td>393</td>
<td>7.27 (m, 6 H), 6.99 (m, 2 H), 3.80 (s, 3 H), 3.57 (m, 1 H), 3.40 (m, 4 H), 3.12 (m, 2 H), 2.89 (m, 4 H), 2.36 (m, 2 H), 1.85 (m, 7 H), 1.69 (s, 1 H)</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>1-oxalic acid</td>
<td>(+)-1-[2-(2-[3-(2-methoxyphenyl)pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate</td>
<td>379</td>
<td>7.32 (m, 6 H), 7.03 (d, J = 8.0 Hz, 1 H), 6.96 (t, J = 7.5 Hz, 1 H), 3.81 (s, 3 H), 3.52 (m, 9 H), 2.82 (m, 2 H), 2.44 (m, 1 H), 2.32 (m, 2 H), 2.08 (m, 1 H), 1.89 (s, 4 H)</td>
<td>+0.013 (0.52%)</td>
</tr>
<tr>
<td>20</td>
<td>1-oxalic acid</td>
<td>(-)-1-[2-(2-[3-(2-methoxyphenyl)pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate</td>
<td>379</td>
<td>7.32 (m, 6 H), 7.03 (d, J = 8.0 Hz, 1 H), 6.96 (t, J = 7.5 Hz, 1 H), 3.81 (s, 3 H), 3.52 (m, 9 H), 2.82 (m, 2 H), 2.44 (m, 1 H), 2.32 (m, 2 H), 2.08 (m, 1 H), 1.89 (s, 4 H)</td>
<td>-0.015 (0.63%)</td>
</tr>
<tr>
<td>21</td>
<td>1-oxalic acid</td>
<td>1-[2-(2-[3-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate</td>
<td>417</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>&lt;x0 (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>22</td>
<td>1.oxalic acid</td>
<td>1-{2-{2-[3-(3-fluorophenyl)pyrrolidin-1-y]ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>367</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>1.oxalic acid</td>
<td>1-{2-[2-{3-phenylazetidin-1-y}ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>335</td>
<td>7.41 (m, 5 H), 7.31 (m, 3 H), 7.22 (m, 1 H), 4.34 (d, J = 16.1 Hz, 2 H), 4.07 (m, 3 H), 3.57 (m, 1 H), 3.29 (m, 3 H), 2.65 (m, 2 H), 2.37 (m, 2 H), 1.88 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>1.oxalic acid</td>
<td>1-{2-{2-[3-(3-fluorophenyl)pyrrolidin-1-y]ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>381</td>
<td>7.39 (m, 2 H), 7.30 (m, 2 H), 7.16 (m, 4 H), 3.57 (m, 1 H), 3.39 (m, 4 H), 3.09 (m, 3 H), 2.84 (m, 3 H), 2.36 (m, 2 H), 1.87 (m, 7 H), 1.67 (m, 1 H), 1.06 (t, J = 7.0 Hz, 1 H)</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>1.oxalic acid</td>
<td>1-{2-[2-[3-(3-methoxyphenyl)pyrrolidin-1-y]ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>393</td>
<td>7.34 (m, 1 H), 7.25 (m, 3 H), 7.18 (m, 1 H), 6.83 (m, 3 H), 3.75 (s, 3 H), 3.56 (m, 1 H), 3.35 (m, 2 H), 3.21 (m, 2 H), 2.89 (m, 3 H), 2.74 (m, 2 H), 2.34 (m, 2 H), 1.84 (m, 6 H), 1.63 (m, 2 H)</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>1.oxalic acid</td>
<td>1-{2-[2-{3-phenylpiperidin-1-y}ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>363</td>
<td>7.35 (t, J = 7.7 Hz, 3 H), 7.27 (m, 5 H), 7.19 (m, 1 H), 3.56 (m, 1 H), 3.31 (m, 3 H), 2.98 (m, 3 H), 2.74 (m, 4 H), 2.34 (m, 2 H), 1.84 (m, 7 H), 1.62 (m, 1 H)</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>1.oxalic acid</td>
<td>1-{2-[2-[3-(4-chlorophenyl)pyrrolidin-1-y]ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>383/385</td>
<td>(DMSO) 7.41 (s, 1 H), 7.33 (m, 4 H), 7.24 (m, 2 H), 7.13 (m, 1 H), 3.48 (m, 4 H), 3.22 (m, 7 H), 2.73 (m, 2 H), 2.25 (m, 2 H), 1.94 (m, 1 H), 1.75 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>1.oxalic acid</td>
<td>1-{2-{2-[3-(3-chlorophenyl)pyrrolidin-1-y]ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>383/385</td>
<td>(DMSO) 7.47 (d, 1 H, J = 1.9 Hz), 7.39 (m, 2 H), 7.31 (m, 4 H), 7.22 (m, 1 H), 3.56 (m, 4 H), 3.30 (m, 8 H), 2.83 (m, 2 H), 2.36 (m, 3 H), 1.86 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>1.oxalic acid</td>
<td>1-{2-[2-[3-(benzyloxy)pyrrolidin-1-y]ethyl[phenyl]piperidin-2-one oxalate}</td>
<td>379</td>
<td>7.20 (m, 9 H), 4.43 (s, 2 H), 4.22 (s, 1 H), 3.49 (m, 1 H), 3.33 (s, 2 H), 3.25 (d, J = 5.3 Hz, 2 H), 3.20 (m, 1 H), 3.11 (m, 2 H), 2.72 (m, 2 H), 2.36 (s, 1 H), 2.25 (m, 1 H), 2.09 (m, 1 H), 2.00 (m, 1 H), 1.79 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>αD (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>--------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>30</td>
<td>1-oxalic acid</td>
<td>1-[2-[2-[3-(4-fluorophenyl)azetidin-1-yl]ethyl]phenyl]piperidin-2-one oxalate</td>
<td>353</td>
<td>7.49 (m, 2 H), 7.43 (m, 1 H), 7.32 (m, 2 H), 7.23 (m, 3 H), 4.30 (m, 2 H), 4.02 (m, 3 H), 3.58 (m, 1 H), 3.29 (m, 3 H), 2.64 (m, 2 H), 2.46 (m, 1 H), 2.35 (m, 1 H), 1.85 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>1-oxalic acid</td>
<td>3-(1-[2-[2-(oxopiperidin-1-yl)phenyl]ethyl]azetidin-3-yl)benzonitrile oxalate</td>
<td>360</td>
<td>7.97 (s, 1 H), 7.77 (s, 2 H), 7.59 (s, 1 H), 7.42 (s, 1 H), 7.32 (s, 2 H), 7.22 (s, 1 H), 4.33-4.30 (d, 2 H), 4.10 (s, 3 H), 2.64-2.33 (m overlap with solvent peak), 1.88 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>1-oxalic acid</td>
<td>1-[2-[2-[3-(2-fluorophenyl)azetidin-1-yl]ethyl]phenyl]piperidin-2-one oxalate</td>
<td>353</td>
<td>7.52-7.19 (m, 8 H), 4.40-4.06 (m, 6 H), 3.34-3.25 (m, 4 H), 2.72-2.60 (m, 2 H), 2.38-2.31 (m, 1 H), 1.89 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>1-oxalic acid</td>
<td>1-[2-[2-[3-(cyclohexylpyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one oxalate</td>
<td>355</td>
<td>7.43 (internal standard), 7.37-7.34 (m,1H), 7.31-7.25 (m,2H), 7.19-7.15 (m,1H), 6.88-6.71 (internal standard), 3.67-3.51 (m,3H), 3.37-3.17 (m,4H), 3.15-2.6 (m,4H), 2.45-2.32 (m,2H), 2.14-1.80 (m,6H), 1.73-1.49 (m,6H), 1.25-1.02 (m,4H), 0.95-0.81 (m,2H), 0.16 (internal standard)</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>1-oxalic acid</td>
<td>1-[2-[2-[3-(2-hydroxyphenyl)pyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one oxalate</td>
<td>365</td>
<td>7.17 (m, 1 H), 7.08 (m, 2 H), 6.98 (m, 2 H), 6.86 (m, 1 H), 6.62 (m, 1 H), 6.56 (m, 1 H), 3.48 (m, 2 H), 3.35 (m, 1 H), 3.23 (m, 2 H), 3.06 (m, 4 H), 2.60 (m, 2 H), 2.22 (m, 1 H), 2.09 (m, 2 H), 1.88 (m, 1 H), 1.64 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>2-oxalic acid</td>
<td>1-[2-[2-[3-(pyridin-2-yl)pyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one oxalate</td>
<td>350</td>
<td>8.56 (d, J = 4.5 Hz, 1 H), 7.80 (td, J = 7.5, 1.5 Hz, 1 H), 7.41 (d, J = 7.3 Hz, 2 H), 7.33 (m, 3 H), 7.23 (m, 1 H), 3.56 (m, 9 H), 2.85 (m, 2 H), 2.44 (m, 2 H), 2.34 (m, 1 H), 2.13 (m, 1 H), 1.86 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>1-oxalic acid</td>
<td>1-[2-[2-[3-(pyridin-2-yl)pyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one oxalate</td>
<td>350</td>
<td>8.56 (d, J = 4.5 Hz, 1 H), 7.80 (td, J = 7.5, 1.5 Hz, 1 H), 7.41 (d, J = 7.3 Hz, 2 H), 7.33 (m, 3 H), 7.23 (m, 1 H), 3.56 (m, 9 H), 2.85 (m, 2 H), 2.44 (m, 2 H), 2.34 (m, 1 H), 2.13 (m, 1 H), 1.86 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>1-oxalic acid</td>
<td>1-[2-[2-[3-(4-fluorophenyl)pyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one oxalate</td>
<td>367</td>
<td>7.18 (m, 3 H), 7.08 (m, 2 H), 6.96 (m, 3 H), 3.23 (m, 9 H), 2.59 (m, 2 H), 2.17 (m, 2 H), 2.08 (m, 1 H), 1.79 (m, 1 H), 1.62 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>λₒ (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>38</td>
<td>1.oxalic acid</td>
<td>1-(2-[2-(3R)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one oxalate</td>
<td>355</td>
<td>7.38 (m, 1 H), 7.30 (m, 2 H), 7.21 (m, 1 H), 3.58 (m, 1 H), 3.47 (m, 1 H), 3.31 (m, 3 H), 3.17 (m, 2 H), 2.97 (m, 1 H), 2.79 (m, 2 H), 2.56 (m, 4 H), 2.32 (m, 1 H), 2.17 (m, 1 H), 1.88 (d, J = 5.0 Hz, 4 H), 1.73 (dd, J = 12.0, 8.3 Hz, 1 H)</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>1.trifluoroacetate</td>
<td>1-(2-[2-(3S)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one trifluoroacetate</td>
<td>355</td>
<td>7.38 (m, 1 H), 7.30 (m, 2 H), 7.21 (m, 1 H), 3.58 (m, 1 H), 3.47 (m, 1 H), 3.31 (m, 3 H), 3.17 (m, 2 H), 2.97 (m, 1 H), 2.79 (m, 2 H), 2.56 (m, 4 H), 2.32 (m, 1 H), 2.17 (m, 1 H), 1.88 (d, J = 5.0 Hz, 4 H), 1.73 (dd, J = 12.0, 8.3 Hz, 1 H)</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>1.oxalic acid</td>
<td>1-(2-[2-(3S)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one oxalate</td>
<td>355</td>
<td>7.36 (m, 1 H), 7.29 (m, 2 H), 7.19 (m, 1 H), 3.57 (m, 1 H), 3.33 (m, 2 H), 3.09 (m, 4 H), 2.75 (m, 3 H), 2.45 (m, 2 H), 2.35 (m, 1 H), 2.14 (m, 1 H), 1.89 (m, 4 H), 1.69 (m, 1 H)</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>1.oxalic acid</td>
<td>4-(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]piperidin-3-yl)benzonitrile oxalate</td>
<td>388</td>
<td>7.85 (d, J = 8.1 Hz, 2 H), 7.53 (d, J = 8.1 Hz, 2 H), 7.28 (m, 4 H), 3.57 (m, 1 H), 3.44 (m, 3 H), 3.32 (m, 1 H), 3.07 (m, 4 H), 2.83 (m, 3 H), 2.36 (m, 2 H), 1.89 (m, 7 H), 1.70 (m, 1 H)</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>1.oxalic acid</td>
<td>(-)-4-(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]piperidin-3-yl)benzonitrile oxalate</td>
<td>374</td>
<td>7.60 (d, J = 8.0 Hz, 2 H), 7.36 (d, J = 8.2 Hz, 2 H), 7.17 (m, 1 H), 7.08 (m, 2 H), 6.99 (m, 1 H), 3.29 (m, 9 H), 2.60 (m, 2 H), 2.16 (m, 3 H), 1.83 (m, 1 H), 1.63 (m, 4 H)</td>
<td>-0.076 (0.53%)</td>
</tr>
<tr>
<td>43</td>
<td>1.15.oxalic acid</td>
<td>(+)-4-(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]piperidin-3-yl)benzonitrile oxalate</td>
<td>374</td>
<td>7.60 (m, 2 H), 7.36 (m, 2 H), 7.16 (m, 1 H), 7.08 (m, 2 H), 6.98 (m, 1 H), 3.51 (m, 1 H), 3.43 (m, 1 H), 3.35 (m, 1 H), 3.23 (m, 2 H), 3.15 (d, J = 7.0 Hz, 1 H), 3.03 (m, 3 H), 2.59 (m, 2 H), 2.32 (dd, J = 0.9, 0.4 Hz, 1 H), 2.20 (m, 1 H), 2.12 (m, 1 H), 1.82 (m, 1 H), 1.65 (m, 4 H)</td>
<td>+0.081 (0.5%)</td>
</tr>
<tr>
<td>44</td>
<td>1.oxalic acid</td>
<td>1-(2-[2-[3-(2-methoxyphenyl)azetidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate</td>
<td>365</td>
<td>7.41-7.20 (m, 6 H), 7.02-6.96 (m, 2 H), 4.34-4.30 (m, 2 H), 4.16-4.01 (m, 2 H), 3.79 (s, 2 H), 2.66-2.61 (m, 1 H), 2.37-2.33 (m, 1 H), 1.88 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>1.oxalic acid</td>
<td>1-(2-[2-[3-(2-fluorophenyl)azetidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate</td>
<td>353</td>
<td>7.26-6.93 (m, 8 H), 4.15-4.07 (m, 2 H), 3.92-3.81 (m, 3 H), 2.52-2.39 (m, 2 H), 2.20-2.14 (m, 1 H), 1.70 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>αD (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>46</td>
<td>1-oxalic acid</td>
<td>1-(2-[[3-(3,4-difluorophenyl)pyrrolidin-1-yl]ethyl]phenyl)piperdin-2-one oxalate</td>
<td>385</td>
<td>7.53 (m, 1 H), 7.41 (m, 2 H), 7.32 (m, 2 H), 7.23 (m, 2 H), 3.71 (m, 1 H), 3.57 (m, 2 H), 3.42 (m, 2 H), 3.33 (m, 1 H), 3.21 (m, 2 H), 2.81 (m, 2 H), 2.40 (m, 2 H), 2.30 (m, 1 H), 2.03 (m, 1 H), 1.87 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>1-oxalic acid</td>
<td>1-(2-[[3-(3-methoxyphenyl)azetidin-1-yl]ethyl]phenyl)piperdin-2-one oxalate</td>
<td>365</td>
<td>7.41 (s, 1 H), 7.35 (d, J = 3.0 Hz, 1 H), 7.22 (m, 2 H), 7.14 (m, 1 H), 6.90 (m, 2 H), 6.79 (d, J = 8.0 Hz, 1 H), 4.24 (m, 2 H), 3.98 (m, 3 H), 3.70 (s, 3 H), 3.49 (m, 1 H), 3.23 (m, 3 H), 2.56 (m, 2 H), 2.42 (s, 1 H), 2.26 (d, J = 16.8 Hz, 1 H), 1.79 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>1-oxalic acid</td>
<td>1-(2-[[3-benzylpyrrolidin-1-yl]ethyl]phenyl)piperdin-2-one oxalate</td>
<td>363</td>
<td>7.37 (m, 1 H), 7.30 (m, 4 H), 7.21 (m, 4 H), 3.57 (m, 1 H), 3.31 (m, 4 H), 3.17 (m, 2 H), 2.93 (m, 1 H), 2.75 (m, 4 H), 3.49 (m, 1 H), 2.02 (m, 1 H), 1.85 (m, 4 H), 1.68 (m, 1 H)</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>1-oxalic acid</td>
<td>1-(2-[[3-(2-methoxyphenoxy)pyrrolidin-1-yl]ethyl]phenyl)piperdin-2-one oxalate</td>
<td>395</td>
<td>(DMSO) 7.38 (m, 1 H), 7.31 (m, 2 H), 7.21 (m, 1 H), 6.99 (m, 3 H), 6.90 (m, 1 H), 5.03 (s, 1 H), 3.78 (m, 3 H), 3.58 (m, 2 H), 3.35 (m, 4 H), 3.18 (m, 2 H), 2.80 (m, 2 H), 2.33 (m, 2 H), 2.09 (m, 1 H), 1.84 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td>4-[[1-[2-[[2-oxopyrrolidin-1-yl]phenyl]ethyl]pyrrolidin-3-yl]oxy]benzonitrile</td>
<td>390</td>
<td>7.36 (d, J = 8.2 Hz, 2 H), 7.08 (m, 1 H), 6.92 (m, 1 H), 6.69 (d, J = 8.6 Hz, 2 H), 4.66 (m, 1 H), 3.38 (m, 1 H), 3.22 (m, 1 H), 2.73 (m, 3 H), 2.52 (m, 4 H), 2.38 (m, 3 H), 2.16 (m, 1 H), 1.79 (m, 5 H)</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>1-oxalic acid</td>
<td>1-(2-[[3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl]ethyl]phenyl)piperdin-2-one oxalate</td>
<td>357</td>
<td>7.38 (m, 1 H), 7.31 (m, 2 H), 7.21 (m, 1 H), 3.84 (m, 2 H), 3.57 (m, 1 H), 3.25 (m, 9 H), 2.79 (m, 2 H), 2.46 (m, 1 H), 2.33 (m, 1 H), 2.05 (m, 2 H), 1.88 (m, 4 H), 1.56 (m, 4 H), 1.20 (m, 2 H)</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td></td>
<td>1-[2-[[3-benzylazetidin-1-yl]ethyl]phenyl]piperdin-2-one</td>
<td>349</td>
<td>7.28 (m, 6 H), 7.19 (m, 1 H), 7.10 (m, 3 H), 3.58 (m, 1 H), 3.42 (m, 3 H), 2.90 (m, 4 H), 2.78 (m, 1 H), 2.67 (m, 1 H), 2.51 (m, 4 H), 1.96 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td></td>
<td>1-[2-[[3-(pyridin-3-yl)pyrrolidin-1-yl]ethyl]phenyl]piperdin-2-one</td>
<td>350</td>
<td>8.51 (s, 1 H), 8.44 (d, J = 4.7 Hz, 1 H), 7.62 (d, J = 8.0 Hz, 1 H), 7.35 (m, 1 H), 7.27 (m, 2 H), 7.22 (dd, J = 7.6, 4.9 Hz, 1 H), 7.13 (m, 1 H), 3.60 (m, 1 H), 3.40 (m, 2 H), 3.09 (m, 1 H), 2.78 (m, 6 H), 2.61 (m, 3 H), 2.36 (m, 2 H), 1.91 (m, 5 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>αD (589 nm)</td>
</tr>
<tr>
<td>-----</td>
<td>-------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>54</td>
<td>1 trifluoro acetic acid</td>
<td>1-(2-[2-[3-[4,4-difluorocyclohexyl]pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one trifluoroacetate</td>
<td>391</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>1 oxalic acid</td>
<td>4-[(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl)oxy]benzonitrile oxalate</td>
<td>376</td>
<td>7.69-7.67 (d, 2 H), 7.25-7.07 (m, 4 H), 6.93-6.91 (d, 2 H), 5.01 (s, 1 H), 4.34-4.25 (m, 2 H), 3.82-3.08 (m, overlap with solvent peak), 2.55-2.18 (m, overlap with solvent peak), 1.74 (s, 4 H)</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>1 trifluoro acetic acid</td>
<td>1-(2-[3-(2-methylpropyl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one trifluoroacetate</td>
<td>329</td>
<td>7.54 (m, 3 H), 7.35 (m, 1 H), 4.05 (m, 2 H), 3.82 (m, 1 H), 3.61 (m, 2 H), 3.48 (m, 1 H), 3.15 (m, 4 H), 2.84 (m, 2 H), 2.66 (m, 2 H), 2.42 (m, 1 H), 2.19 (m, 4 H), 1.90 (m, 1 H), 1.75 (m, 1 H), 1.54 (m, 2 H), 1.10 (m, 6 H)</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>1 trifluoro acetic acid</td>
<td>1-(2-[3-propyl]pyrrolidin-1-yl)ethyl]phenyl)piperidin-2-one trifluoroacetate</td>
<td>315</td>
<td>11.12 (m, 1 H), 9.33 (s, 2 H), 7.33 (m, 3 H), 7.14 (m, 1 H), 3.85 (m, 2 H), 3.62 (m, 1 H), 3.36 (m, 3 H), 2.96 (m, 3 H), 2.64 (m, 2 H), 2.42 (m, 2 H), 2.23 (m, 1 H), 2.00 (m, 4 H), 1.70 (m, 1 H), 1.36 (m, 4 H), 0.81 (m, 3 H)</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td></td>
<td>3-[(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]azetidin-3-yl)oxy]benzonitrile</td>
<td>376</td>
<td>7.40 (m, 1 H), 7.28 (m, 4 H), 7.14 (m, 1 H), 7.00 (m, 2 H), 4.75 (m, 1 H), 3.83 (m, 2 H), 3.61 (m, 1 H), 3.42 (m, 1 H), 3.15 (m, 2 H), 2.79 (m, 2 H), 2.57 (m, 4 H), 1.98 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td></td>
<td>2-[1-(2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]azetidin-3-yl)oxy]benzonitrile</td>
<td>376</td>
<td>7.59 (m, 1 H), 7.50 (m, 1 H), 7.33 (m, 1 H), 7.28 (m, 3 H), 7.12 (m, 1 H), 7.02 (m, 1 H), 6.70 (d, 1 H), 4.87 (m, 1 H), 3.91 (m, 2 H), 3.62 (m, 1 H), 3.45 (m, 1 H), 3.24 (m, 2 H), 2.88 (m, 1 H), 2.74 (m, 1 H), 2.59 (m, 4 H), 1.97 (m, 3 H)</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td>1-(2-[2-[3-(4-fluorophenoxo)azetidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>369</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td></td>
<td>1-(2-[2-[3-(3-methoxyphenoxy)azetidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>381</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>αD (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>--------</td>
<td>------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>62</td>
<td>1-(2-[2-[3-(2-bromobenzyl)azetidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>427/429</td>
<td>7.53 (m, 1 H), 7.29 (m, 2 H), 7.23 (m, 2 H), 7.10 (m, 3 H), 3.57 (m, 1 H), 3.42 (m, 3 H), 3.00 (m, 2 H), 2.88 (m, 3 H), 2.69 (m, 1 H), 2.53 (m, 5 H), 1.96 (m, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>4-[(1-[(2-[2-(2-oxopiperidin-1-yl)pyridin-3-yl]ethyl]pyrroloidin-3-yl)benzonitrile</td>
<td>375</td>
<td>8.35 (m, 1 H), 7.81 (m, 1 H), 7.71 (m, 2 H), 7.44 (m, 2 H), 7.31 (m, 1 H), 3.87 (m, 1 H), 3.43 (m, 3 H), 2.88 (m, 1 H), 2.75 (m, 1 H), 2.64 (m, 5 H), 2.32 (m, 3 H), 1.87 (m, 4 H), 1.70 (m, 1 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>1-[(2-[2-[3-(4-methyl-1,3-thiazol-5-yl)pyrroloidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>370</td>
<td>8.33 (s, 1 H), 7.12 (m, 1 H), 7.05 (m, 2 H), 6.91 (dd, J₁ = 5.0 Hz, J₂ = 3.6 Hz, 1 H), 3.43 (m, 2 H), 3.23 (m, 1 H), 2.89 (d, J = 0.9 Hz, 1 H), 2.59 (m, 6 H), 2.34 (m, 3 H), 2.19 (m, 4 H), 1.78 (m, 5 H), 1.54 (m, 2 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>1-oxalic acid</td>
<td>1-[(2-[2-[3-(5-bromo-2-methoxyphenoxy)azetidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate</td>
<td>459</td>
<td>(DMSO) 7.40 (m, 1 H), 7.30 (m, 2 H), 7.18 (m, 2 H), 6.98 (m, 2 H), 4.99 (m, 1 H), 4.36 (m, 4 H), 3.95 (m, 3 H), 3.80 (m, 3 H), 3.59 (m, 2 H), 3.36 (m, 1 H), 3.16 (m, 2 H), 2.65 (m, 2 H), 2.37 (m, 2 H), 1.87 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>1-oxalic acid</td>
<td>1-[(2-[2-(3-phenoxyazetidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate</td>
<td>351</td>
<td>(DMSO) 7.40 (m, 1 H), 7.31 (m, 4 H), 7.20 (m, 1 H), 7.01 (t, 1 H, J = 7.3 Hz), 6.86 (d, 2 H, J = 8.0 Hz), 5.00 (m, 1 H), 4.37 (m, 4 H), 3.84 (m, 3 H), 3.58 (m, 1 H), 3.31 (m, 1 H), 3.17 (m, 2 H), 2.62 (m, 3 H), 2.36 (m, 1 H), 1.86 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>1-[(2-[2-(3-tert-butylpyrroloidin-1-yl)ethyl]phenyl)piperidin-2-one</td>
<td>329</td>
<td>7.39-7.33 (m, 1H), 7.33-7.27 (m, 3H, including CDCl₃), 7.17-7.13 (m, 1H), 3.66-3.45(m, 2H), 2.94-2.70 (m,5H), 2.63-2.56 (m, 3H), 2.49-2.40 (m, 1H), 2.35-2.25 (m, 1H), 2.16-2.07 (m, 1H), 2.04-1.94 (m,4H), 1.89-1.80 (m,1H), 1.66-1.55 (m,1H), 0.9 (s, 9H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>1-oxalic acid</td>
<td>1-[(2-[2-[3-(2-methoxyphenoxy)azetidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate</td>
<td>381</td>
<td>(DMSO) 7.33 (m, 1 H), 7.23 (m, 2 H), 7.13 (m, 1 H), 6.93 (m, 2 H), 6.80 (m, 1 H), 6.71 (m, 1 H), 4.84 (m, 1 H), 4.32 (m, 4 H), 3.91 (m, 3 H), 3.70 (s, 3 H), 3.49 (m, 1 H), 3.24 (m, 1 H), 3.13 (m, 2 H), 2.55 (m, 2 H), 2.27 (m, 1 H), 1.77 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>1-(2-[2-[3-(2-chloro-2,2-difluoroethyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>371/373</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>1-(3-[2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one</td>
<td>351</td>
<td>8.56 (d, J = 4.0 Hz, 1 H), 8.41 (m, 1 H), 7.86 (d, J = 7.5 Hz, 1 H), 7.79 (t, J = 7.5 Hz, 1 H), 7.38 (m, 2 H), 7.31 (m, 1 H), 3.84 (m, 1 H), 3.76 (m, 2 H), 3.40 (m, 6 H), 2.85 (m, 2 H), 2.37 (m, 3 H), 2.12 (m, 1 H), 1.87 (m, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>1-oxalic acid</td>
<td>351</td>
<td>8.56 (d, J = 4.0 Hz, 1 H), 8.41 (m, 1 H), 7.86 (d, J = 7.5 Hz, 1 H), 7.79 (t, J = 7.5 Hz, 1 H), 7.38 (m, 2 H), 7.31 (m, 1 H), 3.84 (m, 1 H), 3.76 (m, 2 H), 3.40 (m, 6 H), 2.85 (m, 2 H), 2.37 (m, 3 H), 2.12 (m, 1 H), 1.87 (m, 4 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>1-(3-[1-acetyl]piperidin-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>398</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>1-(2-[2-[3-(pyridin-4-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>350</td>
<td>8.47 (s, 2 H), 7.33 (m, 1 H), 7.25 (dd, J1 = 5.2 Hz, J2 = 3.8 Hz, 2 H), 7.17 (d, J = 3.4 Hz, 2 H), 7.11 (dd, J1 = 5.5 Hz, J2 = 3.7 Hz, 1 H), 3.58 (m, 1 H), 3.41 (m, 1 H), 3.31 (m, 1 H), 3.01 (m, 1 H), 2.58 (m, 3 H), 2.33 (m, 1 H), 1.87 (m, 5 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>1-(2-[2-[3-(2-fluoropyridin-3-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>368</td>
<td>8.06 (m, 1 H), 7.77 (m, 1 H), 7.36 (m, 1 H), 7.29 (m, 1 H), 7.13 (m, 2 H), 3.61 (m, 2 H), 3.45 (m, 1 H), 3.05 (m, 1 H), 2.80 (m, 7 H), 2.59 (m, 2 H), 2.35 (m, 1 H), 1.92 (m, 6 H), 1 additional proton due to an impurity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>1-(2-[2-[3-(tetrahydrofuran-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one</td>
<td>343</td>
<td>7.29 (m, 1 H), 7.22 (m, 2 H), 7.14 (m, 1 H), 3.58 (m, 4 H), 3.33 (m, 1 H), 3.25 (m, 1 H), 3.12 (m, 4 H), 2.97 (m, 1 H), 2.70 (m, 2 H), 2.37 (d, J = 2.3 Hz, 1 H), 2.29 (m, 2 H), 1.85 (m, 8 H), 1.58 (m, 1 H), 1.38 (m, 1 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>1-oxalic acid</td>
<td>343</td>
<td>7.29 (m, 1 H), 7.22 (m, 2 H), 7.14 (m, 1 H), 3.58 (m, 4 H), 3.33 (m, 1 H), 3.25 (m, 1 H), 3.12 (m, 4 H), 2.97 (m, 1 H), 2.70 (m, 2 H), 2.37 (d, J = 2.3 Hz, 1 H), 2.29 (m, 2 H), 1.85 (m, 8 H), 1.58 (m, 1 H), 1.38 (m, 1 H)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| n° | ADDUCT | IUPAC_NAME | LC-MS (MH⁺) | NMR description (CDCl₃ otherwise specified) | αD (589 nm)  
|---|---|---|---|---|---
<p>| 77 | 1.trifluoroacetic acid | (+)-1-(2-[2-3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one trifluoroacetate | 357 | 7.29 (m, 1 H), 7.21 (m, 2 H), 7.12 (m, 1 H), 3.76 (m, 2 H), 3.49 (dd, J = 12.0, 6.8 Hz, 1 H), 3.16 (m, 8 H), 2.78 (m, 1 H), 2.69 (m, 2 H), 2.37 (m, 1 H), 2.26 (m, 1 H), 1.95 (m, 2 H), 1.78 (m, 4 H), 1.57 (m, 1 H), 1.47 (m, 2 H), 1.35 (m, 1 H), 1.12 (m, 2 H) | +0.006 (0.6%) |
| 78 | 1.oxalic acid | (+)-1-(2-[2-3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one oxalate | 357 | 7.29 (m, 1 H), 7.21 (m, 2 H), 7.12 (m, 1 H), 3.76 (m, 2 H), 3.49 (dd, J = 12.0, 6.8 Hz, 1 H), 3.16 (m, 8 H), 2.78 (m, 1 H), 2.69 (m, 2 H), 2.37 (m, 1 H), 2.26 (m, 1 H), 1.95 (m, 2 H), 1.78 (m, 4 H), 1.57 (m, 1 H), 1.47 (m, 2 H), 1.35 (m, 1 H), 1.12 (m, 2 H) | +0.003 (0.52%) |
| 79 | 1.oxalic acid | 1-(3-[2-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate | 356 | 8.37 (m, 1 H), 7.88 (m, 1 H), 7.30 (m, 1 H), 3.85 (m, 2 H), 3.47 (m, 1 H), 3.37 (m, 1 H), 3.17 (m, 4 H), 2.94 (m, 1 H), 2.79 (m, 2 H), 2.59 (m, 2 H), 2.35 (m, 1 H), 2.18 (m, 1 H), 1.93 (m, 4 H), 1.72 (m, 1 H), missing H obscured by solvent (H₂O) |  |
| 80 | 1.oxalic acid | 1-(3-[2-[(3S)-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one | 356 | 8.40 (d, 1H), 7.83 (d, 1H), 7.37 (quad, 1H), 3.66 (m, H₂O), 3.47 (m, 3H), 3.38 (m,3H), 3.25 (m, 5H), 2.93 (m,1H), 2.80 (m, 2H), 2.52 (dmso), 2.38 (m, 1H), 2.19 (m, 1H), 1.91 (m, 4H), 1.73 (m, 1H) |  |
| 81 | 1.trifluoroacetic acid | 1-(2-[2-3-(tetrahydro-2H-pyran-3-yl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one trifluoroacetate | 357 | - |  |
| 82 | 1.oxalic acid | 1-(2-[2-3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one | 380 | - |  |
| 83 | 1.oxalic acid | 1-(2-[2-3-(5-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl)phenyl)piperidin-2-one | 368 | 8.47 (s, 1 H), 7.64 (m, 1 H), 7.37 (m, 2 H), 7.25 (m, 2 H), 7.16 (d, J = 4.0 Hz, 1 H), 3.54 (m, 2 H), 3.02 (s, 1 H), 2.79 (s, 0 H), 2.60 (m, 3 H), 2.36 (m, 4 H), 2.18 (m, 3 H), 1.88 (m, 7 H) |  |</p>
<table>
<thead>
<tr>
<th>n°</th>
<th>ADDUCT</th>
<th>IUPAC_NAME</th>
<th>LC-MS (MH&lt;sup&gt;+&lt;/sup&gt;)</th>
<th>NMR description (CDCl&lt;sub&gt;3&lt;/sub&gt; otherwise specified)</th>
<th>&lt;x&gt; (589 nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>84</td>
<td>1-(2-{2-[3-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl phenyl}piperidin-2-one</td>
<td>368</td>
<td>8.39 (d, &lt;i&gt;J&lt;/i&gt; = 4.6 Hz, 1 H), 7.66 (t, &lt;i&gt;J&lt;/i&gt; = 9.1 Hz, 1 H), 7.35 (m, 2 H), 7.26 (m, 2 H), 7.16 (m, 1 H), 3.75 (m, 1 H), 3.58 (m, 1 H), 3.13 (m, 2 H), 2.94 (m, 1 H), 2.67 (m, 5 H), 2.35 (m, 4 H), 2.16 (m, 3 H), 1.87 (m, 5 H)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>1-(2-{2-[3-(2-fluoro-2-methylpropyl)pyrrolidin-1-yl]ethyl phenyl}piperidin-2-one</td>
<td>347</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>1-[2-{2-[3-oxo-2-(pyrrolidin-1-yl)ethyl]pyrrolidin-1-yl]ethyl phenyl}piperidin-2-one</td>
<td>384</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>1-oxalic acid 1-(2-{2-[3-(4-methyl-1,3-thiazol-2-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate</td>
<td>370</td>
<td>8.29 (s, 1 H), 8.18 (m, 1 H), 8.11 (m, 2 H), 8.02 (m, 2 H), 4.76 (m, 1 H), 4.52 (m, 1 H), 4.37 (m, 1 H), 4.18 (m, 4 H), 4.00 (m, 2 H), 3.60 (m, 2 H), 3.23 (m, 1 H), 3.15 (m, 4 H), 2.98 (m, 1 H), 2.88 (s, 1 H)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>1-(3-[2-[3-(5-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one</td>
<td>369</td>
<td>8.39 (m, 2 H), 7.70 (d, &lt;i&gt;J&lt;/i&gt; = 7.6 Hz, 1 H), 7.31 (m, 1 H), 7.20 (m, 2 H), 3.99 (m, 1 H), 3.56 (m, 1 H), 3.38 (m, 1 H), 3.11 (m, 2 H), 2.78 (m, 7 H), 2.55 (m, 2 H), 2.33 (m, 1 H), 2.01 (m, 6 H), 1.77 (m, 2 H)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>1-oxalic acid 1-(3-[2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate, isomer A</td>
<td>351</td>
<td>8.56 (m, 1 H), 8.40 (m, 1 H), 7.87 (m, 1 H), 7.78 (m, 1 H), 7.40 (m, 2 H), 7.30 (m, 1 H), 2.85 (m, 2 H), 2.42 (m, 2 H), 2.15 (m, 1 H), 1.86 (m, 4 H), missing H obscured by solvent (H20)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>1-oxalic acid (+)-1-{2-[3-(4,4-difluorocyclohexyl)pyrrolidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one oxalate</td>
<td>392</td>
<td>(DMSO) 8.41 (d, 1 H, &lt;i&gt;J&lt;/i&gt; = 3.6 Hz), 7.83 (m, 1 H), 7.38 (m, 1 H), 3.84 (m, 1 H), 3.34 (m, 6 H), 2.88 (m, 3 H), 2.34 (m, 1 H), 2.08 (m, 4 H), 1.79 (m, 9 H), 1.39 (m, 1 H), 1.20 (m, 2 H) +0.010 (0.51%, 365 nm)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>&lt;x0 (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------</td>
<td>----------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>91</td>
<td>1.oxalic</td>
<td>acid (-)-1-[3-{2-[3-(4,4-difluorocyclohexyl)pyrroli din-1-y]ethyl]pyridin-2-y]piperidin-2-one oxalate</td>
<td>392</td>
<td>(DMSO) 8.40 (dd, 1 H, J = 4.6, 1.4 Hz), 7.83 (dd, 1 H, J = 7.5, 1.1 Hz), 7.37 (dd, 1 H, J = 7.6, 4.8 Hz), 3.84 (d, 2 H, J = 6.7 Hz), 3.30 (m, 7 H), 2.81 (d, 3 H, J = 7.4 Hz), 2.05 (m, 5 H), 1.80 (m, 8 H), 1.19 (m, 2 H)</td>
<td>-0.008</td>
</tr>
<tr>
<td>92</td>
<td>1.oxalic</td>
<td>acid 1-[3-{2-[3-(6-methoxy pyridin-2-yl)pyrro lidin-1-yl]ethyl}pyridin-2-y]piperidin-2-one oxalate</td>
<td>381</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>93</td>
<td>1.oxalic</td>
<td>acid 1-[3-{2-[3-(6-methoxy pyridin-2-yl)pyrro lidin-1-yl]ethyl}pyridin-2-y]piperidin-2-one oxalate</td>
<td>381</td>
<td>1H 1.03 s 6.84 1H 2.68 d 4.05 d 0.68 1H 2.88 s 1.32 1H 3.12 m 2.15 1H 3.58 m 2.30 1H 4.32 m 32.10 1H 7.47 d 1.07 d 8.18 1H 7.71 d 1.05 d 7.13 1H 8.14 dd 1.08 d 6.97 d 4.86 1H 8.29 s 1.55 1H 8.44 t 1.05 t 7.65 1H 8.64 d 1.00 d 7.15 1H 9.18 d 1.00 d 3.53</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>1.oxalic</td>
<td>acid 1-[3-{2-[3-(6-propan-2-yloxy)pyridin-2-yl)pyrrol idin-1-y]ethyl}pyridin-2-y]piperidin-2-one oxalate</td>
<td>409</td>
<td>9.21 (d, J = 4.5 Hz, 1 H), 8.66 (d, J = 7.5 Hz, 1 H), 8.43 (t, J = 7.8 Hz, 1 H), 8.17 (dd, J1 = 7.5 Hz, J2 = 4.8 Hz, 1 H), 7.69 (d, J = 7.2 Hz, 1 H), 7.42 (d, J = 8.2 Hz, 1 H), 6.05 (m, 1 H), 4.65 (m, 1 H), 4.54 (m, 1 H), 4.46 (m, 1 H), 4.23 (m, 6 H), 3.64 (m, 2 H), 3.31 (m, 1 H), 3.17 (m, 2 H), 2.94 (m, 1 H), 2.66 (m, 4 H), 2.08 (d, J = 6.1 Hz, 6 H)</td>
<td>-</td>
</tr>
<tr>
<td>95</td>
<td>1.oxalic</td>
<td>acid 1-[3-{2-{3-[3-{2,2,2-trifluoroethyl}pyrro lidin-1-y]ethyl}pyridin-2-y]piperidin-2-one oxalate</td>
<td>356</td>
<td>(DMSO) 8.39 (m, 1 H), 7.83 (m, 1 H), 7.35 (m, 1 H), 3.85 (m, 1 H), 3.47 (m, 1 H), 3.28 (m, 5 H), 2.97 (m, 1 H), 2.80 (m, 2 H), 2.56 (m, 3 H), 2.33 (m, 1 H), 2.18 (m, 1 H), 1.88 (m, 4 H), 1.72 (m, 1 H)</td>
<td>-</td>
</tr>
<tr>
<td>96</td>
<td>1.oxalic</td>
<td>acid 6-{1-[2-[2-(2-oxopiperidin-1-yl)pyridin-3-y]ethyl]pyrrol idin-3-yl}pyridine-2-carbonitrile oxalate</td>
<td>376</td>
<td>9.21 (dd, J1 = 4.4 Hz, J2 = 1.1 Hz, 1 H), 8.86 (t, J = 7.8 Hz, 1 H), 8.77 (m, 1 H), 8.66 (m, 1 H), 8.56 (d, J = 7.9 Hz, 1 H), 8.17 (dd, J1 = 7.6 Hz, J2 = 4.8 Hz, 1 H), 4.62 (m, 4 H), 4.14 (m, 6 H), 3.65 (m, 2 H), 3.13 (m, 3 H), 2.92 (m, 2 H), 2.66 (m, 4 H)</td>
<td>-</td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>&lt;xD (589 nm)</td>
</tr>
<tr>
<td>-----</td>
<td>--------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>97</td>
<td>1-oxalic acid</td>
<td>1-(3-[2-[3-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate</td>
<td>369</td>
<td>9.22 (dd, J₁ = 8.4 Hz, J₂ = 4.0 Hz, 2 H), 8.66 (d, J = 7.3 Hz, 1 H), 8.54 (m, 1 H), 8.24 (m, 1 H), 8.18 (m, 1 H), 4.78 (m, 2 H), 4.66 (m, 2 H), 4.49 (m, 1 H), 4.14 (m, 6 H), 3.64 (m, 2 H), 3.16 (m, 3 H), 2.98 (m, 1 H)</td>
<td></td>
</tr>
<tr>
<td>98</td>
<td></td>
<td>1-[3-(2-[3-[6-(trifluoromethyl)pyridin-2-yl]pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one</td>
<td>419</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td></td>
<td>1-[3-(2-[3-[5-(fluoropyridin-2-yl)oxy]azetidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one</td>
<td>371</td>
<td>8.32 (m, 1 H), 8.08 (m, 1 H), 7.74 (m, 1 H), 7.67 (m, 1 H), 7.27 (m, 1 H), 6.86 (m, 1 H), 5.03 (m, 1 H), 3.81 (m, 1 H), 3.64 (m, 2 H), 3.28 (s, 1 H), 2.94 (m, 2 H), 2.61 (m, 2 H), 2.34 (m, 4 H), 1.83 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>1-oxalic acid</td>
<td>1-(3-[2-[3-[4-fluorophenoxy]azetidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate</td>
<td>370</td>
<td>8.40 (m, 1 H), 7.85 (m, 1 H), 7.35 (m, 1 H), 7.15 (m, 2 H), 6.90 (m, 2 H), 4.96 (m, 1 H), 4.33 (s, 2 H), 3.82 (m, 3 H), 3.36 (m, 1 H), 3.22 (m, 2 H), 2.65 (m, 2 H), 2.30 (m, 1 H), 2.09 (m, 1 H), 1.85 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>1-oxalic acid</td>
<td>1-(3-[2-[3-[2-fluorophenoxy]azetidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate</td>
<td>370</td>
<td>9.18 (m, 1 H), 8.64 (m, 1 H), 8.18 (m, 1 H), 8.07 (m, 1 H), 7.94 (m, 1 H), 7.79 (m, 2 H), 5.83 (m, 1 H), 5.15 (m, 3 H), 4.65 (s, 3 H), 4.15 (m, 1 H), 3.99 (m, 2 H), 3.43 (m, 2 H), 3.14 (m, 1 H), 2.64 (m, 4 H)</td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>1-oxalic acid</td>
<td>(-)-1-(3-[2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate</td>
<td>351</td>
<td>(DMSO) 8.55 (m, 1 H), 8.40 (m, 1 H), 7.87 (m, 1 H), 7.77 (m, 1 H), 7.40 (m, 2 H), 7.29 (m, 1 H), 3.88 (m, 1 H), 3.73 (m, 2 H), 3.39 (m, 6 H), 2.86 (m, 2 H), 2.56 (s, 1 H), 2.37 (m, 2 H), 2.13 (m, 1 H), 1.84 (m, 4 H)</td>
<td>-0.144 (0.5%)</td>
</tr>
<tr>
<td>103</td>
<td></td>
<td>1-(3-[2-[3-[6-methylpyridin-2-yl]pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one</td>
<td>365</td>
<td>8.31 (dd, J₁ = 4.7 Hz, J₂ = 1.5 Hz, 1 H), 7.78 (d, J = 7.6 Hz, 1 H), 7.53 (t, J = 7.7 Hz, 1 H), 7.27 (dd, J₁ = 7.4 Hz, J₂ = 4.8 Hz, 1 H), 7.02 (t, J = 6.5 Hz, 2 H), 3.81 (m, 1 H), 3.38 (m, 1 H), 2.94 (t, J = 8.3 Hz, 1 H), 2.71 (m, 1 H), 2.58 (m, 6 H), 2.36 (m, 5 H), 2.12 (m, 1 H), 1.88 (m, 5 H)</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>λmax (nm)</td>
</tr>
<tr>
<td>-----</td>
<td>------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>104</td>
<td>1-oxalic</td>
<td>1-[3-(2-[3-[6-(1 H-pyrazol-1-yl)pyrroldin-2-yl]pyrrolidin-1-yl]ethyl)pyrroldin-2-yl]piperidin-2-one oxalate</td>
<td>417</td>
<td>(DMSO) 8.75 (m, 1 H), 8.42 (m, 1 H), 8.00 (m, 1 H), 7.87 (m, 1 H), 7.81 (m, 2 H), 7.34 (m, 2 H), 6.60 (m, 1 H), 2.86 (m, 2 H), 2.34 (m, 1 H), 2.19 (m, 1 H), 1.83 (m, 4 H), 1.03 (m, 1 H), missing H are obscured by solvent (H₂O)</td>
<td>589</td>
</tr>
<tr>
<td>105</td>
<td></td>
<td>1-[3-(2-[3-(4-methoxypyrroldin-2-yl)pyrroldin-1-yl]ethyl)pyrroldin-2-yl]piperidin-2-one</td>
<td>382</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>106</td>
<td>1-oxalic</td>
<td>1-[3-(2-[3-[6-(4-fluorophenyl)pyrroldin-2-yl]pyrroldin-1-yl]ethyl)pyrroldin-2-yl]piperidin-2-one</td>
<td>445</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>107</td>
<td></td>
<td>1-[3-(2-[3-[6-(cyclobutyloxy)pyrroldin-2-yl]pyrroldin-1-yl]ethyl)pyrroldin-2-yl]piperidin-2-one oxalate</td>
<td>421</td>
<td>(DMSO) 9.20 (m, 1 H), 8.66 (d, J = 7.0 Hz, 1 H), 8.45 (t, J = 7.8 Hz, 1 H), 8.17 (dd, J1 = 7.6 Hz, J2 = 4.8 Hz, 1 H), 7.72 (d, J = 7.2 Hz, 1 H), 7.45 (d, J = 8.2 Hz, 1 H), 5.91 (t, J = 7.4 Hz), 4.46 (m, 4 H), 4.15 (m, 7 H), 3.64 (m, 2 H), 3.18 (m, 4 H), 2.86 (m, 3 H), 2.62 (m, 5 H), 2.42 (d, J = 10.1 Hz, 1 H)</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td></td>
<td>1-[3-(2-[3-[6-(2,2,2-trifluoroethoxy)pyrroldin-2-yl]pyrroldin-1-yl]ethyl)pyrroldin-2-yl]piperidin-2-one</td>
<td>449</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>109</td>
<td></td>
<td>1-[3-(2-[3-[6-(difluoromethoxy)pyrroldin-2-yl]pyrroldin-1-yl]ethyl)pyrroldin-2-yl]piperidin-2-one</td>
<td>417</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>n°</td>
<td>ADDUCT</td>
<td>IUPAC_NAME</td>
<td>LC-MS (MH⁺)</td>
<td>NMR description (CDCl₃ otherwise specified)</td>
<td>&lt;x0 (589 nm)</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>110</td>
<td>1-[3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one</td>
<td>419</td>
<td>(DMSO) 9.55 (s, 1 H), 9.26 (d, 1 H, J = 4.4 Hz), 9.06 (s, 1 H), 8.46 (t, 1 H, J = 7.6 Hz), 8.04 (m, 1 H), 7.98 (m, 1 H), 4.69 (m, 0 H), 4.22 (m, 2 H), 3.77 (m, 1 H), 3.49 (m, 7 H), 3.17 (m, 2 H), 2.97 (m, 1 H), 2.72 (m, 5 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>1-oxalic acid 1-[3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}-5-(trifluoromethyl)pyridin-2-yl]piperidin-2-one oxalate</td>
<td>421</td>
<td>(DMSO) 8.52 (d, 2H, J = 8.03 Hz), 8.39 (d, 2H, J = 8.03 Hz), 8.35 (s, 1H), 4.54 (s, 3H), 2.62 (m, 3H), 4.44 (m, 2H), 4.33 (m, 2H), 4.17 (broad m, 2H), 3.98 (m, 2H), 3.38 (t, 2H), 3.18 (m, 2H), 2.82 (m, 1H), 2.62 (m, 3H), other signals masked by solvent peaks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>1-(5-fluoro-3-[2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one (80/20 mixture of enantiomers)</td>
<td>369</td>
<td>9.27 (m, 1 H), 9.13 (d, 1 H, J = 2.9 Hz), 8.61 (d, 1 H, J = 9.3 Hz), 8.47 (td, 1 H, J = 7.7, 1.8 Hz), 8.07 (d, 1 H, J = 7.9 Hz), 7.99 (m, 1 H), 4.58 (m, 1 H), 4.24 (dd, 1 H, J = 9.5, 7.4 Hz), 3.79 (t, 1 H, J = 8.4 Hz), 3.43 (m, 6 H), 3.15 (d, 3 H, J = 14.8 Hz), 2.96 (dd, 1 H, J = 2.4, 1.1 Hz), 2.79 (m, 1 H), 2.66 (m, 5 H)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Example 20. [3H]-5-carboxytryptamine (5-CT) binding assay.

Cell culture conditions and membrane preparation:

HEK293 Flip-In cells stably expressing human 5-HT7D receptor were generated in-house. Cells were subcultured in DMEM supplemented with 10% dialyzed FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin and 200 µg/ml hygromycin. Cells were grown at 37°C in a humidified atmosphere containing 5% CO2. Membrane preparations were performed as described in Gillard et al., Eur. J. Pharmacol. (2006) 536, 102-108.

[3H]-5-carboxytryptamine (5-CT) binding assay:

The affinity of compounds for human 5-HT7D receptors was measured in a competition assay against [3H]5-CT. This binding assay was adapted from Plassat et al. (1993). Briefly, membranes of HEK293 Flip-In cells expressing human 5-HT7D receptors (1-5 µg proteins per assay) were incubated at 25°C for 180 min in 0.2 ml of a 50 mM Tris-HCl buffer (pH 7.4) containing 2 mM MgCl2, 0.3-0.4 nM [3H]5-CT and increasing concentrations of test compounds. The non-specific binding (NSB) was defined as the residual binding observed in the presence of 10 µM serotonin (5-HT). Membrane-bound and free radioligand were separated by rapid filtration through glass fiber filters presoaked in 0.1% polyethyleneimine. Samples and filters were rinsed with ice-cold 50 mM Tris-HCl buffer (pH 7.4). Radioactivity trapped onto the filters was counted by liquid scintillation in a β-counter.

Compounds of formula I according to the invention show pKi values of at least 7.0.


The antagonism of test compounds on human 5-HT7D was assessed in a cAMP assay by measuring the rightward shifts of a concentration-response curve of 5-CT and the decrease in 5-CT maximal effect. Briefly, human 5-HT7D HEK293 Flip-In cells were preincubated at 750 cells per well for 60 min at 25°C in 40 µl of HBSS buffer (pH 7.4) containing 20 nM HEPES, 0.1 mM IBMX and test compound. 5-CT was added at increasing concentrations and samples were incubated for another 60 min. Termination of the incubation and measurement of cAMP levels by HTRF were performed according to the guidelines provided with the kit (HTRF cAMP dynamic kit - 62AM2PEC, CisBio International, France). Reference 5-HT7 antagonist compound was mianserin.

Best compounds of formula I according to the invention have an unsurmountable effect, i.e. they inhibit the maximum effect induced by 5-CT.

Example 22. Dural extravasation model of migraine.

In the established model of dural extravasation, a compound-induced reduction of plasma protein extravasation into the dura is thought to be predictive of activity in the
dural inflammation observed in migraine (Johnson, Neuroreport, 1997, 8, 2237-2240). Sprague-dawley rats (280-350g) are anesthetized (pentobarbital 60mg/kg i.p.), the femoral vein is then catheterized (PE 50 ID 0.58mm, OD 0.965mm) for Fluorescein isothiocyanate-bovine serum albumin (FITC-BSA) infusion and drug injection, and a tracheotomy is performed to ease breathing. The rat body temperature is maintained at 37°C.

The rat is then placed on a stereotaxic frame (Kopf instruments); the anterio-prosteriority reference (0) is taken at the interear bar. Following a midline sagittal scalp incision, two craniotomies are performed manually (with a 2.2 mm strawberry shape manual probe; position: + 5.4 mm from interear line, + 3.8 mm from the middle suture). Two stimulating electrodes (A-M Systems Stainless steel insulated electrodes 0.10 diameter, 12 MΩ, inclination 8°, width between the electrodes: 1.6 mm) are then introduced in the left trigeminal ganglia (9.1mm depth from the surface of the skull). The position is confirmed by the blink of the left eye following stimulation (1 pulse 60µA).

The test compound is administered intravenously (1 ml/kg); Approximately 5 min post injection, FITC-BSA (Sigma A9771 prepared at 50mg/kg in phosphate buffer solution Sigma P4417) is perfused (0.3 ml/2 min) via the femoral vein catheter.

At the end of the perfusion, the trigeminal ganglia is stimulated electrically (60µA, 200ms, 4Hz) for 3 min.

Alternatively, the compound is dosed orally before anaesthesia approximately 45 min before electrical stimulation as described above. Immediately following the stimulation, the rat are killed by exsanguination, the top of the skull is removed, and the left (ipsilateral to the stimulation) and right (contralateral to the stimulation) dura maters are collected and placed in filtered water then on microscope slides, and let to dry (30° protected from the light, minimum 3h).

The electrode position in the trigeminal ganglia (Anterio-posterior and dorso/ventral) is verified under microscope (x16). The level of fluorescence in dura maters ipsi- and contra- lateral to the trigeminal ganglia stimulation is quantified with a digital camera (Hamamatsu C4742-98 filter for FITC objective Nikon 2.8X) and analysis software (WIT5.3, Logical vision). Preferred compounds are those effectively preventing fluorescence ipsilateral to the trigeminal ganglia stimulation and therefore preventing extravasation.
Claims

1. 2-Oxo-piperidinyl derivatives according to formula I, their geometrical isomers, enantiomers, diastereomers and mixtures, or a pharmaceutically acceptable salt thereof,

\[ \text{(I)} \]

wherein

- X is either CH or N; Y is either -NR\(^4\)- or -CH=CH-; with the proviso that X is N when Y is -NR\(^4\)-;
- n is an integer selected from 1, 2 or 3; m is 1 or 2;
- R\(^1\) is a substituted or unsubstituted C-1-4 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocycle, a substituted or unsubstituted C3-8 cycloalkyl; or R\(^1\) is a -O-R\(^8\) moiety;
- R\(^2\) is a substituted or unsubstituted C-1-4 alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl;
- R\(^3\) is hydrogen, substituted or unsubstituted C-1-4 alkyl or halogen; and
- R\(^4\) is hydrogen or C-1-4 alkyl.

2. A compound according to claim 1 having formula I-A,
wherein

X is either CH or N;

n is an integer selected from 1, 2 or 3; m is 1 or 2;

R1 is a substituted or unsubstituted C-alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocycle, a substituted or unsubstituted C3-cycloalkyl; or R1 is a -O-R^ moiety whereby R2 is a substituted or unsubstituted C-alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and

R3 is hydrogen, substituted or unsubstituted C-alkyl or halogen.

3. A compound according to claim 1 having formula I-B,

![Chemical Structure](image)

wherein

n is an integer selected from 1, 2 or 3; m is 1 or 2;

R1 is a substituted or unsubstituted C-alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heterocycle, a substituted or unsubstituted C3-cycloalkyl; or R1 is a -O-R^ moiety whereby R2 is a substituted or unsubstituted C-alkyl, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and

R4 is hydrogen or C-alkyl.

4. A compound according to any of the preceding claims, wherein R1 is benzyl, 2-bromobenzyl, tert-butyl, 2-methylpropyl, 2-fluoro-2-methylpropyl, 2-chloro-2,2-difluoroethyl, 2-oxo-2-(pyrrolidin-1-yl)ethyl, 2,2,2-trifluoroethyl, propyl, phenyl, 2-carbamoylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 3,4-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-(methylcarbamoyl)phenyl, 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, 2-
5. A compound according to claim 1 having formula I-C,

![Chemical Structure](image)

wherein

X is either CH or N;

R¹ is a substituted or unsubstituted C-1.4 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted C₃-₆ cycloalkyl; or R¹ is a -O-R² moiety;

R² is a substituted or unsubstituted C-1.4 alkyl aryl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; and

R³ is hydrogen, substituted or unsubstituted C-1.4 alkyl or halogen.

6. A compound according to claim 1 having formula I-D,
wherein

X is either CH or N;

R1 is a substituted or unsubstituted C-14 alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted C3-6 cycloalkyl; or R1 is a -O-R^ moiety; and

R2 is a substituted or unsubstituted C14-alkyl aryl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

7. A compound according to claim 1 having formula I-E,

![Chemical structure]

wherein

X is either CH or N;

R1 is a substituted or unsubstituted C-14 alkyl, a substituted or unsubstituted phenyl, a substituted or unsubstituted pyridinyl, a substituted or unsubstituted pyrimidinyl, a substituted or unsubstituted thiazolyl, a substituted or unsubstituted piperidinyl, a substituted or unsubstituted tetrahydropyranyl, a substituted or unsubstituted tetrahydrofurany1, a substituted or unsubstituted cyclohexyl; or R1 is a -O-R2 moiety; and

R2 is a substituted or unsubstituted benzyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted pyridinyl; preferably a benzyl or a substituted or unsubstituted phenyl.

8. A compound according to any of the preceding claims selected from the group comprising:

(+)-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate;

N-methyl-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzamide oxalate;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate;
2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}piperidin-3-yl)benzamide oxalate;
1-[2-(2-{3-[2-(trifluoromethyl)phenyl]pyrrolidin-1-yl}ethyl)phenyl]piperidin-2-one oxalate;
1-(2-{2-[3-(2-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(3-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(4-methoxyphenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(2-fluorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(2-chlorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-[2-(2-{3-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]pyrrolidin-1-yl}ethyl)phenyl]piperidin-2-one oxalate;
(+)-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate;
(-)-2-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate,
1-[2-[2-(3-phenylpyrrolidin-1-yl)ethyl]phenyl]piperidin-2-one;
3-(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl)benzonitrile oxalate;
4-(1-[2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl]pyrrolidin-3-yl)benzonitrile oxalate;
(-)-1-[2-[2-[3-(2-(pyrrolidin-1-ylcarbonyl)phenyl]pyrrolidin-1-yl]ethyl]phenyl]piperidin-2-one;
1-(2-[2-[3-(2-methoxyphenyl)piperidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
(+)-1-(2-[2-[3-(2-methoxyphenyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
(-)-1-(2-[2-[3-(2-methoxyphenyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
1-[2-[2-[3-(trifluoromethyl)phenyl]pyrrolidin-1-yl]ethyl]phenyl]piperidin-2-one oxalate;
1-(2-{2-[3-(3-fluorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-{2-[2-(3-phenylazetidin-1-yl)ethyl]phenyl}piperidin-2-one oxalate; 
1-(2-{2-[3-(3-fluorophenyl)piperidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-(2-{2-[3-(3-methoxyphenyl)piperidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-{2-[2-(3-phenylpiperidin-1-yl)ethyl]phenyl}piperidin-2-one oxalate; 
1-(2-{2-[3-(4-chlorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-(2-{2-[3-(3-chlorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-(2-{2-[3-(benzyloxy)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-(2-{2-[3-(4-fluorophenyl)azetidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
3-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl)benzonitrile oxalate; 
1-(2-{2-[2-(3-cyclohexylpyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one oxalate; 
1-(2-{2-[2-(3-(2-hydroxyphenyl)pyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one dioxalate; 
1-(2-{2-[3-(3-fluorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one; 
1-(2-{2-[3-(4-fluorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate; 
1-(2-{2-[3-(3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one oxalate; 
1-(2-{2-[3-(3-(4-fluorophenyl)pyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one trifluoroacetate; 
1-(2-{2-[3-(3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one oxalate; 
4-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate; 
(-)-4-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate;
(+)-4-(1-{2-[2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl)benzonitrile oxalate;
1-(2-{2-[3-(2-methoxyphenyl)azetidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(3-fluorophenyl)azetidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(3,4-difluorophenyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-{2-[3-(3-methoxyphenyl)azetidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-{2-[2-(3-benzylpyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one oxalate;
1-(2-{2-[3-(2-methoxyphenoxy)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
4-{1-[2-{2-(2-oxopiperidin-1-yl)phenyl]ethyl}pyrrolidin-3-yl]oxy}benzonitrile oxalate;
1-(2-{2-[3-(2-methylpropyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one trifluoroacetate;
1-{2-[2-(3-benzylazetidin-1-yl)ethyl]phenyl}piperidin-2-one;
1-(2-{2-[3-(pyridin-3-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;
1-(2-{2-[3-(4,4-difluorocyclohexyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one trifluoroacetate;
4-{[1-{2-{2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl]oxy}benzonitrile oxalate;
1-(2-{2-[3-(2-methylpropyl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one trifluoroacetate;
1-{2-[2-(3-propylpyrrolidin-1-yl)ethyl]phenyl}piperidin-2-one trifluoroacetate;
3-{[1-{2-{2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl]oxy}benzonitrile;
2-{[1-{2-{2-(2-oxopiperidin-1-yl)phenyl]ethyl}azetidin-3-yl]oxy}benzonitrile;
1-(2-{2-[3-(4-fluorophenoxy)azetidin-1-yl]ethyl}phenyl)piperidin-2-one;
1-(2-{2-[3-(3-methoxyphenoxy)azetidin-1-yl]ethyl}phenyl)piperidin-2-one;
1-(2-{2-[3-(2-bromobenzyl)azetidin-1-yl]ethyl}phenyl)piperidin-2-one;
4-(1-{2-{2-(2-oxopiperidin-1-yl)pyrrolidin-3-yl]ethyl}pyrrolidin-3-yl)benzonitrile;
1-(2-{2-[3-(4-methyl-1,3-thiazol-5-yl)pyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;
1-(2-{2-[3-(5-bromo-2-methoxyphenoxy)azetidin-1-yl]ethyl}phenyl)piperidin-2-one oxalate;
1-(2-[3-(phenoxyazetidin-1-yl)ethyl]phenyl)piperidin-2-one oxalate;
1-{2-[3-tert-butylpyrrolidin-1-yl]ethyl}phenyl)piperidin-2-one;
1-(2-[3-(2-methoxyphenoxy)azetidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
1-(2-[3-(2-chloro-2,2-difluoroethyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(3-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one;
1-(3-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;
1-(2-[3-(1-acetylpiperidin-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[3-(pyridin-4-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[3-(2-fluoropyridin-3-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[3-(tetrahydrofuran-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[3-(tetrahydrofuran-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
(+)-1-(2-[3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one trifluoroacetate;
(+)-1-(2-[3-(tetrahydro-2H-pyran-4-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
1-(3-[3S]-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin -2-one oxalate;
1-(3-[3S]-3-(2,2,2-trifluoroethyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl)piperidin-2-one oxalate;
1-(2-[tetrahydro-2H-pyran-3-yl]pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one trifluoroacetate;
1-(2-[3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
1-(2-[3-(5-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[[3-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[[3-(2-fluoro-2-methylpropyl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-[2-(2-[[3-oxo-2-(pyrrolidin-1-yl)ethyl]pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one;
1-(2-[[3-(4-methyl-1,3-thiazol-2-yl)pyrrolidin-1-yl]ethyl]phenyl)piperidin-2-one oxalate;
1-(3-[[2-[[3-(5-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one;
1-(3-[[2-[[pyridin-2-yl]pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one oxalate, isomer A;
(+)-1-(3-[[2-[[3-(4,4-difluorocyclohexyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one oxalate;
(-)-1-(3-[[2-[[3-(4,4-difluorocyclohexyl)pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one oxalate;
1-(3-[[2-[[3-(6-methoxypyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one;
1-(3-[[2-[[6-(propan-2-yloxy)pyrrolidin-2-y1]ethyl]pyridin-2-y1]piperidin-2-one oxalate;
1-[3-[[2-[[3-(2-[[3-[(5-fluoropyridin-2-yl)oxy]azetidin-1-yl]ethyl)pyridin-2-yl]piperidin-2-one oxalate;
6-((1-[[2-[[2-[(oxopiperidin-1-yl)pyridin-3-yl]ethyl]pyrrolidin-3-yl]pyridine-2-carbonitrile oxalate;
1-(3-[[2-[[3-(3-fluoropyridin-2-yl)pyrrolidin-1-yl]ethyl]pyridin-2-yl]piperidin-2-one oxalate;
1-[3-[[2-[[3-(trifluoromethyl)pyrrolidin-2-y1]ethyl]pyridin-2-y1]piperidin-2-one;
98

1-(3-{2-[3-(4-fluorophenoxy)azetidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one oxalate;
1-(3-{2-[3-(2-fluorophenoxy)azetidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one oxalate;
(-)-1-(3-{2-[3-(pyridin-2-yl)pseudoephedrine-1-yl]ethyl}pyridin-2-yl)piperidin-2-one oxalate;
1-(3-{2-[3-(6-methylpyridin-2-yl)pseudoephedrine-1-yl]ethyl}pyridin-2-yl)piperidin-2-one oxalate;
1-[3-(2-[3-[6-(1H-pyrazol-1-yl)pyridin-2-yl]pseudoephedrine-1-yl]ethyl]pyridin-2-yl]piperidin-2-one oxalate;
1-(3-{2-[3-(4-methoxypyrimidin-2-yl)pseudoephedrine-1-yl]ethyl}pyridin-2-yl)piperidin-2-one;
1-[3-{2-[3-[6-(2,2,2-trifluoroethoxy)pyridin-2-yl]pseudoephedrine-1-yl]ethyl}pyridin-2-yl]piperidin-2-one;
1-[3-{2-[3-[6-(cyclobutylamino)pyridin-2-yl]pseudoephedrine-1-yl]ethyl}pyridin-2-yl]piperidin-2-one oxalate;
1-[3-(2-[3-[6-(6-fluoropyrimidin-2-yl)pseudoephedrine-1-yl]ethyl]pyridin-2-yl]piperidin-2-one oxalate;
1-(5-fluoro-3-{2-[3-(pyridin-2-yl)pyrrolidin-1-yl]ethyl}pyridin-2-yl)piperidin-2-one.

9. A compound according to any of claims 1 to 8 for use as a medicament.

10. A pharmaceutical composition comprising an effective amount of a compound according to claims 1 to 8 in combination with a pharmaceutically acceptable diluent or carrier.

11. A compound according to any of claims 1 to 8 for use in the treatment of migraine.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

- INV. C07D401/10
- C07D401/14
- C07D405/14
- C07D413/14
- C07D417/14

**ADD.**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

- Minimum documentation searched (classification system followed by classification symbols)
  - C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

- EPO-Internal
- CHEM ABS Data
- WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP 1 997 807 AI (ESTEVE LABOR DR [ES])</td>
<td>1-11</td>
</tr>
<tr>
<td></td>
<td>3 December 2008 (2008-12-03)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>claims 1,20,24-26</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "S" document member of the same patent family

Date of the actual completion of the international search: 7 January 2013

Date of mailing of the international search report: 15/01/2013

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer: Gutke, Hans-JLirgen
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 1997807</td>
<td>A1</td>
<td>03-12-2008</td>
<td>NONE</td>
</tr>
</tbody>
</table>